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SUMMARY 
 
 
Natural products have played an important role in the treatment and prevention of 
human diseases for thousands of years. But in spite of many advantages over synthetic 
compounds of natural products as a source of new drug molecules, many large 
pharmaceutical companies decreased natural products drug discovery research in the 
1990s and early 2000s. However, recent developments in natural product research, 
along with unrealized expectations from present lead generation strategies, have led 
renewed interest in natural product discovery. 
 
Keeping the immense potentiality of drug discovery from natural products in mind, the 
present study thus investigated the activity of the extracts and phytochemicals from 
three medicinal plants (Centella asiatica, Passiflora incarnata, and Vitis vinifera), and 
semi-synthetic analogues of active compounds on recombinant GABAA receptors, 
expressed in Xenopus laevis oocytes, using the two electrode voltage clamp technique. 
The goal is to discover lead molecules for the treatment of cognitive deficit, anxiety, 
depression, which are related to GABAergic system. The extraction of these plants was 
performed using a Soxhlet extractor with solvents of different polarities. The isolation 
and structure elucidation was accomplished by using both chromatographic (TLC, 
column chromatography, HPLC) and spectroscopic (
1
H NMR, 
13
C NMR, 2D-NMR, 
Mass spectrometry, IR) techniques. 
 
All the crude extracts from Centella asiatica, at a concentration of 50 µg/mL, induced 
direct currents at α1β2γ2L and α2β2γ2L but not at α5β3γ2L receptors, with the greatest 
current induced by the ethanolic extracts (84.5 ± 8.1 nA) at α1β2γ2L, and 80.0 ± 12.2 nA 
at α2β2γ2L receptors. All of the extracts, except ethyl acetate, also positively modulated 
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the GABA-induced current, with the greatest modulation by ethanolic extracts (37.5 ± 
7.0 % on α1β2γ2L, and 30.5 ± 10.6% on α2β2γ2L receptors), followed by aqueous extracts 
(29.5 ± 9.2 % on α1β2γ2L and 21.0 ± 3.2 % on α2β2γ2L receptors). Interesting results were 
observed for the pure compounds; despite the similar structure of asiatic 40 and 
madecassic acids 41, there were substantial differences in their modulation of GABA-
induced current. None of the compounds induced a direct current when applied alone, at 
a concentration of 100 µM. Asiatic acid 40 negatively modulated the GABA-induced 
current at all three subtypes of GABAA receptors, with IC50s of 37, 64, and 427 µM at 
the α1β2γ2L, α5β3γ2L, α2β2γ2L receptors, respectively. On the contrary, madecassic acid 41 
only inhibited the GABA-induced current at the α2β2γ2L receptor, with an IC50 of 
428µM. On the other hand, among the semi-synthetic analogues, the amide of asiatic 
acid, 2α,3β,23-trihydroxy-urs-12-en-28-amide 158 negatively modulated the GABA-
induced current at all three subtypes of GABAA receptors, with enhanced negative 
modulation compared to asiatic acid 40 at the α1β2γ2L (IC50, 14µM)  and α2β2γ2L (IC50, 
28µM) subtypes of GABAA receptors. The negative modulation on the α5β3γ2L receptor 
(IC50, 134 µM) was lower than that of asiatic acid 40. 2α,3β, 23-O-triacetylmadecassic 
acid 160, which is the acylated form of madecassic acid 41, negatively modulated the 
GABA-induced current at all three GABAA receptors, with the greatest modulation at 
α2β2γ2L (IC50, 106 µM), which was followed by α5β3γ2L (IC50, 205 µM), and α1β2γ2L 
(IC50, 828 µM). The effects of these compounds were not sensitive to the 
benzodiazepine antagonist flumazenil at α1β2γ2L and α2β2γ2L receptors, and the inverse 
agonist L655,708 at the α5β3γ2L receptor. 
 
The crude ethanolic extracts of passionflower (at a concentration of 100 μg/mL) 
induced direct currents at all three subtypes of GABAA receptor, with the greatest 
current at α5β3γ2L (1645 ± 135 nA), and also positively modulated the EC10 GABA-
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induced current at all three subtypes of receptors, with the greatest modulation at α1β2γ2L 
(2010 ± 578%), followed by at α5β3γ2L (1135 ± 45%), and α2β2γ2L (192 ± 19%). None of 
the pure compounds induced direct currents when applied alone, and all of them 
negatively modulated the EC10 and/or EC50 GABA-induced current, except for a slight 
positive modulation by kaempferol 72 at α1β2γ2L receptors, with the greatest inhibition 
by isoorientin 85 and orientin 83, which inhibited the EC10 GABA-induced current at 
α2β2γ2L receptors by 48.2 ± 0.77 % and 35.8 ± 0.44 % respectively. 
 
Although, resveratrol 110 and its dehydrodimer trans-ε-viniferin 111 have similar 
structural features, their effects on recombinant GABAA receptors were different. 
Resveratrol 110, at a concentration of 100 μM induced a small current (22.0 ± 3.5 nA) 
at the α1β2γ2L, but not at the α2β2γ2L or α5β3γ2L subtypes. It did not modulate the GABA-
induced current at α2β2γ2L and α5β3γ2L, but potentiated the GABA-induced current at 
α1β2γ2L, with an EC50 value of 58μM. On the contrary, trans-ε-viniferin 111 negatively 
modulated the GABA-induced (IGABA) at all three subtypes, with an IC50 of 5.8 μM on 
the α1β2γ2L receptor, followed by IC50 of 19μM on α2β2γ2L and IC50 of 21μM on 
α5β3γ2L.The effect was not sensitive to benzodiazepine antagonist flumazenil at α1β2γ2L, 
α2β2γ2L receptors, and the inverse agonist L655,708 at the α5β3γ2L receptor. The results 
from the current study thus suggest that-  
 
 The traditional claims for the use of Centella asiatica as a memory enhancer may be 
due to the asiatic acid 40, which inhibits the GABA-induced current at α5β3γ2L receptors, 
and this compound, along with its amide, may be leads for the enhancement of 
cognition of memory. However, as the effects of the compound are not selective for 
α5β3γ2L receptors, selective analogues need to be synthesized and, in addition to being 
tested on GABAA receptors, need to be tested on animal models of cognition and 
memory impairment. 
xxx 
 
 The traditional claims for passionflower as an anxiolytic herb are supported by the 
effects of its extracts on GABAA receptors, but not by the effects of the pure 
compounds. In order to confirm the anxiolytic effects, pure compounds, and mixture of 
pure compounds, should be tested on animal models for their putative anxiolytic effect. 
 Despite the structural similarity between resveratrol 110 and trans-ε-viniferin 111, these 
compounds modulate the GABA-induced current in GABAA receptors in different 
ways. As trans-ε-viniferin acts as a negative allosteric modulator at all three subtypes of 
GABAA receptors, in order to increase the selectivity, analogues of this compound 
should be designed and, in addition to being tested on GABAA receptors, should again 
be tested in animal models. 
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1.  Introduction 
1.1.  Overview of natural products drug discovery 
Compounds derived from natural sources such as plants, animals, and microorganisms, 
which possess biological activity are termed natural products [1]. These natural 
products are often secondary metabolites of the host and are thus not directly essential 
for its survival. The biological effectiveness of a large number of natural products can 
be explained by a concept known as ‘long term co-evolution’ within biological 
communities  this leads to the development of compounds from closely evolved 
interacting organisms which have influence on the biological activities of neighbouring 
species.  Considering the similar physiology of human and other mammals, it is quite 
conceivable that these compounds will be biologically active in humans as well [2, 3]. 
Another important attribute of natural products is their ability to interact with multiple 
targets because of their complex structures and biosynthetic pathways, which are 
usually a result of a wide range of enzymatic processes. For example, the biosynthesis 
of the flavone quercetin involves at least three synthetase enzymes, with different 
structures and molecular binding pockets, yet the core structure of quercetin with 
inherited diverse binding groups, is able to interact with all of them [4]. 
 
1.2.  Natural products as a source of lead compounds in drug discovery 
Natural products have played an important role in the treatment and prevention of 
human diseases for thousands of years [5] and a large fraction of the drugs in current 
pharmacopoeia is either sourced from or inspired by natural products. In fact, at least 
25-50% of current marketed drugs originate from natural products [6] and it has been 
reported that 49% of the 877 small molecule new chemical entities (NCEs) introduced 
in the market during the period 1981-2002 are natural products, semi-synthetic natural 
product analogues, or synthetic compounds based on natural product pharmacophores 
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[7]. During the period 2005-2007, 13 natural products and natural product derived drugs 
were approved, 5 of which (the peptides exenatide and ziconotide and the small 
molecules ixabepilone, retapamulin, and trabectedin) are the first members of new drug 
classes. The importance of natural products in drug discovery is further supported by 
the fact that 6 of 27 (22%) drugs launched in 2005, 2 of 21 (9%) in 2006, and 5 of 21 
(24%) in 2007 are natural products or are derived from natural products [8]. Recent 
analysis shows that, from January 2008 to December 2013, 25 natural products and 
natural product derived drugs have been approved for marketing. Among these, 5 are 
classified as natural products (NPs), 10 as semi-synthetic natural products (SS NPs), 
and 10 as natural products derived. Of these 25 marketed drugs, 12 represent new 
human dug classes; romidepsin, fingolimod (lead: myricocin), eribulin (halichondrin B), 
mifamurtide (muramyl dipeptide), fidaxomicin, spinosad (spinosyn), brentuximab 
vedotin (dolatsatin), ingenol mebutate, dapagliozin (phlorizin), omacetaxine 
mepesuccinate, carfilzomib (epoxomicin), and ado-trastuzumab emtansine (maytansine) 
[9]. 
 
Analysis of recently approved drugs with natural product origins revealed that they 
cover a wide range of therapeutic areas including anti-cancer, anti-infective, anti-
diabetic, and others. Natural products show great diversity in their chemical structures; 
an analysis of recently approved drugs from natural product origins show that half of 
them are in close compliance with Lipinski’s rule of five for orally available 
compounds. Others have higher molecular weight, more rotatable bonds, and more 
stereogenic centres but, regardless of all other characteristics, most of the natural 
products have a low log P value. Although an increase in log P can often yield a greater 
affinity for the molecular target, this tends to be outweighed by physico-chemical/ 
pharmacokinetic parameters such as solubility, permeability, plasma protein binding, 
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metabolic turnover, and toxicity [10]. In general, natural products are more readily 
absorbed than synthetic drugs [11]. 
 
In spite of many advantages over synthetic compounds and the successful history of 
natural products as a source of new drug molecules, many large pharmaceutical 
companies decreased natural product drug discovery research in the 1990s and early 
2000s. The reasons associated for this decline in natural product research included; the 
perceived disadvantages of natural products (including access and supply difficulties), 
the complexity of natural product chemistry, the inherent slowness of working with 
natural products, and concerns regarding intellectual property [12-14]. In addition, at 
that time there was increasing focus upon the speed of high throughput screening (HTS) 
in testing compounds for biological activity and combinatorial chemistry was 
considered to be a better approach for the generation of libraries for drug like molecules 
to support HTS campaigns [15, 16].  
 
Despite the high expectations for drug discovery based upon combinatorial chemistry, 
only one de novo new chemical entity, the anti-tumour drug sorafenib 1 (Nexavar), has 
been approved during the period 1981-2006 [17].  
 
 
In recent decades, the decline in natural product research in the pharmaceutical industry 
is thus mainly due to the lack of compatibility of natural products extract libraries with 
high throughput screening. However, recent developments in natural product research, 
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along with unrealized expectations from present lead-generation strategies, have led to 
renewed interest in natural product drug discovery [18]. 
 
1.3.  Medicinal plants as a source of lead compounds in drug discovery 
The use of plants as medicinal agents was first recorded at least 60,000 years ago [19] 
but plant based therapeutics play an important role in current healthcare systems and 
their use in different cultures is extensively documented [20, 21]. In 1985, the World 
Health Organization (WHO) reported that, in developing countries, 65% of the 
population use plant based therapeutics as their primary means of health care. In 
developed countries, these therapeutics play an indirect, but important role  [22].   
Apart from traditional uses, plants act as a source of drugs for the treatment of various 
diseases in modern medicine. One of the approaches in plant based drug discovery is to 
exploit their ethnomedical uses. Several drugs in current use have been obtained by 
using this approach, Figure 1, including;  
• khellin 2, which was isolated from Ammi visnaga (L) Lamk. and led to the 
development of cromolyn (in the form of sodium cromoglycate) 3 for the 
treatment of asthma, and the anti-arrythmic drug amiodarone 4, 
• galegine 5, which was isolated from Galega officinalis L., and was the basis for 
the development of metformin 6 and other bisguanidine-type antidiabetic drugs, 
• papaverine 7 which was isolated from Papaver somniferum and was the basis 
for the development of verapamil 8, an antihypertensive drug [19].  
• Other examples include the discovery and development of antimalarial drug 
quinine 9, which was isolated from the Cinchona species, particularly Cinchona 
officinalis, and artemisinin 10 isolated from Artemisia annua. 
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During the period of 2000-2005, five new drugs were approved for the treatment of 
different diseases which originate from plants including; apomorphine 11 an analogue 
of morphine which is isolated from Papaver somniferum, for the treatment of 
Parkinson’s disease. Tiotropium bromide 12, a derivative of atropine which is isolated 
from Atropa belladonna, is used for the treatment of bronchospasms related to chronic 
obstructive pulmonary disease (COPD). Nitisinone 13 is a derivative of leptospermone, 
an important new class of herbicides from Callistemon citrinus, used in the treatment of 
hereditary tyrosinaemia type 1 (HT-1). Galantamine hydrochloride 14 isolated from 
Galanthus nivalis was approved for the treatment of Alzheimer’s disease, while 
arteether 15, Figure 2,  is an antimalarial drug developed from artemisinin 10 [23]. 
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Figure 1:  Drugs developed from plants based upon their ethnomedical uses. 
 
  
 
Figure 2:  Drugs developed from natural products. 
 
Plants have been in use for the treatment of cancer for a long time [24]. The well-known 
clinically used anticancer drugs, vinblastine 16 and vincristine 17 isolated were isolated 
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from the rosy periwinkle (Catharanthus roseus). Paclitaxel (18) (Taxol
®
), Figure 3, is 
the most common plant-derived anticancer drug in current use  its use  for the 
treatment of ovarian cancer was approved by the FDA in 1992, and it was approved for 
the treatment of breast cancer in 1994. Paclitaxel was originally isolated from the leaves 
of the Pacific Yew (Taxus brevifolia). Docetaxel 19 was the first semi-synthetic 
derivative of paclitaxel to be approved for clinical use [25]. 
 
 
Figure 3:  Clinically used plant derived anticancer drugs. 
 
The role of plants in drug discovery would not be complete without a mention of the 
story of aspirin 20, one of the most widely used drugs in history, Figure 4. Aspirin was 
launched in 1897 by Bayer Company, but plant extracts rich in salicylates had been 
used since Egyptian times for the treatment of fever and other diseases [26]. Around 
1763, Reverend Stone, an English clergyman, undertook a clinical trial on the extracts 
of white willow bark, which was then in use for the treatment of aches and pains, fever, 
and chills. He administered willow bark extracts to 50 patients suffering from fever and 
found them to be effective. During the early nineteenth century, French, Italian, and 
German chemists tried to isolate the active principle but the crude substance obtained 
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was no more efficacious than the raw material due to a lack of chemical purity. In 1853, 
a French chemist, Charles Frederic Gerhardt, prepared acetylsalicylic acid by heating 
the willow bark extracts with acetyl chloride but the structure of this semi-synthetic 
derivative was not determined and this compound was thus ignored as a potential drug 
[27]. The synthesis and structural elucidation of salicylic acid 21, Figure 4 was 
performed by Kolbe in 1860, while Hoffmann synthesized acetyl salicylic acid 
(Aspirin), which was patented by the Bayer Company in 1899 [28]. 
 
Figure 4: Analgesic and antipyretic drugs developed from willow 
(Salicaceae). 
 
1.4.  Plant-derived drugs in the treatment of neurological disorders 
There is a high prevalence of neurological disorders, including Alzheimer’s disease 
(AD), Parkinson’s disease (PD), migraine, epilepsy, multiple sclerosis, anxiety, 
depression etc., and it has been reported that both mental and neurological disorders 
constitute 12% of total disability adjusted life years (DALYs) lost. The projected burden 
from these disorders will be increased by 15% by the year 2020 [29]. Some of the 
earliest drugs for the treatment of pain and central nervous system disorders were 
derived from plants, including morphine 22 from Papaver somniferum, cocaine  23 
from Erythroxylon coca, and physostigmine 24 from Physostigma venenosum [30]. 
 
In addition to the earliest drugs, a significant number of plant-derived drugs are in use, 
or in clinical trials, for the treatment of various neurological disorders. Galantamine 14, 
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isolated from Galanthus woronowii (Snowdrop) is an approved drug for the treatment 
of mild to moderate dementia in Alzheimer’s disease [31]. (-)-Phenserine 25, a 
derivative of physostigmine, showed some success in Phase II clinical trials for the 
treatment of Alzheimer’s disease but in phase III trial, the effect was not different from 
placebo and subsequently abandoned from further development [32, 33], while a 
physostigmine analogue, rivastigmine  26, is the only approved drug for the treatment of 
mild to moderate dementia in AD and PD [31]. The indole alkaloid vincamine 27 
isolated from Vinca minor (Lesser Periwinkle) and its synthetic derivative, vinpocetine 
28, Figure 5,  are reported to improve short term memory [34].  
 
There are many plant-derived drugs in different stages of clinical trial for the treatment 
of various neurological disorders. RS-1259 29, which contains structural features 
resembling both rivastigmine  26 and fluoxetine (Prozac) 30 inhibits both acetylcholine 
esterase (AChE) and the serotonin transporter, in vitro and ex vivo,  improved cognitive 
impairment in spatial short term memory tests in rats [35]. Huperzine-A 31, isolated 
from Huperzia serrata, completed phase II clinical trials for the treatment of AD [36]. 
Morphine6-glucoronide 34, a mammalian metabolite of morphine, completed phase III 
clinical trials, and in a successful trial, it has been found to be as effective as morphine, 
but with reduced side effects [36, 37]. Lobeline 32, isolated from various Lobelia 
species, completed phase II trials for the treatment of methamphetamine addiction and 
attention deficit hyperactive disorder (ADHD) [38, 39]. Dexanabinol 33 completed 
phase III clinical trials for traumatic brain injury, and there was not any significance 
difference between drug and placebo group, as per extended Glasgow outcome scale. 
However, dexanabinol was not associated with hepatic, renal, or cardiac toxic effects 
[40]. NGX-4010 35, a synthetic trans-capsaicin in a dermal delivery system, completed 
phase III clinical trials for the treatment of post-herpetic neuralgia and HIV-related 
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neuropathic pain with positive results [41, 42]. Cogane (P58, PYM-50028) 36 is derived 
from a plant known as Asian tonic and completed phase II clinical trials for the 
treatment of AD- and PD-type dementia, and had no beneficial effects. ZT-1  37,  
Figure 6,  a Schiff’s base prodrug of huperzine-A completed phase II clinical trial for 
the treatment of AD [29].  
 
The search for new drugs for the treatment neurological disorders actually began in the 
19
th
 century but, studies on plants with antipsychotic effects are very few in numbers. 
Although the efficacy of plant based therapy has been proven in pre-clinical and clinical 
trials, there have been relatively few concentrated efforts towards the discovery of novel 
compounds for the treatment of neurological disorders. As with the discovery of natural 
anticancer agents, a concentrated effort to discover plant-derived drugs is necessary for 
the treatment of different neurological disorders [43].  
 
 
Figure 5: Plant-derived drugs used in the treatment of neurological 
disorders. 
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Figure 6: Plant-derived drugs in different stages of clinical trials for the 
treatment of neurological disorders. 
 
1.5.  Centella asiatica    
1.5.1.  Overview 
 
Centella asiatica L. belongs to the family Apiaceae and has been is in use as a 
medicinal plant for centuries. It is also known as Hydrocotyle asiatica, Indian 
pennywort, Brahmi, and thankuni.  The use of this plant as an herbal remedy, along with 
various other therapeutic applications, has been well documented in South East Asia 
and India for hundreds of years. In fact, this plant is positioned between traditional and 
modern, scientifically-oriented  medicine [44].  
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1.5.2.  Botanical description 
 
Centella asiatica is the most common species among 50 different species of the genus 
Centella  it is distributed in both tropical and subtropical regions of the world, 
including Southeast Asia, Sri Lanka, Australia, parts of China, the Western South Sea 
Islands, Madagascar, South Africa, Southeast USA, Mexico, Venezuela, Columbia, and 
Eastern parts of South America. All the remaining species grow in South Africa [44, 
45].  
 
C. asiatica is a faintly aromatic, stoloniferous, perennial creeping herb that reaches  
heights up to 15 cm (6 inches) [46]. The flower of this plant is light violet in colour and 
flowering time is between August and September. The leaf size is variable, and the 
petioles are generally 5-10 in number, longer than the lamina, which is 10-40 mm long 
and 20-40 mm wide. The width of the petioles may sometimes reach 70 mm. The 
petioles of leaves arise like rosettes from a node and the individual rosettes are 
connected through narrow aerial stolons. The leaves (usually 2 to 5 cm in diameter) are 
thin and soft, with palmate nervation, and are hairless or only have a few hairs. The 
fruits (2 to 5 fruits in each umbel) are brownish-grey, enclosed in a pericarp having 1-2 
cm large elliptical bracts [44, 46, 47]. Centella asiatica grows in moist land, at an 
altitude 0 - 2500 meters above sea level [44]. 
 
  
 
Figure 7:  Centella asiatica (Adapted from Singh et al., 2010) 
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1.5.3.  Centella asiatica and its uses in traditional medicine 
 
Centella asiatica is widely used as a traditional medicine in Ayurveda, the Indian 
system of traditional medicine, and the traditional medicine systems of other South 
Asian countries. In Ayurveda, it is used for the treatment of headache, body ache, 
insanity, asthma, leprosy, ulcers, eczema, and wound healing. It is also used for the 
alleviation of anxiety related symptoms, and to aid relaxation and mental calmness 
during meditation [48-51].  In Bangladesh, the whole plant is used in the treatment of 
dysentery, asthma, dog bites, itching, malaria, leucorrhoea, tumour, and wounds. In 
Nepal, leaf juice, crushed leaf, and root extracts are used for the treatment of 
indigestion, leprosy, poor memory, and rheumatism, while in China, Centella asiatica is 
used for the treatment of dysentery, vomiting, jaundice, scabies, leprosy, urinary 
difficulties, measles, and tuberculosis. In Malaysia, it is used as an antihypertensive, 
detoxicant, diuretic, cardio-depressant, and sedative [52, 53].  
 
Apart from these traditional uses, Centella asiatica has been reported to exhibit various 
biological activities including; wound healing [54, 55], beneficial effects in scar 
management [56], anti-cancer activity [57, 58], beneficial effects in the treatment of 
ulcerations and eczema [59], antioxidant activity [60], antibacterial and antifungal 
activity [61], healing effects in acetic acid-induced gastric ulcers [62], anti-nociceptive 
effects [63], inhibition of inducible nitric oxide synthase (iNOS) in gastric ulcers [64], 
and inhibitory effects on the growth of SVK-14 keratinocytes [65]. 
 
As with crude extracts, compounds isolated from Centella asiatica have also been 
reported to possess various pharmacological effects. Asiaticoside 38, Figure 9, a 
pentacyclic triterpene saponin from Centella asiatica, has been reported to exert a range 
of pharmacological activities, which include wound healing.  
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The underlying mechanism for the wound healing effect has been studied by different 
research groups, and it has been shown that asiaticoside; increases type I collagen 
synthesis through activation of transforming growth factor beta (TGF-β) receptor I 
kinase (TβRI-kinase) [66, 67], reduces  TGF-β1 expression,  induces Smad7 expression 
[68], increases fibroblast proliferation and synthesis of the extracellular matrix, and up-
regulates 54 genes in human fibroblasts which are known to be associated with cell 
proliferation, cell cycle progession, and the synthesis of the extracellular matrix [67, 
69]. Asiaticoside 38 has also been reported to alleviate adriamycin-induced nephropathy 
in rats [70], to have immunomodulatory, anti-inflammatory, and antiviral activity [70], 
to have antipyretic and anti-inflammatory effects in lipopolysaccharide-treated rats [71], 
to promote the healing of acetic acid-induced gastric ulcers [62], and to inhibit of 
collagen-induced arthritis in mice [72]. 
 
Madecassoside 39, Figure 9, is the most abundant triterpene saponin in Centella 
asiatica. It is widely prescribed as the crude drug, for the treatment of wound and scar 
management, in Southeast Asia and China [73]. Previous studies have revealed that it 
has a range of biological activities, which include anti-inflammatory and antioxidant 
activity  [73], protective effects against oxidative stress in HUVEC cells [74], the 
alleviation of inflammatory responses in collagen-induced rheumatoid arthritis in mice 
[73, 75], protective effects against reperfusion injury (both in vitro and in vivo) [76, 77], 
cardio-protective effects in LPS-mediated sepsis (through the inhibition of TNF-α both 
in vitro and in vivo) [78], and induction of apoptosis in keloid fibroblasts as a result of 
effects on a mitochondrial pathway [79]. 
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Asiatic acid  40, Figure 9, is the aglycone of asiaticoside, which has been reported for 
numerous pharmacological effects, including; anti-nociceptive and anti-inflammatory 
activity [80], the attenuation of high fat diet-induced hyperlipidemia, hepatic steatosis, 
and epididymal fat deposit [81], protection against ethanol-induced liver toxicity [82], 
protection against galactosamine/lipopolysaccharide (D-GalN/LPS)-induced liver 
toxicity [83], beneficial effects in scar management through the inhibition of TGF-β1-
induced collagen, and plasminogen activator inhibitor-1 (PAI-1) expression [56], 
antidiabetic and antihyperlipidemic activity in streptozocin-induced diabetic rats [84]. 
 
Madecassic acid 41 is the aglycone of madecassoside 39. Both madecassoside and 
madecassic acid have been reported to have anti-inflammatory activity. Madecassic acid 
was found to be more potent than madecassoside as an anti-inflammatory agent on LPS-
induced RAW 264.7 murine macrophage cells as a result of its inhibition of 
inflammatory mediators (inducible nitric oxide synthase (iNOS), cyclooxygenase 2 
(COX-2), tumour necrosis factor α (TNF-α), IL-1β, and IL-6) and down regulation of 
NF-κB activation [85]. Madecassic acid 56 has also been reported to stimulate collagen 
I synthesis in human fibroblasts [86]. 
 
1.5.4.  Centella asiatica and its uses in the treatment of neurological disorders 
 
Centella asiatica is a psychoactive medicinal plant that has been in use for centuries in 
the Indian Ayurvedic system of medicine for the treatment of anxiety, the alleviation of 
depression-related symptoms, and the improvement of learning and memory [87, 88] 
[89]. Apart from its traditional uses as a memory enhancer, it has been reported to 
improve the memory and the general mental ability of mentally retarded children [90]. 
Centella asiatica has also been reported to have protective effects against colchicine-
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induced memory impairment in rats [91], to lead to improvements in pentylenetetrazole 
(PTZ)-induced learning deficits [90], to lead to improvements in learning and memory 
[92], to attenuate d-galactose-induced memory impairment in mice [93], to inhibit α-
synuclein aggregation (an important etiological factor in Parkinson’s disease) [94], to 
inhibit acetylcholinesterase and butyrylcholinesterase, important enzymes in the 
pathogenesis of Alzheimer’s disease [95, 96], to inhibit tyrosinase, a key enzyme in the 
pathogenesis of Parkinson’s disease [96], to increase learning ability and memory 
retention power in rats [97], and to lead to a significant reduction of both amyloid β 1–
40 and 1–42 in PSAPP mice [98]. In some small clinical trials, including both males and 
females, administration of Centella asiatica was found to have cognition enhancing 
effects [99-101].  
 
The anxiolytic effects of Centella asiatica have also been supported by pharmacological 
studies; methanolic extracts had anxiolytic-like effects in acutely stressed animals, [102, 
103],  while the attenuation of anxiety related disorders and a reduction in stress have 
been observed after the treatment of generalized anxiety disorder in 33 volunteers (18 
males, 15 females) with a 70% ethanolic extract of Centella asiatica [104]. Moreover, it 
has been reported that the titrated extracts of Centella asiatica had similar effects to 
diazepam, on stress-induced change in physiological markers (e.g. corticosterone and 
body weight) and their involvement of GABAergic mechanisms [105]. In a double 
blind, placebo controlled trial on 40 healthy subjects (20 drug group, 20 placebo 
groups), administration of Centella asiatica (12 g single dose, which was prepared by 
blending of 24, 500 mg capsule of powdered Centella asiatica, with grape juice) 
reduced the peak acoustic startle response (ASR) after 30 and 60 minutes of 
administration, thus indicating the anxiolytic effects of this plant [106].  
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Investigation of the effects of the aqueous extract of Centella asiatica on the GABA 
metabolising enzymes, glutamic acid decarboxylase (GAD) and γ-aminobutyric acid 
transaminase (GABA-T), revealed that the extract stimulated GAD activity by over 40% 
[107]. Which particular component(s) of Centella asiatica extracts is (are) responsible 
for this activity has not been reported. Moreover, no studies have been published on the 
activity of Centella asiatica or any of its constituents on the different subtypes of 
GABAA receptor. 
 
The pure compounds which have been isolated from Centella asiatica have also been 
found to be effective in the treatment of various neurological disorders. For example, 
asiaticoside  38 and its derivatives have been patented for the enhancement of cognition 
and the treatment of dementia [108]. Asiaticoside 38 also found to be effective in the 
treatment of various neurological disorders, with reported anti-anxiety and 
antidepressant effects in male mice using various behavioural tests (splash, tail 
suspension, and forced swimming tests) [102, 109].  
 
Asiaticoside 38 (at a concentration of 1 μM) afford protection against the amyloid beta 
(Aβ) and H2O2-induced death of B103 cells [110], and to lead to an improvement in the 
learning and memory ability in six month old senescence-accelerated prone (SAMP8) 
male mice, through a reduction in both  the amount and deposition of  the Aβ peptide. It 
has also been found to  increase the level of acetylcholine, while decreasing the effect 
acetylcholinesterase [111], and to lead to the attenuation of transient bilateral common 
carotid artery occlusion (tBCCAO)-induced memory deficits in mice by reducing 
microglial activation, inhibiting the gene expression of cytokines related to 
inflammation, and down- regulating the activation of the P38, AMPK pathway [112]. 
Finally, treatment with asiaticoside also results in the attenuation of  1-methyl-4-phenyl-
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1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism, by increasing dopamine and 
glutathione (GSH) levels, and reducing malonyldialdehyde (MDA) levels in the 
striatum in rat brain [113]. 
 
Asiatic acid 40 has been reported to attenuate H2O2 or rotenone (an inhibitor of 
mitochondrial complex I that ultimately leads to apoptosis)-induced toxicity in SH-
5YSY neuronal cells [114], and to have neuroprotective effects both in vitro and in vivo 
[115], as a result of protective effects against Glu- and Aβ-induced neurotoxicity [116] 
[117]. It has also been found that treatment with asiatic acid led to an improvement in 
learning and memory in monosodium glutamate (MSG)-induced dementia in mice 
[118].  
 
Madecassoside 39 has been reported to exhibit protective effect against ischemia-
reperfusion (I/R) injury in cerebral neurons in male rats by reducing the infarct volume, 
apoptosis of neurons, level of both malondialdehyde (MDA) and nitric oxide (NO), and 
increasing superoxide dismutase (SOD) effect, and the level of pro-inflammatory 
mediators (IL1β/6 and TNF-α) [119].  It has also been reported to play an important role 
in the treatment of Alzheimer’s disease by protecting neural cells against Aβ25–35 
induced autophagosomes, through class III PI3K/Beclin-1/BCl-2 pathway [120]. The 
MPTP-induced early Parkinson’s signs in male rats [121], and improvement of d-
galactose induced impairment in learning and memory has also been reported for this 
molecule [122].  
 
1.5.5.  Major compounds isolated from Centella asiatica 
 
Various research groups have reported the isolation and identification of natural 
products from Centella asiatica and more than 70 compounds, including triterpene 
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saponins, polyacetylenes, flavones, sterols, essential oils, and lipids have documented 
[123]. The pentacyclic triterpenoids, because of their widespread biological activities, 
are the most important constituents,  isolated from this plant [124]. 
 
1.5.5.1. Triterpenoid saponins 
 
The group of natural products which comprise an isoprenoidal aglycone covalently 
linked to one or more sugar groups (glycone) are termed the saponins [125]. Most 
saponins are the secondary metabolites of plants but some are derived from marine 
animals such as the sea cucumber (Holothuroidea) [126], and starfish (Asteroides) 
[127].  In plants, these compounds are considered to be part of the natural defence 
system because of their anti-microbial, antifungal, allelopathic, insecticidal, and 
molluscicidal effects [128]. 
The biosynthesis of triterpenes (which consist of 6 isoprene units) in Centella asiatica 
involves four different steps;  
 The formation of isopentenyl diphosphate (IPP), followed by one of two 
pathways; the mevalonic acid or 1-deoxyxylose pathway [129],  
 The association of isoprene units to form the (C5)n isoprenoid backbone, 
 The third step is the formation of the carbon skeletons as a result of the 
cyclization of the isoprenoid backbone, and 
  Finally, hydroxylation and oxidation result in the generation of the individual 
triterpenoids, Figure 8  [130, 131].  
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Figure 8: Biosynthesis of triterpenoids in C. asiatica [Adapted from [45]] 
FPP: Farnesyl pyrophosphate; FPS: Farnesyl pyrophosphate 
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synthase; IPP: Isopentyl diphosphate; DMAPP: dimethylallyl 
diphosphate; , SQS: Squalene synthase; SQE: Squalene epoxide; 
OSC: Oxidosqualene cyclase; α/β-AS: α/β amyrin synthase. 
 
The ursane type pentacyclic triterpenoids, also known as centelloids, which include 
asiaticoside 38, madecassoside 39, asiatic acid 40, and madecassic acid 41, because of 
their versatile pharmacological effects, are the most important and abundant triterpenes 
isolated from different parts of C. asiatica. Other triterpenoids isolated from this plant 
include asiaticosides C 42, D 43, E 44, and F 45; centellasaponins B 46, C 47; 
isothankunic acid 48; oleanane type saponins, e.g. terminolic acid 49; and 
centellasaponin D 50, Figure 9 [44, 45, 132]. The list of triterpenes isolated from 
Centella asiatica are summarized in Table 1 and their structures are shown in Figure 9. 
 
 
Figure 9: General structures of the triterpenoids isolated from Centella 
asiatica. For ursane (R6 = R7 = methyl), for oleanane (R7 = R8 = 
methyl), and the double bonds are present at C12-C13, C13-C18, and 
C20-C21. 
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Table 1: List of triterpenoids isolated from Centella asiatica [Adapted 
from [45, 132, 133] 
Compounds Name  R1 R2 R3 R4 R5 R6 R7 R8 R9 C=C 
Asiaticoside  38 OH OH CH3 CH2OH H CH3 CH3 H COO-glc (1-6) 
glc (1-4) rha 
12-13 
Madecassoside  39 OH OH CH3 CH2OH OH CH3 CH3 H COO-glc (1-6) 
glc (1-4) rha 
12-13 
Asiatic acid  40 OH OH CH3 CH2OH H CH3 CH3 H COOH 12-13 
Madecassic acid  41 OH OH CH3 CH2OH OH CH3 CH3 H COOH 12-13 
Asiaticoside C  42 OH OH CH3 CH2OAc H CH3 CH3 H COO-glc (1-6) 
glc (1-4) rha 
12-13 
Asiaticoside D  43 OH OH CH3 CH3 H CH3 CH3 H COO-glc (1-6) 
glc(1-4) rha 
12-13 
Asiaticoside E  44 OH OH CH3 CH2OH H CH3 CH3 H COO-glc (1-6) 
glc 
12-13 
Asiaticoside F 45 H OH CH3 CH2OH H CH3 CH3 H COO-glc (1-6) 
glc(1-4) rha 
12-13 
Centellasaponin B  
46 
OH OH CH3 CH2OH OH CH3 CH3 H COO-glc (1-6) 
glc 
12-13 
Centellasaponin C  
47 
OH OH CH3 CH3 OH CH3 CH3 H COO-glc (1-6) 
glc(1-4) rha 
12-13 
Isothankunic acid   
48 
H OH H CH2OH OH CH3 CH3 H COOH 12-13 
Terminolic acid  49 OH OH CH3 CH2OH OH H CH3 CH3 COOH 12-13 
Centellasaponin D  
50 
H OH CH3 CH2OH OH H CH3 CH3 COO-glc (1-6) 
glc (1-4) rha 
13-18 
Methyl asiatate 51 OH OH CH3 CH2OH H CH3 CH3 H COOCH3  
Methyl brahmate  52 OH OC
H3 
CH3 CH2OH OH CH3 CH3 H COOCH3 12-13 
Brahmol 53 OH OH CH3 CH2OH OH CH3 CH3 H CH2OH 12-13 
Arabinoside 54  OH O-
L-
Ara 
CH3 CH2OH OH CH3 CH3 H COOH 12-13 
Isothankuniside  55  H OH H CH2OH OH CH3 CH3 H COO-glc (1-6) 
glc (1-4) rha 
12-13 
Madasiatic acid 56 OH OH CH3 CH3 OH CH3 CH3 H COOH 12-13 
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Apart from the above mentioned triterpenoids, two dammarane type triterpenoids, 
namely the centellosides A 68 and B  69, along with two new compounds ginsenoside 
Mc 70 and Y 71, have been isolated, Figure 10  [134]. 
Scheffuroside B  57 OH OH CH3 CH2OH H CH3 CH3 H COO-glc (1-6) 
glc (1-4) rha 
20-21 
2α,3β,23-trihydroxy-
urs-20-en-28-oic 
Acid  58 
OH OH CH3 CH2OH H CH3 CH3 H COOH 20-21 
2α,3β,20,23 
tetrahydroxy-urs-en-
28-oic 
Acid 59 
OH OH CH3 CH2OH H CH3 CH3 OH COOH 20-21 
2α,3β,23-trihydroxy-
urs-12-en-28-oic 
Acid  60  
OH OH CH3 CH2OH H H CH3 CH3 COOH 12-13 
3β,6β,23-trihydroxy-
olean-12-en-28-oic 
Acid  61  
H OH CH3 CH2OH OH H CH3 CH3 COOH 12-13 
Asiaticoside B  62  OH OH CH3 CH2OH OH H CH3 CH3 COO-glc (1-6) 
glc (1-4) rha 
 
Centellasapogenol A  
63  
OH OH CH3 CH2OH H H CH3 CH3 COOH 13-18 
Centellasaponin A 
64 
OH OH CH3 CH2OH H H CH3 CH3 COO-glc (1-6) 
glc (1-4) rha 
13-18 
Asiatcoside G  65 OH OH CH3 CH2OH H CH3 CH3 OH COO-glc (1-6) 
glc (1-4) rha 
12-13 
23-O-acetyl 
madecassoside  66 
OH OH CH3 CH2OAc OH CH3 CH3 H COO-glc (1-6) 
glc (1-4) rha 
12-13 
23-O 
acetylasiaticoside 
B 67 
OH OH CH3 CH2OAc OH H CH3 CH3 COO-glc (1-6) 
glc (1-4) rha 
12-13 
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Figure 10:  Structure of dammarane monodesmosides isolated from Centella 
asiatica [134]. 
 
1.5.5.2.  Flavonoids and cinnamates isolated from Centella asiatica 
 
Although flavonoids are not the major components of Centella asiatica, their isolation 
has been reported by a number of research groups, for example Nheim et al., 2011 
reported the isolation of kaempferol 72, quercetin  73, isoquercetin 74, and astragalin  
75 [132].  
 
Other compounds isolated from different parts of the plant Centella asiatica include 
3,4-di-O-caffeoylquinic acid 76, 1,5-di-O-caffeoylquinic acid 77, 3,5-di-O-caffeoyl 
quinic acid  78, and 4,5-di-O-caffeoylquinic acid 79, Figure 11 [135, 136].  
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Figure 11:  Structures of flavonoids, isolated from Centella asiatica. 
 
1.6.  Overview of Passiflora incarnata 
 
Passiflora incarnata L., commonly known as passionflower, maypop, or marcuja, 
belongs to the family Passifloraceae. The genus Passiflora L. consists of around 520 
species, most of which  are vines and commonly found in Central or South America, 
North America, Southeast Asia, and Australia [137].  
 
Passiflora incarnata  is recorded and described as the first passionflower in the mid-16
th
 
century. Among all the reported species of the genus Passiflora, Passiflora incarnata L. 
and  Passiflora edulis Sims have been the most widely investigated with regards to their 
chemical composition and biological activities [138]. Of these two, Passiflora incarnata 
L. is the most extensively used herbal drug in the current Western phytotherapy, for its 
sedative and anxiolytic activity; it is usually used alone, or in combination with other 
known sedative constituents (such as valerian, hawthorn, and kava kava) [138-140]. 
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Because of its extensive clinical applications, Passiflora incarnata  has been included as 
an official plant in the pharmacopoeias of many countries, including Great Britain, 
United States, India, France, Egypt, Germany, and Switzerland [141]. 
 
1.6.1.  Botanical Description 
 
Passiflora incarnata is an herbaceous, evergreen, perennial climbing vine that grows 
rapidly up to 6 m (ca. 20 feet) [142, 143]. The individual shoots of the plant are up to 10 
m long, sometimes with huge branching. Additional shoots are often developed from 
hypocotyls, underground roots, and rhizomes [144].  
 
The passionflower leafing period is December to January, while the plant is in flower 
from June to July and the seeds ripen from September to November. Leaves are 
alternate, marked by two deciduous stipules. The petioles of the leaves are up to 8 cm in 
length, having two sessile nectaries close to the base of the laminae. Flowers bloom on 
peduncles which are up to 10 cm in length. The flower has 5 petals and 5 sepals, which 
are purplish to whitish, similar, and alternating. The flower has 3 styles, typically 3 
stamens, and 5 greenish-white sepals with terminal appendages. The fruits are ovoid or 
subglobose, up to 7 cm in length having 3-6 longitudinal sutures. At the beginning, the 
fruits are smooth, green in colour and when they mature they become wrinkled and 
yellowish to red in colour [143, 144]. 
 
1.6.2.  Passiflora incarnata and its uses as traditional medicine 
 
The use of Passiflora incarnata dates back to 8000 to 2000 B.C. while the Spanish 
learned about passionflower from the pre-Columbian people who used to use this plant 
as sedative for the treatment of insomnia and nervousness [145]. Passiflora incarnata 
was thus introduced into Europe, where it was extensively cultivated and incorporated 
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as a phytotherapy in traditional medicine. It has since been used in European traditional 
medicine for the treatment of different ailments, including; anxiety, nervousness, 
constipation, dyspepsia, mild infections, and insomnia. Passiflora incarnata has been 
used for disparate indications in different countries, for example, in Poland, the plant is 
used in the treatment of hysteria and neurasthenia [146, 147], while in Turkey, 
passionflower is used in the treatment of dysmenorrhoea, epilepsy, insomnia, neurosis, 
and neuralgia [146].  In North America, it also has different uses; in Mexico, it is used 
for the management of insomnia, and anxiety or nervousness [148], while in the US, it 
is used for the treatment of diarrhoea, premenstrual syndrome, dysmenorrhoea, 
neuralgia, burns, haemorrhoids, insomnia, muscle cramps, hysteria, neuralgia, and as a 
pain reliever for various conditions.  For example, the Cherokees use passionflower, in 
particular tea from the root of the plant, as a tonic for the liver and for skin boils [141].  
In addition to Europe and America, passionflower is also used in traditional medicine in 
other parts of the world; in Asia, it has been used to treat morphine addiction, insomnia, 
anxiety, and hypertension in the Indian system of traditional medicine [149]. In 
Australia, meanwhile, the plant is cultivated and used for the treatment of anxiety and 
insomnia [147]. 
 
1.6.3.  Use of Passiflora incarnata in neurological disorders 
Passiflora incarnata is an important traditional medicine for the treatment of anxiety, 
insomnia, and seizures [150]. The traditional uses of this plant have been supported by 
many pharmacological studies and clinical trials, and the extracts have been tested in 
many pre-clinical experiments, although their the mode of action is still under debate 
[143].  
The anxiolytic effects of different parts and extracts of passionflower have been 
reported by numerous research groups. For example, a benzoflavone moiety from the 
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methanolic fraction has been reported to have significant anti-anxiety activity in an 
elevated plus maze test [151]. In another study, the same authors reported that the 
methanolic extracts of different parts of passionflower possess significant anti-anxiety 
effect but the root extracts did not show any anxiolytic activity,  suggesting decreased 
levels of active constituents in this part of the plant [152]. Ethanolic extracts (at a dose 
of 375 mg/kg) of passionflower were shown to exerted  anxiolytic-like responses in 
mice in the elevated plus maze model [153].  
Though most pharmacological studies support the traditional claims for the anxiolytic 
effects of passionflower, a study conducted by Elsas et al., 2010 contradicted these 
claims. These researchers examined five different extracts of passionflower, which were 
tested in the elevated plus maze test for their anxiolytic effects. Surprisingly, all of them 
were found to be anxiogenic rather anxiolytic, although these results may be due to the 
result of a lower baseline of anxiety levels in the animals used in comparison to other 
studies [154]. 
 
A study on mechanism of action of passionflower extracts revealed that their anxiolytic 
activity is associated with effects on GABAA receptors. The anxiolytic effect of an 
ethanolic extracts was found to be antagonised by the GABAA / benzodiazepine receptor 
antagonist, flumazenil, but not by the specific 5HT1A receptor antagonist, WAY-
100635, indicating that the anxiolytic effect of passionflower extracts is mediated 
through the GABAergic system [155]. These findings are not in agreement with the 
results of Appel et al., 2011.  From the results of the Grundmann et al., 2009 study, it 
could be assumed that, as the anxiolytic effect of passionflower is inhibited by 
flumazenil, they must share the same pharmacology, i.e. interaction with the 
benzodiazepine binding site. The data from the Appel et al., 2011 study, however, 
suggested that the passionflower extracts interacts with the GABA binding site of 
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GABAA receptors, not with the benzodiazepine binding site.  It has also been suggested 
that the anxiolytic effects of passionflower may be a result of binding to GABAB 
receptors [156].  
 
Individual compounds from passionflower have also been screened for their anxiolytic 
activities; for example, the anxiolytic activity of the flavonoid chrysin has been tested in 
rats.  Chrysin had similar effect to midazolam, but with decreased magnitude (based on 
the length of time mice stayed in the open arm in the elevated plus maze test) [157]. In a 
comparison of the anxiolytic effects of apigenin and chrysin, chrysin (but not apigenin) 
was found to exert an anxiolytic effect at a dose of 1 mg/kg in rats [158]. In addition to 
these pre-clinical studies, some clinical studies have been conducted to assess the 
anxiolytic effects of Passiflora incarnata. In a randomized, double blind trial on 36 
outpatients diagnosed with generalized anxiety disorder (GAD), administration of 
passionflower extracts (45 drops each day of Passipay
TM
, Iran Darouk Pharmaceutical 
Company, Iran) was found to be as effective as oxazepam for the treatment of GAD 
[159]. 
 
In a randomized, double blind, placebo-controlled clinical trial on 60 patients (aged 
between 25-55 years) undergoing spinal anaesthesia, the effect of passionflower extracts 
on hemodynamics parameters,  the State-Trait Anxiety Inventory (STAI) and sedation 
scores, and psychomotor functions was analysed. It was found that oral administration 
of aqueous extracts of Passiflora incarnata (700 mg/5 mL) reduced the elevated levels 
of anxiety prior to spinal anaesthesia, while the extracts did not have any effect on 
hemodynamic parameters,  sedation score or psychomotor functions [160]. 
 
Page | 31  
 
In a double blind, placebo-controlled repeated design study on 41 subjects (male 14, 
females 27) suffering from primary insomnia. The dried parts of Passiflora incarnata 
were administered in a teabag, with each teabag containing 2 g of dried leaves, stems, 
seeds, and flowers, and a 2 g parsley tea bag acting as a placebo. It was found that the 
participants receiving the passionflower tea had significant improvements in their sleep 
quality compared to the placebo, but there were no significant changes in the 
polysomnography parameters. [161]. 
 
A substantial amount of the literature mentions the use of passionflower for the 
management of amphetamine-, nicotine-, cannabis-, ethanol-, and benzodiazepine-
induced addictive behaviour [162]. In a randomized, double blind trial on 65 outpatients 
with opiate addiction, the administration of 60 drops of passionflower, along with 
clonidine was been found to be an effective adjuvant for the treatment of opiate 
withdrawal symptoms [163].  
 
1.6.4.  Compounds isolated from Passiflora incarnata 
The aerial parts of passionflower contain flavonoids, maltol, cyanogenic glycosides, and 
indole alkaloids [164, 165]. Flavonoids components of Passiflora incarnata, comprising 
2.5% of the total constituents of the plant. These compounds are used for 
standardization purposes for  extracts from passionflower; for example, according to the 
European Pharmacopoeia, the extracts has to contain at least 1.5% of flavonoids [164].   
 
1.6.4.1.  Flavonoids 
Flavonoids are the most extensively studied plant secondary metabolites and are 
common to all higher plants [166]  so far more than 6,000 flavonoids have been 
identified from different sources. Flavonoids are derived from phenols and are 
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composed of two carbocyclic aromatic rings (C6), one of which is fused to a pyran ring 
(OC3). The classification of flavonoids is based upon the extent of the oxidation of the 
C3 unit, and they are grouped into flavones, flavonols, flavanols, anthocyanins, and 
condensed tannins [166, 167]. 
 
 
1.6.4.1.1.  Flavonoids isolated from Passiflora incarnata 
The flavonoids and flavonoid glycosides present in passionflower are shown in Figure 
12 [164].  
 
 
glc: β-D-ribofuranosyl, soph: sophorose, ara: α-L-arabinopyranosyl, rib: β-D-
ribofuranosyl. 
Compound R
1
 R
2
 R
3
 R
4
 
Apigenin 80 H H H H 
Vitexin  81 H H H glc 
Isovitexin  82 H Glc H H 
Orientin  83 OH H H glc 
Isovitexin 2''-O-β-D glucopyranoside  84 H soph H H 
Isoorientin  85 OH Glc H H 
Isoorientin- 2''-O-β-D glucopyranoside  86 OH soph H H 
Schaftoside  87 H Glc H ara 
Isoschaftoside  88 H Ara H glc 
Lucenin-2   89 OH Glc H glc 
Vicenin-2  90 H Glc H glc 
Apigenin -6-C-glucosyl-8-β-D-ribofuranosyl 
91 
H Glc H rib 
Swertisin 92 H Glc CH3 H 
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Figure 12: Structures of flavonoids isolated from Passiflora incarnata. 
[Adapted from [164]. 
 
1.6.4.2. Alkaloids 
Passiflora incarnata has been reported to contain indole alkaloids with a β-carboline 
ring system in their structures, including harman 94, harmol 95, harmine  96, harmalol  
97, and harmaline  98, Figure 13 [141].  
 
 
 
Figure 13:  Indole alkaloids isolated from Passiflora incarnata. 
 
1.6.4.3. Others compounds isolated from Passiflora incarnata 
Apart from the flavonoids and indole alkaloids, other compounds which have been 
reported from passionflower include γ-benzopyrone derivative maltol, sucrose, essential 
oil containing hexanol (1.4%), benzyl alcohol (4.1%), linalool (3.2%), and a cyanogenic 
glycoside gynocardin [168-170].  
 
Page | 34  
 
1.7.  Vitis vinifera overview 
 
Vitis vinifera L. is the most widely cultivated species among the 60 different species of 
the genus Vitis, it is also known as grapevine, grape, and European grapes. Grapes are 
assumed to be the World’s largest fruit crop, and are consumed in various forms, 
including the fresh fruit, wine, grape juice, and other processed products [171, 172]. 
Vitis vinifera is a perennial woody vine, climbing with tendrils, native to southern 
Europe and Western Asia. Different parts of the plant have been given various trade 
names, for example grape seed extract and grape seed [172].   
                                                                                                                                                                                                                                                                                                                                                                                                                                    
1.7.1.  Vitis vinifera and its uses 
 
Different preparations, used in folk medicine, have been obtained from different parts of 
Vitis vinifera, particularly from the fruits  [173]. In Anatolia, an infusion from the leaves 
of red grapevine varieties is used for blood clotting and in the treatment of diarrhoea. 
The fresh leaves are used externally for wound healing and the treatment of abscesses 
[174], while the leaves are used for the treatment of jaundice, and as a tonic, in 
traditional Turkish medicine [175]. In the Ayurvedic system of traditional medicine, the 
leaves, grapes, and seeds are used as a diuretic, for soothing the digestive tract, for the 
improvement of circulation, to help control swelling and bleeding, for relief from 
constipation and diarrhoea, and for cooling and detoxifying the body [175-178].  
 
In different pharmacological studies, grape seed extracts have been reported to have 
antioxidant and free radical scavenging activity, antimicrobial activity [179-182], and to 
induce endothelium-dependent relaxation of rat aorta [183]. In rats, grape seed tannins 
possess significant anti-hypercholesterolemic effects as a result of the reversal of 
cholesterol transfer, reduction in intestinal cholesterol absorption, and enhancement of 
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the excretion of bile acid [184]. Grape seed polyphenols relax blood vessels by 
activating the protein kinase B/phosphoinositide-3 (PKB/PI3) kinase signalling pathway 
[185], decreases acetaminophen-induced hepatic DNA damage, liver cell death, and 
neutralize acetaminophen-induced changes in B- cell lymphoma extra-large (bcl-XL) 
expression, in mice at a dose of 100 mg/kg [186]. At a dose of 50 mg/kg, these 
polyphenols protect the liver against oxidative damage after bile duct ligation by 
inhibiting neutrophil infiltration and lipid peroxidation [187]. 
 
1.7.2.  Use of Vitis vinifera in the treatment of CNS disorders 
 
Grape seed extracts have been reported to reduce free radical-induced lipid peroxidation 
and hypoxic ischemia-induced brain injury in neonatal rats (dose 50 mg/kg) [188]. They 
have also been reported to have neuroprotective effects against transient forebrain 
ischemia-induced  neuronal injury in the gerbil hippocampus (at a dose of 60 mg/kg) 
[189], to inhibit the accumulation of age-related oxidative DNA damage in spinal and 
different brain regions, and to enhance the memory performance and to lead to a 
reduction in the production of reactive oxygen species (at a dose of 100 mg/kg)  [190, 
191]. 
At a dose of 75 mg/kg, administration of proanthocaynidin for a period of 9 weeks, 
enhanced antioxidant defence mechanisms through the attenuation of lipid peroxidation 
and protein oxidation in the rat brain. Further experiments on the cholinergic system 
revealed that proanthocaynidin moderately inhibits the enzyme acetylcholine esterase 
(AChE), thereby indicating its role in the enhancement of cognition in older rats [192]. 
Resveratrol 110, at a concentration of 5 μg/μL, improved memory formation and the 
induction of long term potentiation (LTP) in cornuammonis 1 (CA1) region of 
hippocampus of 8-9 month old mice. Further studies have revealed that the observed 
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cognition enhancing effect is associated with a reduction in microRNA (miR-134 and 
miR-124) expression, the subsequent up-regulation of cAMP response element-binding 
protein (CREB), and the synthesis of brain-derived neurotropic factor (BDNF) [193]. 
Resveratrol has also been reported to inhibit the GABA current in GABAC receptors 
expressed in Xenopus laevis oocytes [194]. 
 
1.7.3.  Compounds isolated from Vitis vinifera 
Grape seed and skin are the good sources of a range of phytochemicals which include 
flavonoids, polyphenols, anthocyanin, and stilbene derivatives. 
 
1.7.3.1. Flavonoids 
Grape seed contains 4-5% of flavonoids, which include kaempferol-3-O-glucosides 99, 
quercetin 73, quercetin 3-O-glucoside 74, and myricetin  100, Figure 14. 
 
1.7.3.2. Polyphenols 
Vitis vinifera is a rich source of phenolic compounds and about 60-70% of these are 
found in the seeds of this plant. The polyphenols in grape are mainly derivatives of 
flavan-3-ol and include (+)-catechin 101, (-)-epicatechin 102, (-)-epicatechin 3-O-
gallate 103, isorhamnetin 104, laricitrin 105, syringetin 106, quercetin 3-O-(6′′- 
rhamnosyl)-glucoside  107, procyanidin B1 108, and gallic acid 109, Figure 14   [195-
197]. 
 
1.7.3.3. Anthocyanins 
Anthocyanins which have been isolated from Vitis vinifera  include the 3-glucosides, 3-
acetylglucosides, 3-coumaroylglucosides, 3-caffeoylglucosides, 3,5-diglucosides, 3-
acetyl-5-diglucosides, 3-coumaroyl-5-diglucosides, and 3-caffeoyl-5-diglucosides of 
cyanidin, delphinidin, peonidin, petunidin, and malvidin [198]. 
Page | 37  
 
1.7.3.4. Stilbenes 
The isolation of stilbenes and their derivatives has been reported from Vitis vinifera. 
These include; resveratrol (both E and Z resveratrol) 110, trans-ε-viniferin 111, ε-vitisin 
B 112,  pallidol 113, E-astringin 114, Figure 15  [199-203]. 
 
 
Figure 14:  Flavonoids and polyphenols isolated from Vitis vinifera. 
 
Page | 38  
 
 
 
 
Figure 15:  Polyphenols and stilbenes isolated from Vitis vinifera. 
 
 
1.8.  GABA receptor overview 
 
γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central 
nervous system (CNS), and GABAergic neurons constitute 17-20% of all neurons in the 
brain [204]. GABA exerts its effect through three major types of receptors, which have 
been grouped as GABAA, GABAB, and GABAC (GABA ρ) based on their subunit 
composition, gating properties, and pharmacological profiles. GABAA and GABAC are 
ligand gated ion channel receptors (LGICs), whereas GABAB are G-protein coupled 
receptors [205, 206].  
 
In the brain, inhibitory neurotransmission from GABAergic system controls excitatory 
neurotransmission and entrainment of oscillatory activities.  
Enhancement of GABAergic inhibition is the basis of the therapeutic action of the 
benzodiazepine class of drugs, which are used for the treatment of generalized anxiety 
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disorders, anxiety disorders, panic anxiety, sleep disturbances, and epilepsy [207]. 
Moreover, GABA receptors are important therapeutic targets for the treatment of 
depression, cognitive deficits, myopia, nociceptive disorders, and schizophrenia [208-
212].  
 
1.8.1. GABAA receptor overview 
 
GABAA receptors are the major inhibitory receptors in the central nervous system 
(CNS) which belong to the family of cys-loop receptors. These receptors mediate both 
rapid phasic inhibition, through synaptic transmission, and tonic inhibition, through 
extrasynaptic and perisynaptic transmission. Because of their widespread location, 
GABAA receptors play a versatile role in all the functions of brain and thus have 
become the targets for different classes of therapeutic agents. Figure 16 depicts the 
GABAergic synapse in mammalian brain [213].  
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Figure 16: The GABAergic synapse in the mammalian brain. The synthesis 
of GABA from glutamate is catalyzed by glutamic acid 
decarboxylase (GAD). GABA is then transported to vesicles by 
vesicular GABA transporter (vGAT). After sufficient 
depolarization of the presynaptic terminal, GABA vesicles are 
released into the cleft and diffuse rapidly to activate the 
postsynaptic GABAA receptors. GABA is taken from the synaptic 
cleft by, for example, the GAT-1 transporter on presynaptic 
terminals. The GABAA receptor is a GABA gated Cl
-
 and HCO3
-
 
channel.  Adapted from [214]. 
 
1.8.1.1.  GABAA receptor subunits, their distribution and function 
GABAA receptors are membrane bound pentameric chloride selective ion channels 
which are composed mainly of α, β, and γ subunits. There are 19 genes for GABAA 
receptors, which include 19 subunits (α1-6, β1-3, γ1-3, δ, ɛ, θ, π, ρ1-3), and are assembled to 
give the different subtypes of GABAA receptor [215]. The different combinations of 
receptor subunits results in variations in the biophysical and pharmacological properties 
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of the receptors. Most importantly, agonist affinity, receptor kinetics, and sensitivity to 
a variety of clinically important drugs, including benzodiazepines and general 
anaesthetics, are determined by the composition of subunits [216, 217]. For example, 
receptors that are composed of α1-3, α5, γ2, and β2 or β3 are sensitive to the 
benzodiazepines, whereas receptors composed of α4 or α6 or δ instead of γ2 are not 
sensitive to this class of drugs [218]. Simple changes in the receptor subunit 
combinations can lead to dramatically different activities; for example, receptors 
containing α1β2γ2 mediate the sedative and anticonvulsant effects of diazepam, α2βγ2 and 
α3βγ2 containing receptors are responsible for the anxiolytic and muscle relaxing effects 
of this drug, and α5βγ2 may mediate learning and memory processes [219]. 
 
1.8.1.2.  GABAA receptor structure 
Like other members of the ligand-gated ion channels (LGICs) receptor family, GABAA 
receptors consist of five protein subunits arranged around a central pore which 
constitutes the actual ion channel. Each subunit of the GABAA receptor contains a large 
N-terminal domain, of around 200 amino acids, which incorporates part of the agonist / 
antagonist binding site, Figure 17, and N-terminal domain is shaped by a cysteine 
disulphide bridge (the so called cys-loop). Each subunit is completed by four membrane 
spanning domains (M1-4), consisting of around 20 amino acids, an intracellular loop of 
variable length between M3 and M4, and a short extracellular C-terminal. Each of the 
subunits are arranged in such a way that second membrane spanning domain (M2) 
forms the lining of the channel for the transport of Cl
-
 ions [220].  
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A. 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
Figure 17: A. General structure of one of the five protein subunits, showing 
the four transmembrane domains (M1-M4); B. Pentameric 
arrangement of the protein subunits, showing the second 
membrane spanning domains (M2) lining the pore of the ion 
channel. Adapted from [221]. 
 
1.8.1.3.  GABAA receptor binding sites for different ligands 
 
The activation or inhibition of GABAA receptors occurs through the GABA binding site 
as well as through allosteric modulation by benzodiazepines, barbiturates, steroids, 
 NH
2
 
COOH 
    
 
 
 
M1 M2 M3 M4 
  
Cys-cys 
 
M2
β1
α1
γ2
α1
β2
Page | 43  
 
anaesthetics, convulsants and many other agents. In 1996, Johnston et al., proposed that 
there are at least 11 different structure-specific binding sites on GABAA receptors, 
which include; 
 agonist sites, also recognize competitive antagonists,  
 picrotoxinin sites, also interact with γ-butyrolactones, caprolactams, and some 
insecticides, 
 sedative-hypnotic, barbiturate sites, 
 neuroactive steroid sites, 
 benzodiazepine sites, 
 ethanol sites, 
 stereoselective sites for inhaled anaesthetics 
 furosemide sites, 
 sites for Zn2+ ions, 
 sites for other divalent cations, and 
 sites for La3+ ions [222]. 
 
1.8.1.3.1.  GABAA receptor binding sites for GABA 
 
Mutagenesis studies on recombinant GABAA receptors have revealed that some of the 
amino acids on both α and β subunits are important for the binding of GABA 114 and 
muscimol  115, leading to the conclusion that GABA binding sites on GABAA receptors 
are located at the interface of α and β subunits. 
Studies on recombinant GABAA receptors have also demonstrated that the current 
agonists or antagonists lack selectivity for the different subtypes, thus accounting for 
their associated side effects. However, some ligands, such as THIP (4,5,6,7-
tetrahydroisoxazolo [5, 4-c] pyridin-3-ol) is a partial agonists at the GABA binding site, 
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were found to have some subtype-dependent efficacy and potency. For example, THIP  
116, Figure 18,  is approximately 10 times more potent at α4β3δ than at α4β3γ2S receptors 
and its analgesic activity is comparable to that of morphine [223, 224]. 
 
Figure 18:  Agonists acting at GABAA receptors. 
 
1.8.1.3.2.  GABAA receptor binding sites for benzodiazepines 
Benzodiazepines, such as diazepam 117, are the most widely used drugs as 
anticonvulsants, muscle relaxants, sedative-hypnotics, and anxiolytics; they act by 
increasing the effect of GABA on GABAA receptors through allosteric modulation (they 
increase the frequency of GABA-induced opening of the chloride channels or result in a 
longer channel opening time).  Identification of some of the amino acids on the α and γ2 
subunits, which are necessary for the interaction of benzodiazepines (and compounds 
which act at benzodiazepine binding sites) has revealed that these drugs interact at the 
interface of the α and γ2 subunits [225]. Further studies have revealed that the amino 
acids residues H101, Y159, G200, T206, and Y209 on the α1 subunit, and F77 and 
M130 on the γ2 subunit, are important for the formation of the ligand binding pocket at 
the benzodiazepine binding site [226].  
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1.8.1.3.3.  Compounds acting at the benzodiazepine binding site of GABAA 
 receptors 
Different classes of compounds interact at the benzodiazepine binding site of GABAA 
receptors, resulting either in an increase or decrease in the effect of GABA-induced 
current; based on the nature of their effects, these are classified as allosteric agonists, 
inverse agonists, and allosteric antagonists. Compounds which increase the effect of 
GABA are known as allosteric agonists (also known as Positive Allosteric Modulators, 
PAMs), and their activities include; anxiolytic, anticonvulsant, muscle relaxant, and 
sedative-hypnotic. Compounds that reduce the GABA-induced current are known as 
inverse agonists (also known as Negative Allosteric Modulators, NAMs), and their 
activities include; anxiogenic, pre-convulsant, enhancement of vigilance, and an 
increase learning and memory. The third class of compounds do not exert any effects of 
their own, but prevent the interaction of agonists and inverse agonists, and are known as 
allosteric antagonists.  In addition to these classifications, some compounds which have 
weak agonist or antagonist effects are known as partial agonists or partial inverse 
agonists. The effect of a compound as an agonist or inverse agonist is subtype 
dependent; for example, a compound may exert an agonistic effect on one subtype, but 
elicit an antagonistic response in another subtype of GABAA receptors [225, 227]. 
 
1.8.1.3.4.  GABAA receptor binding sites for steroids 
 
Neurosteroids, such as alphaxalone 118, allopregnanolone 119, tetrahydrodeoxy-
corticosterone 120, Figure 19, are potent endogenous modulators of GABAA receptors. 
At low nanomolar concentrations, these compounds increase GABA-induced chloride 
conductance, but at higher concentrations (>1 μM), they act in the same way as the 
barbiturates and result in the direct opening of the GABA-associated chloride channel. 
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These findings have been taken as evidence of the presence of two different 
neurosteroid binding sites on GABAA receptors [228]. 
 
 
Figure 19:  Steroid derivatives acting at GABAA receptors. 
 
Steroids have been shown to enhance both [
3
H]-muscimol and [
3
H]-flunitrazepam 
binding and to reduce the allosteric binding of [
35
S]-TBPS. It has also been found that 
the interaction with GABAA receptors is not competitive with barbiturate binding. 
These results, thus, suggest that the binding site of steroids on GABAA receptors is 
different to that of GABA, the benzodiazepines, the barbiturates, and TPBS [227, 228].   
 
There is a strict structural requirements for steroids interaction at GABAA receptors, 
which is evident from the direct activation of GABAA receptors by (−)-
allopregnanolone but not by its enantiomer (+)-allopregnanolone. The presence of 
specific steroid binding sites for steroids is also evident from the interaction of the 
synthetic steroid, 3α,5α-17-phenylandrost-16-en-3-ol (17-PA) 121 with the GABAA 
receptor. 17-PA is a competitive inhibitor of the binding of (-)-allopregnanolone and did 
not affect the GABA-induced activation of the receptor and its modulation by 
benzodiazepines and barbiturates. It has also been reported that the steroid binding site 
is located in the receptor transmembrane domain.  [229].  
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By considering all the studies on steroid binding sites and the interaction of 
neurosteroids with GABAA receptors, Hosie et al., 2007 concluded that there are 3 to 4 
discrete binding sites for steroids on human  GABAA receptors, including a potentiating 
site (αQ241-αN407/αY410), an activating site (αT236-βY284), and at least 1 (possibly 
2) other(s) for the inhibitory sulfated steroids. They also suggested that the binding site 
of the inhibitory steroids may involve the M1 and/or M2 domains [230]. 
1.8.1.3.5.  GABAA receptor binding sites for flavonoids 
Flavonoids are structurally related phenyl benzopyrones which have been reported for 
the effects on both the peripheral and central nervous system [231]. Recent studies 
involving the rat (or bovine) brain membrane-binding assay have revealed the selective 
binding affinity of flavonoids at the benzodiazepine binding site of GABAA receptors 
[232, 233].  
 
Although other studies [232, 233] have confirmed the binding of flavonoids at the 
benzodiazepine binding site, recent studies on 6-methylflavone indicate that its effect is 
not mediated via the high affinity benzodiazepine binding site [231]. 
 
Several naturally occurring and synthetic flavonoids, such as apigenin 80, chrysin 93, 
genistein 122, hispidulin 123, wogonin  124, (3S)-(-)-3-(4ʹ-hydroxyphenyl)chroman-7-
ol, Figure 20, 125, 4'-hydroxy-7-methoxyisoflavone  126, 3',7-dihydroxyisoflavone 127,  
Figure 21, 6-bromoflavone  128, 6,3'-dinitroflavone  129, 6-bromo-3'- nitroflavone  130, 
Figure 22, 6-methylflavone  131, and 2'-methoxy-6-methylflavone 132, Figure 23,  have 
been reported to exhibit effects on GABAA receptors [234].  
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Figure 20: Some naturally occurring flavonoids that have been reported to 
influence the activation of GABAA receptors [234]. 
 
 
Figure 21: Some naturally occurring flavonoids that displace diazepam 
binding [234]. 
 
Figure 22:  Some synthetic flavonoids that displace diazepam binding [234]. 
 
Figure 23: Some synthetic flavonoids that have been reported to result in 
subtype-specific activation of GABAA receptors [234]. 
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1.8.1.3.6.  GABAA receptor binding sites for divalent cations 
 
Divalent cations modulate different ligand-gated ion channels, including GABAA 
receptors. Zinc and copper, which are released during synaptic activity, have been found 
to be important in synaptic transmission [235]. It has been found that the inhibition of 
GABA-induced current by zinc depends upon the particular α subunit present in the 
GABAA receptor; for example, α6β3γ2L receptors are more sensitive to inhibition by zinc 
than α1β3γ2L receptors. Further studies have revealed that H273 of the α6 subunit is an 
important determinant for the sensitivity of recombinant GABAA receptors to divalent 
cations (zinc, cadmium, and nickel, but not copper). It has also been suggested that the 
N-terminal domain of the α1 subunit provides the regulatory site(s) [236]. Moreover, the 
subunit composition of the receptor is important; a receptor containing the αβγ motif is 
less sensitive to Zn
2+ 
inhibition than one containing αβδ. In particular, the γ2L subunit 
has been found to be less sensitive to inhibition by Zn
2+
 [236].  
 
1.8.2.  GABAA receptors in cognition and memory 
 
Long term potentiation (LTP), a form of neuronal plasticity at glutamatergic synapses, 
is considered as to be a basis for learning and memory and GABAergic inhibition has 
been found to impede this plasticity [237]. Low doses of picrotoxinin (a non-
competitive antagonist, blocking both synaptic and extra-synaptic GABAA receptors) 
were reported to alleviate deficit in memory in a  mouse model of Alzheimer’s disease 
[238]. Further studies on GABAA receptors and their association with cognition and 
memory have revealed that the reduction of α5-GABAA receptors in mice is associated 
with an increase in associative learning, in the form of fear conditioning, a 
hippocampal-dependent memory task. The selective reduction of α5-GABAA receptors 
in hippocampal pyramidal neurons, by a point mutation at position 105 of α5 subunit 
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(H105R), led to an improvement in learning performance [239, 240]. The involvement 
of α5-GABAA receptors in cognition and memory is further supported by 
pharmacological studies  it has been found that the inverse agonist or negative 
allosteric modulators which are selective at the α5 subunit increased the learning 
performance of rats in the Morris water maze test, without any adverse convulsive 
effects [241]. Although, data in humans is very limited, α5IA, an inverse agonist at α5-
GABAA receptors has been shown to reduce ethanol-induced amnesia in healthy 
volunteers [242]. 
 
The distribution pattern of α5 subunits in the brain is both limited and unique; α5 
containing GABAA receptors represent only 5% of the total GABAA receptors but, this 
rises to 20% of all GABAA receptors in the hippocampus. The involvement of α5-
containing GABAA receptors in cognition and memory, and their unique distribution 
pattern, makes them attractive targets for the development of memory enhancing drugs 
[243]. 
 
1.8.3.  GABAB receptors 
 
GABAB receptors are the metabotropic receptors for GABA, the main inhibitory 
neurotransmitter in the brain. In 1979, Bowery and his colleagues reported the existence 
of this GABA receptor while studying the release of [
3
H]-noradrenaline from rat atria. 
Later studies of (RS)-4-amino-3-(4-chlorophenyl) butanoic acid (baclofen) as a GABA 
agonist and the binding of [
3
H]-baclofen confirmed the presence of GABAB receptors 
[244, 245]. These receptors exist as heterodimers of two subunits; GABAB (1) and 
GABAB (2), where GABAB (1) is responsible for binding with GABA, and GABAB (2) is 
associated with G-protein coupling and subsequent signalling [245].  
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1.8.3.1.  GABAB receptors ligands 
 
Baclofen 133 was the first agonist of GABAB  receptors to be discovered and other 
potent agonists, which include 3-aminopropyl phosphinic acid 134 and its methyl 
derivative 135, Figure 24, were developed based on its structure. These compounds 
were not, however, selective in terms of their pharmacological effects.  
 
Figure 24:  Agonists acting at GABAB  receptors. 
 
Allosteric modulators acting at GABAB receptors include CGP7930 136, CGP13501 
137, and GS39783 138; Figure 25 is devoid of the sedative and cognitive effects 
associated with baclofen, and may be effective for the treatment of anxiety. Phaclofen  
139, saclofen  140, and 2-hydroxysaclofen  141, Figure 26, are antagonists acting at 
GABAB  receptors which were developed based on the structure of baclofen [245]. 
  
Figure 25:  Allosteric modulators acting at GABAB  receptors. 
 
Figure 26:  Antagonists acting at GABAB  receptors.  
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1.8.4.  GABAC receptors 
GABAC receptors are either homooligomeric or pseudo-heterooligomeric ligand-gated 
ion channel receptors composed of ρ subunits. Five different ρ subunits (ρ1-5) have been 
identified, two of which (ρ1 and ρ2) have been cloned from humans, and three (ρ1-3) from 
rats. More than 92% sequence homology has been observed between the human and rat 
ρ subunits but, in spite of the sequence identity between the rat and human ρ2 subunits; 
unlike the human ρ2 subunit, the rat  ρ2 subunit does not form homooligomeric receptors 
in Xenopus laevis oocytes; forming heterooligomeric receptors with the rat ρ1 subunit 
instead [221, 246].  
 
Although both GABAA and GABAC receptors are ligand-gated ion channel receptors, 
with four transmembrane domains, they differ, both physiologically and 
pharmacologically, from each other. For example, GABAC receptors are more sensitive 
to GABA than GABAA receptors, while GABAC receptors are not easily desensitized 
and close slowly in comparison to GABAA receptors [221]. 
 
The ρ subunits of GABAC receptors are distributed in the retina, thalamus, 
hippocampus, pituitary gland, and gut. These receptors have been reported to elicit 
various  physiological responses, including involvement in visual processing, the 
regulation of the sleep cycle, the perception of pain, memory, learning, and the 
regulation of hormones [247, 248]. 
 
1.8.4.1.  Compounds acting at GABAC receptors 
1.8.4.1.1. GABAC receptors agonists and partial agonists 
 
Structure activity relationship (SAR) studies have revealed that GABA, TACA 142, and 
2-FTACA (2-fluoro-trans-4-aminocrotonic acid) 143 act as agonists at GABAC 
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receptors. TAMP (trans-2-(aminomethyl) cyclopropanecarboxylic acid 144, CACA  
145, I4AA (imidazole-4-acetic acid) 146, muscimol 115, isoguvacine 147, and 
homohypotaurine  148, Figure 27 were found to be partial agonists [221]. 
 
  
 
Figure 27:  Agonists and partial agonist acting at GABAC receptors.  
  
1.8.4.1.2.  Competitive GABAC receptors antagonists 
 
By incorporating a methylphosphinic or ethylphosphinic moiety, the more potent and 
selective antagonists at GABAC receptors, TPMPA 149 and TPEPA 150, Figure 28 
were developed. It has been found that TPMPA is 2 × more potent than TPEPA, 
indicating a reduction in  affinity upon addition of an alkyl group to an alkylphosphinic 
acid [221, 249].  
 
 
Figure 28: Competitive and non-competitive antagonist acting at GABAC 
receptors.  
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1.8.4.1.3. Non-competitive GABAC receptors antagonists 
Picrotoxinin 151 and t-butylbicyclophosphorothionate (TBPS) 152  Figure 28, both 
inhibit homooligomeric ρ1 GABAC receptors, but this inhibition is 30 and 250 × lower 
than that of GABAA receptors respectively [249]. 
 
1.9.  Aims of this project 
 
The traditional claims that Centella asiatica is effective in the treatment of anxiety, the 
alleviation of depression-related symptoms, and the improvement of learning and 
memory are supported by various pharmacological studies. Those studies on the 
improvement of cognition, mostly mention the effect on the cholinergic system, 
particularly the enzyme acetylcholinesterase (AChE) [87, 88, 98]. No studies have, 
however, reported the effect of this plant on the GABAergic system in terms of 
cognition and memory. A recent study by Wu et al., 2014 described the failure of 
targeting Aβ production in the management of Alzheimer’s disease, however, these 
workers found that the reduction of GABA-induced tonic inhibition recovers the 
impairment of long term potentiation and memory deficits in 5xFAD mice [250]. This 
reduction of GABA-induced tonic inhibition is thus a novel target for the management 
of Alzheimer’s disease. The effects of an aqueous extract of C. asiatica have been 
investigated on the GABA-metabolising enzymes, glutamic acid decarboxylase (GAD) 
and γ-aminobutyric acid transaminase (GABA-T), and it was found to be active in the 
stimulation of GAD [107]. Which particular component(s) of C. asiatica extract is (are) 
responsible for this activity has not been reported. Moreover, no studies have been 
published on the activity of C. asiatica, and its constituents, on the different subtypes of 
GABAA receptor. 
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In spite of numerous reports on the pharmacological effects of Passiflora incarnata  
particularly the treatment of insomnia, anxiety, and depression with passionflower 
extracts  there is no consensus on the active constituents responsible for the observed 
pharmacological effects [251]. In addition, while the involvement of the GABAergic 
system has been confirmed, to the best of our knowledge, no work has reported the 
testing of both extracts and pure compounds from P. incarnata on the different subtypes 
of GABAA receptors expressed in Xenopus laevis oocytes. 
 
ε-Viniferin glucoside, isolated from Vitis Vinifera, has been found to inhibit AChE and 
to enhance memory in older rats; it also inhibits Aβ (25-35), (1-40) and (1-42) fibril formation 
and Aβ induced toxicity of PC12 cells [252, 253]. Resveratrol, the monomer of ε-
viniferin has been reported to improve memory formation and the induction of LTP (at 
a concentration of 5 μg/μL). It has also been reported to inhibit the GABA-induced 
current in GABAC receptors expressed in Xenopus laevis oocytes [194]. No reports 
have, however, been published on the screening of both extracts and pure compounds of 
Vitis vinifera on different subtypes of GABAA receptors expressed in Xenopus laevis 
oocytes. 
 
The aims of the current project are; 
1. The extraction of Centella asiatica using solvents of different polarities and 
testing the crude extracts on different subtypes of GABAA receptors expressed 
in Xenopus laevis oocytes. 
2. The isolation and structure elucidation of compounds from Centella asiatica and 
their testing on different subtypes of GABAA receptors. 
3. The synthesis of analogues of active compounds and their testing on different 
subtypes of GABAA receptors. 
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4. The extraction, isolation, and structure elucidation of compounds from 
Passiflora incarnata and their testing on different subtypes of GABAA 
receptors.  
5. The extraction, isolation and structure elucidation of compounds from Vitis 
vinifera and their testing on different subtypes of GABAA receptors. 
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CHAPTER 2 
 
Extraction, isolation and structure elucidation of 
compounds from Centella asiatica and their testing on 
different GABAA receptor subtypes and the EA.hy926 cell 
line 
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2.  Introduction 
As mentioned in section 1.5.4, Centella asiatica is a psychoactive medicinal plant, 
which is traditionally used for the treatment of anxiety, the alleviation of depressive 
symptoms, and the enhancement of cognition and memory. These traditional claims 
have been supported by both pre-clinical [102-103] and clinical pharmacological studies 
[99-102,104,106], with some of the studies suggesting the involvement of the 
GABAergic system in the anxiolytic and anti-depressive effects. For example, in one of 
the studies, the aqueous extracts has been tested on GABA metabolising enzymes, and 
found to stimulate glutamic acid decarboxylase (GAD) activity by over 40% [107]. To 
date, however, no investigations have been reported on the effects of both the extracts 
and pure compounds on the different subtypes of GABAA receptors. 
 
As mentioned previously, the GABAergic system is the major inhibitory 
neurotransmitter system in the CNS and is an important therapeutic target for the 
treatment of various neurological disorders, including anxiety, depression, and 
schizophrenia. Of the different subtypes of GABAA receptors, α5-containing receptors 
are particularly involved in cognition and memory response, and this has been 
confirmed by both mutational and pharmacological studies. The α5-containing GABAA 
receptors have thus become an important therapeutic target for the treatment of 
cognition and memory impairment. 
 
The aims of the present study are the extraction of Centella asiatica with solvents of 
different polarities, the isolation and structure elucidation of pure compounds, and their 
testing on the different GABAA receptor subtypes. The ultimate goals are to test the 
traditional claims of memory enhancement, in terms of the effect of these compounds 
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on the GABAergic system, and to discover lead compounds for the treatment of 
cognition and memory impairment, anxiety, and depression. 
 
The extraction of the plant was performed using a Soxhlet extractor, while for the 
isolation, chromatographic (thin layer and flash column chromatography) techniques 
were employed. Structure elucidation involved 
1
H NMR, 
13
C NMR, cDEPT, gCOSY, 
gHMQC, and gHMBC spectroscopy, and mass spectrometry. For testing on receptors, 
the different subtypes of GABAA receptors were expressed in Xenopus laevis oocytes, 
and the current was measured using the two electrode voltage clamp technique. The 
testing on the EA.hy926 cell line was performed as per standard tissue culture 
techniques. 
 
2. 1.  Materials and methods 
2.1.1.  Materials for the extraction and isolation 
Petroleum ether (PE), dichloromethane (DCM), ethyl acetate (EtOAc), ethanol (EtOH), 
and all the other solvents unless otherwise stated were purchased from Chem-supply, 
Gillman, South Australia. Madecassic acid, ethylα-D-fructofuranoside (isolated from 
Centella asiatica), asiatic acid (isolated and purchased from LKT laboratories, USA), 
asiaticoside and madecassoside were purchased from LKT laboratories, USA. Silica gel 
used in column chromatography was Merck silica gel 60H, particle size 5–40 μm, 
Merck aluminium backed TLC plate pre-coated with silica gel (0.2 mm, 60 F254).  
 
2.1.2.  Instrumentation 
Nuclear magnetic resonance (
1
H NMR, 
13
C NMR, gCOSY, gHMQC, gHMBC, and 
DEPT) spectra were recorded on a 400 MHz Varian Gemini 300 spectrometer (Palo 
Alto CA, USA). Mass spectra were obtained from a Thermo Finnigan (Waltham, MA, 
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USA) Polaris Q Ion Trap system using a direct exposure probe. Melting points were 
determined using a Stuart SMP10 melting point apparatus (Stone, Staffordshire, UK). 
Ultra high performance liquid chromatography (UHPLC) was performed on a Shimadzu 
system equipped with an LC-30 AD solvent delivery system, an SPD-M30A photodiode 
array, an DGU-20ASR degassing unit, an SIL, 30 AC autosampler, and an CBM-20A 
communication bus module. Infrared (IR) spectra were recorded on Fourier Transform 
Infrared Spectrometry (IRTracer-100) equipped with single reflection ATR accessory 
(MIRacle 10), Shimadzu.  
 
2.1.3.  Extraction and isolation 
2.1.3.1. General protocol  
The whole dried plant was ground into a coarse powder and extracted with solvents of 
different polarities (from low to higher polarity) using a Soxhlet extractor. The 
following general protocol was followed for extraction and isolation of pure compounds 
from studied plants, Figure 29. 
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Collection of plant materials 
 
Identification of plant materials by expert  
Grinding the plant materials into coarse powder using a 
grinding machine 
Extraction with solvents of different polarities starting with 
PE then DCM, EtOAc and EtOH 
Crude extracts were subjected to chromatography (TLC, 
column chromatography, HPLC) and spectroscopy (NMR, 
Mass spectrophotometer, IR) for isolation, purification, and 
structural elucidation of compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: General protocol for extraction, isolation and characterization of 
compounds from plants. 
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2.1.4.  Collection and extraction of Centella asiatica  
The whole Centella asiatica was collected from Newtons Pharmacy, 119 York Street, 
Sydney, Australia, and the identification was confirmed by Dr George Li, Senior 
Lecturer, Pharmaceutical Chemistry (Herbal Medicines), Faculty of Pharmacy, 
University of Sydney, Australia. After grinding into a coarse powder, a 20 g sample was 
extracted in a Soxhlet extractor under reflux for 8 h for each solvent, using solvents 
(220 mL) of increasing polarity; petroleum ether (bp 30-60
0
C), followed by DCM (bp 
41
0
C), EtOAc (bp 77
0
C), and then EtOH (bp 78
0
C). After extraction for 8 h, the solvent 
was allowed to cool, evaporated under reduced pressure to give the crude extracts; 
petroleum ether extract (254 mg), DCM extracts (381 mg), EtOAc extracts (842 mg), 
and EtOH extracts (1.592 g). After examining the NMR spectrum, the crude extracts 
containing interesting chemical structures in appreciable amounts were subjected to 
chromatography for the isolation of pure compounds. 
 
For comparative HPLC analysis, Centella asiatica was collected from two different 
sources (dried whole plant from Newtons Pharmacy and fresh whole plant from the 
Camperdown Campus, University of Sydney, Australia). After grinding into a coarse 
powder, 3.62 g of each was extracted with EtOH (150 mL) by maceration, which was 
followed by filtration through a sintered funnel, and evaporation under reduced pressure 
to give the crude extracts (426 mg from the freshly collected plant, and 389 mg, from 
the plant purchased from Newtons Pharmacy). 
 
2.1.5.  Isolation of madecassic acid 41 
The ethyl acetate extracts (830 mg) was  adsorbed onto a small amount of silica, and the 
silica was loaded onto a column, and subjected to flash column chromatography, eluting 
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with hexane/ethyl acetate (100:0 to 0:100), then DCM/methanol (100:0 to 70:30). A 
total of 112 fractions (20 mL) were collected, and analysed by TLC; identical fractions 
were then pooled. Fractions 95-100, which had three common spots, were combined 
and the solvent was evaporated under reduced pressure to give a mixture (288 mg), 
which was subjected to flash column chromatography on silica, eluting with DCM / 
MeOH (100:0 to 0:100). A total of 90 fractions (15 mL) were collected; fractions 56-58, 
which had single spot in common, were combined, and the solvent was evaporated 
under reduced pressure to give madecassic acid 41 (41 mg), obtained as white 
amorphous powder; mp 297-301
0
C (lit.[254] mp 295-300
0
C);  
1
H NMR (400 MHz, 
DMSO-d6) δ11.89 (1H, brs, H-28), 5.13 (1H, t, J = 3.6 Hz, H-12), 3.49 (2H, m), 3.28 
(1H, d, J = 11.2 Hz, H-23
a
), 3.16 (1H, d, J = 11.2 Hz, H-23
b
), 3.04 (1H, d, J = 9.6 Hz, 
H-3), 2.08 (1H, d, J = 11.2 Hz, H-18), 1.81-1.92 (6H, m), 1.6 (1H, dd, J = 4.4, 4.4 Hz, 
H-1), 1.32-1.55 (9H, m), 1.24 (4H, m, H-25, H-19), 1.12 (1H, s), 1.01-1.05 (1H, m), 
0.96 (2 x 3H, s), 0.81-0.84 (3H, m), 0.87 (2 x 3H, s), 0.79 (3H, d, J = 6.4 Hz, H-29), 
0.64-0. 67 (2H, m); 
1
H NMR (400 MHz, DMSO-d6 + D2O) 5.09 (1H, t, J = 3.6 Hz, H-
12), 3.53 (2H,m), 3.29 (1H, d, J = 11.2 Hz, H-23
a
), 3.17 (1H, d, J = 11.2 Hz, H-23
b
), 
3.04 (1H, d, J = 9.6 Hz, H-6), 2.01 (1H, d, J = 11.2 Hz, H-18), 1.71-1.86 (3H, m), 1.68 
(1H, m, H-19), 1.29-1.54 (5H, m), 1.19 (3H, s, H-26), 1.06 (1H, s), 0.95-1.01 (1H, m), 
0.91 (3H, m), 0.83 (3H, s), 0.76-0.78 (1H, m), 0.73 (3H, d, J = 6.4 Hz, H-29), 0. 61-0.67 
(2H, m);
 13
C NMR (100 MHz, DMSO-d6) δ178.7 (quat, C-28), 138.0 (quat, C-13), 125 
.0 (CH, C-12), 76.1 (CH, C-3), 67.9 (CH, C-2), 66.3 (CH, C-6), 64.0 (CH2, C-6), 52.9 
(CH, C-9), 49.6 (CH2, C-1), 47.7 (CH, C-5), 47.3 (quat, C-17), 46.9 (CH, C-20), 43.5 
(quat, C-4), 42.6 (quat, C-14), 38.9 (CH, C-19), 38.8 (CH, C-18), 38.7 (quat, C-8), 37.3 
(quat, C-10), 36.7 (CH2, C-22), 30.6 (CH2, C-15), 27.9 (CH2, C-16),  24.3 (CH2, C-7), 
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23.8 (CH3, C-27), 23.4 (CH2, C-11), 21.5 (CH3, C-30), 18.7 (CH3, C-25), 18.5 (CH3, C-
26), 17.4 (CH3, C-29), 15.4 (CH3, C-24); ESI- MS, m/z (%) 527 (100%), [M + Na]
+
. 
It is to be mentioned here that the doublets and multiplet at δ 3.49, 3.29, 3.17, and 3.04 
ppm are visible after D2O shake. 
The structure of the compound madecassic acid was determined by comparing the 
1
H 
NMR, 
13
C NMR, cDEPT, gCOSY, gHMQC, and gHMBC spectra and mass spectrum 
with published data  [133]. 
 
2.1.6.  Identification of asiatic acid 40 
Fractions 46-50 obtained from the repeated flash column chromatography of fractions 
95-100 had two spots in common. These fractions were combined and the solvent was 
evaporated under reduced pressure to give the mixture (38 mg). This mixture was 
analysed against an asiatic acid standard by TLC, and one of the spots had same Rf 
value as asiatic acid. No further purification of this extracts was conducted. 
 
2.1.7.  Isolation of ethyl α-D-fructofuranoside 153 
The ethanol  extracts (1.387 g) was adsorbed onto a small amount of silica, and the 
silica was loaded onto the column and  subjected to flash column chromatography on 
silica, eluting with DCM/MeOH (100:0 to 0:100). A total of 72 fractions (20 mL) were 
collected, and analysed by TLC and identical fractions were combined. Fractions 41-49 
were combined and the solvent was evaporated under reduced pressure. The positive 
results obtained from testing of this fraction on GABAA receptors prompted further 
purification of these fractions. 
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Fractions 41-49 (95 mg) were subjected to flash column chromatography, eluting with 
DCM/MeOH (100:0 to 0:100). A total of 65 fractions (10 mL) were collected, analysed 
by TLC, and identical fractions were combined and the solvent was evaporated under 
reduced pressure. Fractions 29-32, which had a single common spot on TLC analysis, 
were combined and the solvent was evaporated under reduced pressure to give ethyl α-
D-fructofuranoside 153 (16 mg), as a sticky solid (16 mg);  mp 55-58
0
C ; 
1
H NMR (400 
MHz, CD3OD) δ 4.03 (1H, d, J = 4.6 Hz, H-3), 3.88 (1H, dd, J = 6.8 and 4.6 Hz, H-4), 
3.83 (1H, ddd, J = 6.8, 4.8, and 2.8 Hz, H-5),  3.75 (1H, dd, J = 12.0 Hz and 2.8 Hz, H-
6
a
), 3.56-3.69 (5H, m), 1.17 (3H, t, J = 7.2 Hz, H-2'); 
13
C NMR (100 MHz, CD3OD) 
δ107.3 (quat, C-2), 82.6 (CH, C-5), 81.63 (CH, C-3), 77.0 (CH, C-4), 61.3 (CH2, C-1), 
60.0 (CH2, C-6), 56.2 (CH2, C-1'), 14.6 (CH3, C-2'); ESI MS, m/z (%) 230 (100%) [M + 
Na]
+
. 
The structure of the compound was confirmed by comparing the 
1
H and 
13
C NMR 
spectroscopic data, and mass spectrum, with published data [255]. 
 
2.1.8. Comparative HPLC analysis of Centella asiatica from two differently 
sourced samples  
The HPLC analysis of the ethanolic extracts of Centella asiatica, obtained from two 
different sources, was conducted as per the method of Alqahtani (unpublished).  The 
column used for this analysis was a Luna, C18 (Phenomenex, 250 mm × 4.60 mm; 
particle size: 5 μ). The mobile phase was composed of A (10% acetonitrile with 0.2% 
phosphoric acid) and B (90% acetonitrile with 0.2% phosphoric acid). The gradient 
used is described in Appendix AI.1. The flow rate was 1.0 mL/min, with an injection 
volume of 10 μL. The sample was dissolved in MeOH at a concentration of 5 mg/mL, 
and then filtered through Iso-Disc 
TM
 filters (0.45 µ) before injection. 
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2. 2.   Materials and methods for tissue culture 
2.2.1.   Cell line and culture conditions 
Human cardiovascular endothelial cells (EA.hy926) were kindly provided by Dr. 
Shanhong Ling (Monash University Central Clinical School, Australia). The cells were 
cultured in Dulbecco’s Modified Eagle Medium (4500 mg/L glucose, L-glutamine, 
sodium pyruvate, and sodium bicarbonate, liquid, sterile-filtered) with 10% FBS, 
containing100 U/mL of penicillin and streptomycin (Sigma Aldrich, Australia)  and 
grown in a 5% CO2 incubator at 37
0
C as previously described [256]. 
 
2.2.2.   Cell Treatment 
Cells were seeded at a density of 1.5 × 10
5 
cells/mL and allowed to adhere and grow to 
confluence for 24-48 h. Once confluent, the cells were exposed to hydrogen peroxide 
for 20 h. To determine the protective effect of the extracts, the cells were pre-treated 
with them (final concentration of DMSO was 0.1%) for 4 h, followed by combined 
incubation with hydrogen peroxide for another 20 h. 
 
2.2.3.  3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) 
dye reduction assay 
 
The 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) dye reduction 
assay, which measures intracellular metabolism to reflect cell viability, was performed 
as previously described [256]. After 20 h of treatment with the agents indicated, MTT 
(final concentration 0.5 mg/mL) was added and incubated for 4 h at 37
0
C. After 
incubation, the supernatant was removed and the formazan crystals were dissolved in 
DMSO. The contents were transferred to a 96 well plate and the absorbance measured at 
550 nm using a microplate reader. 
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2.3.  Materials and methods for Electrophysiology 
2.3.1.  Materials  
Human α1, α2, α5, β2, β3 and γ2L DNA in pcDM8 (Invitrogen, CA, USA) were donated 
by Dr. Paul Whiting (Merck, Sharpe and Dohme Research Labs, Harlow, UK). Xenopus 
laevis were obtained from South Africa and housed in the Department of Veterinary 
Science, University of Sydney. GABA was obtained from Sigma-Aldrich Chemical Co. 
Ltd. (Castle Hill, NSW). Flumazenil and L655,708 were purchased from Tocris 
Bioscience, Minneapolis, USA. 
 
2.3.2.  Transformation of Escherichia coli 
Plasmid vectors containing α1, α2, α5, β2, β3 and γ2L human GABAA cDNA were 
transformed into ultra-competent E. coli cells (MC1061/P3-Invitrogen, USA). Aliquots 
of cells (50 μL) were combined with samples of the plasmid DNA (2.5 μL) in pre-
chilled tubes, and were incubated on ice for 30 min. The cells were then heat-shocked at 
42
0
C in a water bath for 45 sec, and then immediately replaced on ice for 2 min. 
 
The transformed cells were then incubated in 450 μL of super optimal broth with 
catabolite repression (SOC) medium, at 37
0
C with shaking (225 rpm, Labec Incushaker, 
Crown Scientific, Sydney, Australia) for 1 h. Following incubation, the cells were then 
plated on LB-agar plates containing ampicillin (25 μg/mL; Sigma-Aldrich) and 
tetracycline 10 μg/mL (Sigma-Aldrich) and incubated for at least 16 h at 370C. 
 
2.3.3.  Growth of bacterial cultures 
Single colonies were chosen from the plates, and transferred into 50 mL tubes 
containing LB broth (5 mL), ampicillin (100 μg/mL) and tetracycline (5 μL of 5 
mg/mL). Alternatively, glycerol stock solution (100 μL), prepared from previous 
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cultures (α1, α2, α5, β2, β3 and γ2L) was used for inoculation of the appropriate medium. 
The cultures were incubated for at least 15 h at 37
0
C with shaking (225 rpm). 
 
2.3.4.  Release of plasmid DNA 
DNA plasmids were released from E. coli using the Promega Wizard
®
 Plus Minipreps 
DNA purification system (Promega, Madison, WI, USA). Cells from the medium (3 
mL) were harvested by centrifugation (14000 rpm; Eppendorf Centrifuge 5417R, 
Eppendorf, Hamburg, Germany) at 25
0
C for 2 min. The supernatant was removed and 
the cells were resuspended in 200 μL cell re-suspension solution. The cells were lysed 
via the addition of 200 μL cell lysis solution. Once the solutions were clear, 200 μL cell 
neutralization solution was added and the mixture was centrifuged for 15 min at 20
0
C 
(14000 rpm). The clear supernatant, containing plasmid DNA, was filtered through 1 
mL of the Wizard minipreps DNA purification resin in a Wizard minipreps column 
under reduced pressure. The plasmid DNA selectively bound to the column and was 
then washed through the column using 2 mL column wash solution. The columns were 
centrifuged in Eppendorf tubes for 20 sec at 20
0
C (14000 rpm) then 50 μL 
diethylpyrocarbonate (DEPC) treated water was added and the mixture heated to 80
0
C. 
After allowing the microcolumns to stand for 1 min, they were centrifuged in Eppendorf 
tubes for 1 min in order to collect the eluent containing plasmid DNA. 
 
2.3.5.  Linearization of plasmid DNA 
α1, α2, α5, β2, β3 and γ2L plasmid solutions (44 μL) were incubated at 37
0
C for 2 h with 3 
μL NOT1 enzyme, 3 μL buffer (50 μM Tris-HCl (pH 7.5), 10mM MgCl2, 100 mM 
NaCl, 0.1 mg/mL BSA). 
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2.3.6.  Purification of plasmid DNA 
Linearized DNA was diluted to 200 μL with DEP-treated water and then purified by 
200 μL phenol:chloroform extraction, followed by a 200 μL chloroform wash. DNA 
was then precipitated from the solution by the addition of 2.5 volumes of cold 100% 
ethanol and 0.1 volumes of 3M sodium acetate. This mixture was cooled at -80 
0
C for a 
minimum of 40 min, and then centrifuged at 4
0
C for 20 min (14000 rpm). The 
supernatant was removed and the remaining pellet combined with 200 μL cold 70% 
ethanol and centrifuged at 4
0
C for 5 min (14000 rpm). The liquid was removed and the 
pellet was resuspended in 7 μL DEPC-treated water. 
 
2.3.7.  Synthesis of mRNA 
RNA was synthesised using a T7 mMessage mMachine kit from Ambion (Austin, TX, 
USA). Reaction buffer (2 μL), NTP/CAP nucleotide bases (10 μL) and enzyme mixture 
(2 μL) were added to linearized DNA and incubated at 370C for 1.5 h. 
 
2.3.8.   Purification of mRNA 
The mRNA mixture was diluted with 130 μL DEPC-treated water and was purified by 
phenol:chloroform extraction (150 μL), followed by a chloroform wash (150 μL). 
mRNA was then precipitated from the solution by the addition of 2.5 volumes of cold 
100% ethanol and 0.3 volumes of 5 mM ammonium acetate solution. The reaction was 
then cooled to -80
0
C for at least 40 min and centrifuged (14000 rpm) at 4
0
C for 20 min. 
The supernatant was discarded, and the pellet was washed with 70% ethanol, followed 
by centrifuging (14000 rpm) at 4
0
C for 5 min. The liquid was discarded and the pellet, 
once dry, was resuspended in nuclease free water (15 μL). 
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2.3.9.  Quantification of RNA 
The quantification of RNA was carried out by heating 2 μL RNA at 940C for 1 min, 
then running it on a 0.9% agarose electrophoresis gel containing 1 μL ethidium bromide 
(5 mg/mL) to check the integrity of the RNA. This was further quantified using a 
Thermo Scientific NanoDrop 1000 Spectrophotometer then the samples were combined 
to achieve the desired combinations and ratio of subunits. For α1β2γ2L, α2β2γ2L, and 
α5β3γ2L GABAA receptors, the RNA for each subunit was injected in the ratio 1:1:2 to 
favour incorporation of the γ subunit. The RNA was then diluted to 0.2-1 ng/nL for 
injection with ddH2O. The resultant mRNA was then stored at -20
0
C until required. 
 
2.3.10.  Preparation of oocytes from Xenopus laevis 
After surgical removal of ovarian lobes from female Xenopus laevis, they were then 
rinsed with oocyte releasing buffer 2 (OR2; 82.5 mM NaCl, 2 mM KCl, 1 mM 
MgCl2.6H2O, 5 mM HEPES, pH 7.5) and was then suspended for 2 h in collagenase (2 
mg/mL in OR2, Bohringer Manheim, Germany) for the separation of oocytes from the 
connective tissues and follicular cells. The separated oocytes were then washed several 
times with ND96 (96 mM NaCl, 2 mM KCl, 1 mM MgCl2.6H2O, 1.8 mM CaCl2, 5 mM 
HEPES, 2.5 mM sodium pyruvate, 0.5 mM theophylline, and 50 μg/mL gentamycin, pH 
7.5) buffer solution. The oocytes were then sorted under a microscope in order to obtain 
mature and healthy cells with clear animal/vegetal pole divisions and without any spots 
or markings on the surface. Before injection, the oocytes were stored in a fridge at 2-
8
0
C.  
 
2.3.11.  Injection of cRNA into Xenopus laevis oocytes 
A micropipette needle was used to inject the oocytes. An automated micropipette puller 
(PUL-100, World Precision Instruments, Inc., Sarasota, FL) was used to make the 
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micropipette needle with a tip diameter of 10-20 mm. Before nuclear injection, the 
prepared needle was filled with mineral oil and placed into a Nanoliter 2000 injector 
(World Precision Instruments, Inc.). The cRNA solution was then drawn into the needle 
using negative pressure. The nano injector was set to inject 50 nL of filled cRNA into 
the cytoplasm of the oocytes. After injection, the oocytes were stored in ND96 buffer 
solution at 18
0
C for 2-5 days and the buffer was replaced every day until recording. 
  
Two-three days after injection, the two electrode voltage clamp technique was used to 
measure the receptor activity with a Digidata 1200, Geneclamp 500 amplifier (Axon 
Instruments, Foster City, CA, USA). Microelectrodes were made by pulling glass 
capillaries (0.94 mm I.D. ×1.2 mm O.D.; Harvard Apparatus Ltd., Kent, UK) using an 
automated micropipette puller (PUL-100, World Precision Instruments, Inc.) and filled 
with 3M potassium chloride solution. Oocytes were placed in the oocyte bath chamber, 
impaled by electrodes having resistance of less than 5 MΩ (usually 0.5 to 2.0 MΩ), and 
the potential of the membrane was set at -60 mV. In the oocyte chamber, the cells were 
perfused with ND96 buffer solution. The current traces elicited due to the application of 
compounds and/or GABA was recorded using a Mac Lab 2e recorder (ADInstruments, 
Sydney, NSW, Australia) and Chart Version 5.1 program. For screening, all compounds 
were dissolved in DMSO to make the stock concentration of 100 mM. Further dilution 
was made with ND96 buffer solution. All the drug solutions were prepared at 0.8% 
DMSO concentration. Drugs were initially tested alone at a concentration of 100 μM to 
observe their effect on the different GABAA receptors. They were then tested in 
combination with either the EC10 and/or the EC50 GABA in order to observe their 
modulatory (positive or negative) effect on GABA induced current.  
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2.4.  Results and discussion  
2.4.1.  Isolation and structure elucidation of madecassic acid 41   
Repeated column chromatography of the EtOAc extracts (830 mg) led to the isolation of 
madecassic acid (41 mg) as a white powder.  
 
The electrospray ionization mass spectrum (ESI-MS) of the compound isolated from the 
ethyl acetate extracts (fractions 56-58) contained a molecular ion peak at m/z 527 
corresponding to [M+Na]
+
 for madecassic acid 41 (C30H48O6). In the 
1
H NMR 
spectrum, a broad singlet at δ11.89 corresponds to the carboxylic acid group on C-17. A 
triplet at δ 5.14 corresponds to the alkene proton (H-12). After shaking the NMR sample 
with D2O, three doublets were visible at δ 3.05, 3.18, and 3.30 ppm. The doublet at δ 
3.30 ppm, with a coupling constant of 11.2 Hz represents one of H-23 protons. In the 
13
C NMR spectrum, the peak at δ 178.7 ppm corresponds to the carboxyl carbon (-
COOH, C-28), while the signals at δ 137.9 and 124.9 ppm, correspond to the carbons at 
C-12 (=CH) and C-13 (quat).  
The cDEPT spectrum of madecassic acid confirmed the presence of 30 different carbons 
; 7 quaternary (q), 9 methine (CH), 8 methylene (CH2), and 6 methyl  (CH3). The 
1
H-
1
H 
connectivity was confirmed by a gCOSY experiment, which shows that H-12 (δ 5.13 
ppm) couples to H-11 (δ 1.9 ppm). At the same time, it shows the correlation between 
H-2 (δ 3.5 ppm) and H-3 (δ 3.04 ppm), H-1 (δ 1.7 ppm) connection to H-25 (δ 1.25 
ppm), H-18 (δ 2.1 ppm) connection to H-19 and H-29 (δ 0.8 ppm). The gCOSY 
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experiment also shows correlation between H-23
a
 (δ 3.2 ppm) and H-23b (δ 3.4 ppm).   
Using a gHMQC experiment, all 23 carbons which are attached to protons were 
identified. In a gHMBC experiment, the H-3 proton (δ 3.04 ppm) showed cross peaks to 
the quaternery carbon C-4(δC 43.4 ppm),. At the same time, the position of quaternary 
carbon C-10 (δC 37.3 ppm) was confirmed from the cross peak with the protons of H-1 
(δ 1.7 ppm). The cross peak between H-3 proton (δ 3.04 ppm) and δC 15.3 ppm 
confirmed the position of C-24.   Morover, the H-27 protons (δ 1.00 ppm) showed cross 
peaks to the quaternary carbon C-13 (δC 138 ppm). 
The structure of the compound madecassic acid was thus determined by comparing the 
1
H NMR, 
13
C NMR, cDEPT, gCOSY, gHMQC, and gHMBC spectra and mass 
spectrum with the published data  [133]. 
 
2.4.2.  Isolation and structure elucidation of asiatic acid 40   
 
Fractions 46-50 were analysed against a standard asiatic acid sample on TLC and, as the 
combined fractions and asiatic acid had the same Rf values, further purification was not 
carried out.  
 
2.4.3.  Isolation and structure elucidation of ethyl α-D-fructofuranoside 153 
 
 Repeated flash column chromatography of the EtOH extracts (1.387 g) led to the 
isolation of ethyl α-D-fructofuranoside 153, which was obtained as a sticky white solid 
(16 mg)  
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The electrospray ionization mass spectrum (ESI-MS) of the compound isolated from the 
EtOH extracts (fractions 29-32) contained a molecular ion peak at m/z 230, 
corresponding to [M+Na]
+
 for ethyl α-D-fructofuranoside 153 (C8H16O6). The chemical 
shifts of the signals in the 
1
H NMR spectrum range from 3-6 ppm, which is typical of a 
carbohydrate ring. The protons at the H-2' position resonate at δ 1.18 as a triplet (J = 7.2 
Hz), the H-3 proton position appears as a doublet at δ 4.03 (J = 4.6 Hz). In the 13C NMR 
spectrum, there were 8 peaks for the 8 carbons in the molecule; the carbon at C-2 (quat) 
resonates at δ 107.3 ppm.  
 
 
2.4.4. Comparative HPLC analysis of Centella asiatica from two differently 
sourced samples 
The HPLC chromatograms obtained for the EtOH extracts of two different sourced 
Centella asiatica samples did not show any significant difference in their chemical 
profile, except for an additional peak in freshly collected sample, with a retention time 
of 42.8 min (Appendix AI.2 and AI.3). 
 
2.4.5. Testing of extracts and pure compounds on different subtypes of 
GABAA receptors  
2.4.5.1.  Screening results of crude extracts on different subtypes of GABAA 
receptors  
 
The screening results for all the crude extracts from Centella asiatica on different 
GABAA receptors are summarised in Table 2. 
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Table 2: Screening results of crude extracts of Centella asiatica on different 
GABAA receptors 
 
Extracts alone or in 
combination with EC10 or 
EC50 GABA 
Effect on different GABAA receptor subtypes 
α1β2γ2L α2β2γ2L α5β3γ2L 
Ethanol extracts (50 µg/mL) 84.5  ±  8.1 nA 80.0  ±  12.2 nA No effect 
Ethanol extracts (50 µg/mL) 
+ EC10 GABA 
37.5 ± 7.0 % 
potentiation 
30.5 ± 10.6 % 
potentiation 
44.0  ±  5.7% 
potentiation 
Aqueous extracts (50 µg/mL) 29.0  ± 7.5 nA 22.0  ± 5.85 nA No effect 
Aqueous extracts (50 µg/mL) 
+ EC10 GABA 
29.5 ± 9.2% 
potentiation 
21.0 ± 3.2 % 
potentiation 
75.0 ± 11% 
potentiation 
Ethyl acetate extracts (50 
µg/mL) 
70.0  ±  4.0 nA 70.2  ± 12.5 nA No effect 
Ethyl acetate extracts (50 
µg/mL) + EC10 GABA 
2.51 ± 1.8% 
inhibition 
2.05 ± 0.25% 
inhibition 
11.1 ± 2.0%  
potentiation 
Dichloromethane extracts (50 
µg/mL) 
13.0  ±  4.0 nA 10.8   ±  3.0 nA No effect 
Dichloromethane extracts (50 
µg/mL) + EC10 GABA 
12.5  ±  4.9% 
potentiation 
8.50 ± 1.6% 
potentiation 
21.8  ±  3.5 % 
potentiation 
Petroleum ether extracts (50 
µg/mL) 
79.5  ±  2.9 nA 28.5  ±  2.9 nA No effect 
Petroleum ether extracts (50 
µg/mL) + EC10 GABA 
12.5  ±  4.9% 
potentiation 
9.50 ± 2.4% 
potentiation 
43.5  ±  8.6% 
potentiation 
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All the crude extracts (at a concentration of 50 µg/mL) induced direct currents at α1β2γ2L 
and α2β2γ2L receptors, when applied alone, with the greatest current induced by the 
EtOH extracts (84.5 ± 8.1 nA at α1β2γ2L, and 80.0 ± 12.2 nA at α2β2γ2L), followed by the 
PE (79.5 ± 2.9 nA at α1β2γ2L), then EtOAc extracts (70.2 ± 12.5 nA at α2β2γ2L receptors), 
Figure 30. In addition to their direct effects on GABAA receptors, all the crude extracts, 
except the EtOAc extracts, positively modulated the EC10 GABA-induced current at the 
α1β2γ2L and α2β2γ2L receptors. The greatest modulation was found for the EtOH extracts 
(37.5 ± 7.0% on α1β2γ2L, and 30.5 ± 10.0% on α2β2γ2L receptors); followed by aqueous 
extracts (29.5 ± 9.2% on α1β2γ2L and 21.0 ± 3.2% on α2β2γ2L receptors).  
 
At α5β3γ2L receptors none of the crude extracts induced a direct current when applied 
alone. However, all the extracts positively modulated the EC10 GABA-induced current, 
with the greatest modulation by the aqueous extracts (75.0 ± 11%), followed by the 
EtOH (44.0 ± 5.7%), PE (43.5 ± 8.6%), DCM (21.8 ± 3.5%), and EtOAc extracts (11.1 
± 2.0%). The large potentiation by the aqueous extracts compared to the other extracts 
may be due to the presence of GABA in this extracts, the presence of which was 
confirmed by this extracts against a standard GABA sample on thin layer 
chromatography (TLC). 
 
 
 
 
 
 
 
Page | 77  
 
 
 
 
 
 
 
 
 
 
 
Figure 30: Typical traces for the effect of EtOH and PE extracts of Centella asiatica 
on the EC10 GABA-induced current at the α1β2γ2L GABAA receptor 
subtype 
 
 
 
 
 
 
 
 
 
Figure 31: Typical traces for the effect of EtOH and aqueous extracts of Centella 
asiatica on the EC10 GABA-induced current at α2β2γ2L GABAA receptor 
subtype. 
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Figure 32: Typical traces for the effect of EtOH and aqueous extracts of 
Centella asiatica on the EC10 GABA-induced current at α5β3γ2L 
GABAA receptor subtype. 
 
2.4.5.2. Testing of pure compounds (both isolated and purchased) on different 
 subtypes of the GABAA receptor 
 
The screening results for the effects of the pure compounds from Centella asiatica  
(isolated and purchased) on different GABAA receptor subtypes are summarised in 
Table 3. 
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Table 3: Screening results of pure compounds (isolated and purchased)  from 
 Centella asiatica on different GABAA receptor subtypes 
 
The modulation of the GABA-induced current on different subtypes of GABAA 
receptors by asiatic acid and madecassic acid was investigated on human recombinant 
Compounds alone and in 
combination with EC10 and / or  
EC50 GABA 
Effect on different GABAA receptor 
subtypes 
α1β2γ2L α2β2γ2L α5β3γ2L 
Asiatic acid 40 (100  µM) No effect No effect No effect 
Asiatic acid 40 (100 µM) + EC10 
GABA 
87.1 ± 2.0% 
inhibition 
58.6 ± 0.25%  
inhibition 
81.3 ± 1.2% 
inhibition 
Madecassic acid 41 (100  µM) No effect No effect No effect 
Madecassic acid 41 (100  µM) + 
EC10 GABA 
No effect 56.2 ± 0.75%   
inhibition 
No effect 
Asiaticoside 38 (100  µM) No effect No effect 16.0  ±  2.5 
nA 
Asiaticoside 38 (100  µM) + EC10 
GABA 
36.0 ± 2.2% 
inhibition 
35.0 ± 2.2% 
inhibition 
28.5 ± 2.8 % 
inhibition 
Madecassoside 39 (100  µM)  No effect No effect No effect 
Madecassoside 39 (100  µM) + EC50 
GABA 
26.1 ± 0.29%  
inhibition  
18.8 ± 3.2 % 
inhibition 
4.12 ± 0.71% 
potentiation 
Ethylα-D-fructofuranoside 153 (100  
µM)  
No effect No effect No effect 
Ethyl α-D-fructofuranoside 153 (100  
µM) +  EC10 GABA 
22.6 ± 2.0% 
inhibition 
6.9 ± 0.25% 
inhibition 
7.42 ± 0.86% 
inhibition 
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α5β3γ2L, α1β2γ2L, and α2β2γ2L receptors. Despite the similar structures of asiatic acid 40 
and madecassic acid 41, with the only difference being an additional hydroxyl group at 
C6 of compound madecassic acid 41, there was a substantial difference in the 
modulation of GABA-induced current.  
 
 
In the initial screening, madecassic acid 41 did not show any agonistic, antagonistic, or 
modulatory effects on the α1β2γ2L or α5β3γ2L subtypes. On the contrary, asiatic acid 40 
had a pronounced negative modulatory effect on all three GABAA receptor subtypes. At 
the α5β3γ2L receptor, asiatic acid 40 inhibited the EC10 and EC50 GABA-induced current, 
by 81.3% and 70.1% respectively. The GABA EC10 and EC50 are the concentrations of 
GABA that elicited a peak current with an amplitude of 10.0% and 50.0% of the 
maximum GABA current observed with 1 mM GABA. These values were calculated 
from the dose-response curves for GABA for each subunit; for example, for the α5β3γ2L 
the EC10 was 2-4 µM and the EC50 was 20-44 µM, Figure 33A. From the dose-response 
curves, the IC50 of asiatic acid was calculated and was found to be 64µM at the α5β3γ2L 
receptor, Figure 34. Asiatic acid 40 showed a more significant negative modulatory 
effect on α1β2γ2L recptors, with an IC50 of 37µM, Figure 35.  The magnitude of the 
negative modulation of α2β2γ2L was much less than that of α1β2γ2L and α5β3γ2L, with an 
IC50 of 427µM, Figure 36. The modulation of the GABA-induced current by madecassic 
acid 41 on α2β2γ2L was similar to that of asiatic acid (IC50, 428 µM), Figure 37. 
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Figure 33: Dose-response curves, showing the effect of different GABA 
concentrations on A.  α5β3γ2L;  B. α1β2γ2L; and C. α2β2γ2L GABAA 
receptors. The data for the dose-response curves are the Mean ± SEM 
(n=3-4 oocytes). 
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Figure 34: A. Dose-response curve for the effect of asiatic acid 40 on the 
EC50 (30 μM) GABA-induced current at α5β3γ2L GABAA 
receptors. B. Typical traces for the negative modulation of the 
EC50 (30 μM) GABA-induced current by different concentrations 
of asiatic acid at α5β3γ2L receptors. The data for the dose- 
response curve are the Mean ± SEM (n=3-4 oocytes). 
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Figure 35: A. Dose-response curve, showing the effect of asiatic acid 40 on 
the EC50 (30 μM) GABA-induced current at α1β2γ2L GABAA 
receptors. B. Typical traces for the negative modulation of the 
EC50 (30 μM) GABA-induced current by different concentrations 
of asiatic acid at α1β2γ2L receptor. The data for the dose- response 
curve are the Mean ± SEM (n=3-4 oocytes). 
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Figure 36: A. Dose-response curve for the effect of asiatic acid 40 on the 
EC50 (100 μM) GABA-induced current at α2β2γ2L GABAA 
receptors. B. Typical traces for the negative modulation of EC50 
(100 μM) GABA-induced current by different concentration of 
asiatic acid at the α2β2γ2L receptor. The data for the dose- 
response curve are the Mean ± SEM (n=3-4 oocytes). 
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Figure 37: A. Dose-response curve for the effect of madecassic acid 41 on 
the EC50 (100 μM) GABA-induced current at α2β2γ2L GABAA 
receptors. B. Typical traces for the negative modulation of the 
EC50 (100 μM) GABA-induced current by different 
concentrations of madecassic acid at α2β2γ2L receptor. The data 
for the dose-response curve are the Mean ± SEM (n=3-4 
oocytes). 
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Asiaticoside 38 and madecassocide 39 (at a concentration of 100 μM) did not induce 
any current at all three subtypes of GABAA receptors, although asiaticoside did induce a 
small current (16.0 ± 2.5 nA) at α5β3γ2L receptors. However, both negatively modulated 
the EC10 GABA-induced current at all three subtypes, except for a slight positive 
modulation (4 ± 0.71 %) by madecassoside at α5β3γ2L receptors. The magnitude of the 
negative modulation was greater for asiaticoside 38 than for madecassocide 39, with the 
greatest modulation on α1β2γ2L (36.0± 2.2% inhibition), which is followed by α2β2γ2L 
(35.0 ± 2.2% inhibition). 
 
 
   
 
 
 
 
 
 
 
  
 
 
 
 
Figure 38: Typical traces for the effect of asiaticoside 38 on the EC10 and 
EC50 GABA-induced current at α1β2γ2L GABAA receptors. 
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Figure 39: Typical traces for the effect of asiaticoside 38 on the EC10 
GABA-induced current at α2β2γ2L GABAA receptors. 
 
 
  
 
 
 
 
 
 
Figure 40: Typical traces for the effect of asiaticoside 38 on the EC10 
GABA-induced current at α5β3γ2L GABAA receptors. 
 
The electrophysiological traces from the screening results of madecassoside 39 and 
ethylα-D-fructofuranoside 153 are included in AII.5 and AII.6.  
 
2.4.5.3.  Binding interactions of most active compound 
 
Asiatic acid 40, which negatively modulated the GABA-induced current at all three 
GABAA receptor subtypes, was further investigated for its binding interaction with these 
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receptors. It was found that, at α1β2γ2L and α2β2γ2L, the effect of asiatic acid is not 
sensitive to the benzodiazepine antagonist flumazenil, which indicates that this acid 
does not interact with high affinity benzodiazepine binding site. At the same time, at the 
α5β3γ2L receptor, the effect was not sensitive to L655,708, which is reported to be 50 
times more selective for the benzodiazepine binding site of GABAA receptors 
containing an α5 subunit than those contain α1, α2 α3, and α4 subunits [257], which 
indicates that  asiatic acid does not interact with the high affinity benzodiazepine 
binding site at the α5β3γ2L subtype, Figure 41. 
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Figure 41: The effect of flumazenil on the inhibition of the EC50 GABA-
induced current by asiatic acid 40 at A. α1β2γ2L; B. α2β2γ2L and the 
effect of L655,708 on asiatic acid-induced inhibition of the EC50 
GABA-induced current on C. α5β3γ2L subtype of GABAA 
receptors. 
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2.5. Effect of Centella asiatica extracts on the hydrogen peroxide-induced 
 cell death of human endothelial EA.hy926 cells  
 
None of the extracts from Centella asiatica exhibited any significant protection against 
the H2O2-induced cell death of EA.hy926 endothelial cells, Figure 42.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Effect of different Centella asiatica extracts on the H2O2-induced 
death of EA.hy926 endothelial cells. The experiments were 
performed in triplicate and gallic acid was used as a positive 
control. 
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Centella asiatica and its compounds have been reported for their effectiveness in 
numerous neurological disorders. For example, the plant has been found to improve the 
memory and the general mental ability of mentally retarded children [258], the aqueous 
extract (at a dose of 150 and 300 mg/kg) has been found to be protective against 
colchicine-induced memory impairment in rats [91], to lead to improvements in 
pentylenetetrazole (PTZ)-induced learning deficits [90], and to attenuate d-galactose-
induced memory impairment in mice [93].  
 
Asiatic acid 40, a pentacylcic triterpene found in Centella asiatica has been patented for 
the treatment of dementia, as a cognitive enhancer, by Hoechst Aktiengesellschaft 
(EP0383171 A2) [116]. The effect of asiatic acid in the treatment of neurological 
disorders has also been reported in a number of studies. For example, asiatic acid, at a 
concentration of 100 mg/kg, improved glutamate-induced memory impairment, and 
attenuated neuronal damage of the pyramidal layer in CA1 and CA3 region of 
hippocampus in mice [118]. The neuroprotective effects of asiatic acid are further 
supported by results showing that asiatic acid (1 μmol/L) reduced the C2-ceramide 
induced cell death of rat cortical neuron cells, and protects SH-SY5Y cells  against 
H2O2 or rotenone-induced cellular injury and mitochondrial dysfunctions [114, 259]. 
 
To the best of our knowledge, no effects on neurological disorders have been reported 
for madecassic acid, but it has been reported to exhibit other pharmacological effects, 
including anti-inflammatory effects as a result of  inhibition of  the production of nitric 
oxide (NO), prostaglandin E2 (PGE2), and tumor necrosis factor-α (TNF-α) [260].  
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Asiaticoside 38 and madecassoside 39 are two triterpene saponin from Centella 
asiatica. Asiaticoside 38 and its derivatives have been patented for the enhancement of 
cognition and the treatment of dementia [108]. It has been found to be effective in the 
treatment of various neurological disorders, with reported anti-anxiety and 
antidepressant effects in male mice as demonstrated in various behavioural tests (splash, 
tail suspension, and forced swimming tests) [102,109]. On the other hand 
madecassoside 39 has been reported to exhibit protective effects against ischemia-
reperfusion (IR) injury in cerebral neurons in male rats [119], and  has been reported to 
play an important role in the treatment of Alzheimer’s disease by  protecting neural cells 
against Aβ25–35 induced autophagosomes through the class III PI3K/Beclin-1/Bcl-2 
pathway [120]. 
 
However, as mentioned earlier in this chapter, to the best of our knowledge, no studies 
has been reported on the effects of the extracts and pure compounds of Centella asiatica 
on recombinant GABAA receptors expressed in Xenopus laevis oocytes. 
 
In the present study, all the extracts, at a concentration of 50 μg/mL, induced a current 
at α1β2γ2L and α2β2γ2L receptors, when applied alone. These extracts also positively 
modulated the GABA-induced current at these receptors. As α1β2γ2 receptors mediate 
sedative and anticonvulsant effects, and α2βγ2 mediate anxiolytic and muscle relaxing 
effects, the results of the current study are in agreement with the results from previous 
studies which investigated the effects of Centella asiatica in the treatment of anxiety 
and depression. 
 
On the contrary, at a concentration of 100 μM, asiatic acid 40 and madecassic acid 41 
did not induce any current at all three subtypes of GABAA receptors, when applied 
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alone. However, although these molecules differ only by a hydroxyl group at the C-6 
position, there was a substantial difference in their modulation of the GABA-induced 
current on recombinant GABAA receptors. Asiatic acid 40 negatively modulated the 
GABA-induced current at all three subtypes but negative modulation by madecassic 
was only observed at the α2β2γ2L subtype.  
 
From dose-response curves, the IC50 of asiatic acid was calculated and it was 64 µM at 
α5β3γ2L GABAA receptor. The greatest negative modulation of the GABA-induced 
current by asiatic acid 40 was at α1β2γ2L (IC50, 37 µM), and the extent of negative 
modulation at α2β2γ2L was lower than that at both α1β2γ2L and α5β3γ2L receptors (α2β2γ2L 
IC50, 427 µM).  The effect of asiatic acid 40 is not sensitive to benzodiazepine 
antagonist flumazenil at the α1β2γ2L and α2β2γ2L receptors, and is not sensitive to inverse 
agonist L655,708 at α5β3γ2L receptors, which strongly indicates the interaction of this 
molecule may not with the high affinity benzodiazepine binding site. The negative 
modulation of GABA-induced current by madecassic acid 41 at α2β2γ2L was similar to 
that of asiatic acid 40 (IC50, 428 µM).  
 
The triterpene saponins of Centella asiatica, asiaticoside 38 and madecassoside 39 (at a 
concentration of 100 μM) did not induce any current at all three subtypes of receptors 
except for a small current (16.0 nA) induced by asiaticoside at α5β3γ2L, when applied 
alone. These compounds negatively modulated the EC50 GABA-induced current at all 
three subtypes of receptors, although madecassoside 39 induced a slight positive 
modulation of the GABA-induced current at the α5β3γ2L receptor. However, none of the 
modulation was greater than 35.0% so it can be concluded that the presence of the sugar 
moiety reduced the modulation of the GABA-induced current. 
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The differential effects of the extracts and the pure compounds may be due to the 
presence of small amounts of GABA in the extracts. The presence of GABA in both the 
EtOH and aqueous extracts was confirmed by TLC.  
Although none of the triterpenes or triterpene saponins from Centella asiatica have 
previously been tested on recombinant GABAA receptors, compounds with similar 
structures have been tested for their modulation of GABAA receptors. The results of 
these tests are in agreement with those from the present study. For example, ursolic acid 
154 and oleanolic acid 155, Figure 43, have similar structures to asiatic acid 40 and 
madecassic acid 41, and ursolic acid 154 has been shown to inhibit the GABA-induced 
current (IC50, 98 μM) on α1β2γ2L receptor. On the other hand, oleanolic acid 155 inhibits 
the 3 mM GABA induced current by 30%, possibly by acting as a channel blocker on 
same receptors [261]. 
 
 
 
Figure 43:  Structures of ursolic and oleanolic acid. 
 
2.6.  Conclusion 
The results of the present study, in particular, the effects of the extracts on α1β2γ2L and 
α2β2γ2L receptors, are in agreement with those from previous studies on the anxiolytic 
effects of Centella asiatica. However, this effect may be due to the presence of a small 
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amount of GABA in the extracts. On the other hand, the results from the study of the 
pure compounds, in particular those for asiatic acid 40, which inhibits the GABA-
induced current at the α5β3γ2L receptor (IC50, 64 µM), suggest that this natural product 
may be one of the contributors to the exerting memory enhancing effects, and that it 
could be a lead compound for the treatment of cognition and memory impairment. 
However, the effect of this molecule is not selective for α5β3γ2L receptor and analogues 
with more selective effects on α5β3γ2L receptor need to be synthesized and, in addition to 
being tested on recombinant GABAA receptors, they should be tested on animal models 
of cognition and memory impairment. 
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CHAPTER 3 
 
 
Synthesis of derivatives of asiatic and madecassic acids 
and their testing on different GABAA receptor subtypes 
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3.  Introduction 
The differential effects exhibited by asiatic acid 40 and madecassic acid 41 on the 
modulation of GABAA receptors, led to the synthesis of their analogues and testing on 
different GABAA receptor subtypes. The objective was to investigate the structure 
activity relationships of these compounds, in particular, the effect of the hydroxyl 
groups in the modulation of the GABA-induced current on different GABAA receptors. 
 
Structurally, asiatic acid 40 has three hydroxyl groups (at C-2, C-3, and C-23), an 
alkene group at C-12, and a carboxylic group at the C-17 position. In previous studies, it 
has been reported that the carboxylic group at C-17 and an ester functional group at the 
C-3 position are essential for the biological effects of pentacyclic triterpenes [262].  It 
has also been reported that the substitution of C-2, C-3, and C-23 hydroxyl groups by 
acetoxy groups, and the C-17 carboxyl group by an amide group, results in greater 
inhibition of cell growth than by asiatic acid itself [263]. The functional groups in 
madecassic acid 41 are the same as those in asiatic acid 40, except for an additional 
hydroxyl group at the C-6 position. 
 
After considering the structural features and biological activities of asiatic acid 
derivatives, we decided to substitute the three hydroxyl groups and the carboxyl group 
of both asiatic and madecassic acids and to then test the derivatives on three different 
subtypes of GABAA receptors. 
 
For this semi-synthesis, standard synthetic methods were employed and the 
characterization of synthesized compounds was performed by comparing the 
spectroscopic (
1
H, 
13
C NMR, mass spectrum, and high resolution mass spectrum, IR 
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spectrum) data to the published literature [264]. The GABAA receptors were expressed 
in Xenopus laevis oocytes, and the receptor activity was measured by the two electrode 
voltage clamp technique. 
 
3.1.  Materials and Methods 
3.1.1.  Chemicals and Reagents 
 
Acetic anhydride, methanol (MeOH), and acetone were purchased from Chem-Supply, 
Gillman, South Australia, hydrochloric acid (HCl), oxalyl chloride, tetrahydrofuran 
(THF), dimethylformamide (DMF), concentrated ammonia solution, sodium hydroxide 
(NaOH), triethylamine, chloromethyl pivalate, pyridine, sodium bicarbonate (NaHCO3), 
sodium sulfate (Na2SO4), sodium chloride (NaCl),  and 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU), were purchased from Sigma Aldrich, Castle Hill, Australia. Asiatic acid and 
madecassic acid were purchased from LKT laboratories, USA. Reveleris
®
 (Grace 
Davidson Discovery Science) aluminium backed TLC plates were used for TLC 
analyses.  
 
3.1.2.  Instrumentation 
 
The same instruments as described in Chapter 2 were used for the structural 
confirmation. High resolution mass spectra (Bruker Apex Qe 7T, Fourier Transform Ion 
Cyclotron Resonance mass spectrometer equipped with an Apollo II MTP ESI/MALDI 
Duel source, Chemistry Dept., University of Sydney) were also obtained on the final 
compounds.  
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3.2.  Methods 
3.2.1.  Semi-synthesis 
3.2.1.1. 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156  
To a solution of asiatic acid 40 (0.20 g, 0.40 mmol) in anhydrous pyridine (10 ml), 
acetic anhydride (1.0 mL, 1.2 mmol) was added slowly, with cooling and stirring. The 
resulting mixture was stirred overnight at room temperature, and the completion of 
reaction was determined by TLC.  After the addition of EtOAc (20 mL), the reaction 
mixture was extracted with 1 M aq. HCl (6 × 20 mL), saturated NaHCO3 (20 mL), then 
brine (20 mL), and dried over anhydrous Na2SO4 (20 mL). The organic layer was 
collected and concentrated under reduced pressure, and the crude product was purified 
by column chromatography on silica, eluting with hexane:ethyl acetate (8:2 to 7:3) to 
give 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156 as a white solid (128 mg, 52%); mp 
143-150
0
C ; max /cm
-1
 3502 (COOH), 1708 (C=O), 1685 (C=O); 
1
H NMR (400 MHz, 
CD3OD) δ5.22 (1H, t, J = 3.2 Hz , H-12), 5.13-5.17 (1H, m, H-2), 5.01 (1H, d, J = 10.4 
Hz, H-3), 3.82 (1H, d, J = 12.0 Hz, H-23
a
), 3.61 (1H, d, J = 12.0 Hz, H-23
b
), 2.19 (1H, 
d, J = 11.2 Hz, H-18), 2.04 (3H, s, OCOCH3), 1.99 (3H, s, OCOCH3), 1.94 (3H,s, 
OCOCH3), 1.90-2.04 (3H, m), 1.65-1.69 (3H, m), 1.61 (1H, d, J = 4.0 Hz), 1.43-1.50 
(5H, m), 1.27-1.37 (6H, m), 1.12 (2 x 3H, s), 1.07 (2H, m, H-1), 0.95 (3H, s, H-24), 
0.89 (3H, s, H-26), 0.87 (3H, d, J = 6.4 Hz, H-29), 0.84 (3H, s, H-27);
 13
C NMR (100 
MHz, CD3OD) δ180.1 (C=O, C-28), 171.0 (C=O, OCOCH3), 170.8 (C=O, OCOCH3), 
170.7 (C=O, OCOCH3), 138.3 (quat, C-13), 124. 9 (=CH, C-12), 74.9 (CH, C-3), 69.6 
(CH, C-2), 64.8 (CH2, C-23), 52.9 (CH, C-18), 47.5 (CH2, C-1), 47.9 (CH, C-5), 43.4 
(CH, C-5), 41.8 (CH, C-19), 41.7 (CH, C-20 ), 39.4 (quat, C-17), 38.9 (2 x quat, C-
4,14), 37.6 (quat, C-8), 36.6 (CH2, C-22), 32.3 (CH2, C-7), 30.3 (CH2, C-21), 29.2 (quat, 
C-10), 27.7 (CH2, C-15), 23.8 (CH2, C-16), 22.9 (CH2, C-11), 22.6 (CH3, C-27), 20.1 
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(CH3, C-30), 19.5 (CH3, OCOCH3), 19.3 (CH2, C-6), 19.3 (CH3, OCOCH3), 17.5 (CH3, 
OCOCH3), 16.3 (CH3, C-25), 16.2 (CH3, C-26), 16.0 (CH3, C-29), 12.8 (CH3, C-24); 
ESI-MS: m/z 637 (100%) [M + Na]
+
. 
 
3.2.1.2. 2α,3β,23-triacetoxy-urs-12-en-28-amide 157 
A mixture of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156 (0.15 g, 0.244 mmol), 
oxalyl chloride (126 µL, 1.5 mmol), and DMF (one drop) was refluxed for 2 h, then the 
excess reagent was removed under reduced pressure to give the acyl chloride 
intermediate. Without purification, a solution of the acyl chloride in THF (12 mL) was 
added dropwise, to a stirred concentrated aqueous ammonia solution at 0
0
C. The 
solution was stirred overnight and completion of the reaction was determined by TLC. 
The resulting mixture was concentrated under reduced pressure. After addition of 
EtOAc (20 mL), the reaction mixture was extracted with 1 M aq. HCl (6 × 20 mL), 
saturated NaHCO3 (20 mL), then brine (20 mL), and dried over anhydrous Na2SO4 (20 
mL). The organic layer was collected and concentrated under reduced pressure, and the 
crude product was purified by column chromatography on silica, eluting with hexane : 
ethyl acetate 1:1 to give the 2α,3β,23-triacetoxy-urs-12-en-28-amide 157 as a white 
solid (83 mg, 55%); mp 141-145
0
C; max/cm
-1
 1739 (C=O), 1735 (C=O),  1670 (C=O), 
1654 (C=O), 1597 (NH, bend); 
1
H NMR (400 MHz, CD3OD) δ5.31 (1H, t, J = 3.6 Hz,  
H-12), 5.12-5.19 (1H, m, H-2), 5.00 (1H, d,  J = 10 Hz, H-3), 3.81 (1H, d,  J = 11.8 Hz, 
H-23
a
), 3.61 (1H, d,  J = 11.8 Hz, H-23
b
), 2.09 (1H, d, J = 11.2 Hz, H-18), 2.03 (3H, s, 
OCOCH3), 1.99 (3H, s, OCOCH3), 1.94 (3H, s, OCOCH3), 1.90-2.04 (3H, m), 1.79-
1.87 (2H, m), 1.61-1.70 (4H,  m), 1.42-1.57 (7H, m), 1.31-1.36 (3H, m), 1.26 (3H, s, H-
25), 1.13, 1.11 (2 x 3H, s), 1.03-1.09 (2H, m, H-1), 0.95 (3H, s, H-24), 0.88 (3H, s,H-
26), 0.86 (3H, s, H-27);
 13
C NMR (100 MHz, CD3OD) δ182.0 (C=O, C-28) , 170.9 
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(C=O, OCOCH3 ), 170.8 (C=O, OCOCH3), 170.7 (C=O, OCOCH3), 138.6 (quat, C-13), 
125.2 (=CH, C-12), 74.9 (CH, C-3), 69.6 (CH, C-2), 64.8 (CH2, C-23), 52.9 (CH, C-18), 
47.4 (CH, C-1), 43.4 (CH, C-5), 41.8 (CH, C-19), 41.7 (CH, C-20), 39.4 (quat, C-17), 
39.3 (quat, C-4), 38.9 (quat, C-14), 37.6 (quat, C-5), 37.3 (CH2, C-1), 32.1 (CH2, C-22), 
31.6 (CH2, C-7), 30.4 (CH2, C-21), 29.0 (quat, C-10), 27.5 (CH2, C-15), 23.8 (CH2, C-
16), 22.9 (CH2, C-11), 22.5 (CH3, C-27), 20.1 (CH3, C-30), 19.5 (CH3, OCOCH3), 19.3 
(CH2, C-6), 19.3 (CH3, OCOCH3), 17.5 (CH3, OCOCH3), 16.3 (CH3, C-25), 16.3 (CH3, 
C-26), 16.0 (CH3, C-29), 12.8 (CH3, C-24); HRMS (ESI) Found: MNa
+
, 636.3873 Calc. 
for C36H55NO7Na: MNa
+
, 636.3876. 
 
3.2.1.3.  2α,3β,23-trihydroxy-urs-12-en-28-amide 158 
To a solution of 2α,3β,23-triacetoxy-urs-12-en-28-amide 157 (0.06, 0.98 mmol) in 
MeOH (2 mL) and THF (3 mL), 4 N NaOH (0.6 mL) was added dropwise and the 
resulting mixture was stirred for 2 h at room temperature. The mixture was acidified 
with aq. HCl and extracted with EtOAc (15 mL). The organic layer was washed with 
saturated NaHCO3 (15 mL), then brine (15 mL), and dried over anhydrous Na2SO4. The 
crude product was concentrated under reduced pressure, and the crude mixture purified 
by column chromatography on silica, eluting with MeOH / DCM (1:20 to 14:86) to give 
2α,3β,23-trihydroxy-urs-12-en-28-amide 158 as a white solid (37 mg, 77%); mp 241-
253
0
C; max/cm
-1
 3200-3500 (OH), 1653 (C=O); 
1
H NMR (400 MHz, CD3OD) δ5.31 
(1H, t, J = 3.2 Hz, H-12), 3.64-3.70 (1H, m, H-2), 3.48 (1H, d, J = 10.8 Hz, H-3), 3.32-
3.34  (3H, m), 3.25 (1H, d, J = 11.2 Hz, H-23), 2.08 (1H, d, J = 10.4 Hz, H-18),  1.91-
2.04 (4H, m), 1.79-1.86 (1H, m), 1.54-1.72 (6H, m), 1.25-1.46 (9H, m), 1.12 (3H, s, H-
25), 1.02 (3H, s, H-24), 0.95 (3H, s, H-26), 0.89 (3H, d, J = 6.4 Hz, H-29), 0.85 (3H, s, 
H-27),  0.67 (3H, s, H-30);
  13
C NMR (100 MHz, CD3OD) δ182.2 (C=O, C-28), 138.7 
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(quat, C-13), 125.5 (=CH, C-12), 76.7 (CH, C-3), 68.2 (CH, C-2), 64.7 (CH2, C-23), 
52.9 (CH, , C-18), 47.5 (CH2, C-1), 47.3 (CH, , C-9), 46.7 (CH, C-5), 46.6 (CH, C-19), 
42.7 (CH, C-20), 42.0 (quat, C-17), 39.4 (quat, C-4), 39.3 (quat, C-14), 38.9 (quat, C-8), 
37.5 (quat, C-10), 37.3 (CH2, C-22), 32.0 (CH2, C-7), 30.5 (CH2, C-21), 27.5 (CH2, C-
15), 23.8 (CH2, C-16), 23.0 (CH2, C-11), 22.6 (CH3, C-27), 20.1 (CH2, C-6), 17.6 (CH3, 
C-30), 16.4 (CH3, C-25), 16.3 (CH3, C-26), 16.2 (CH3, C-29), 12.5 (CH3, C-24); HRMS 
(ESI), Found: MNa
+
, 510.3554 Calc. for C30H49NO4Na: MNa
+
, 510.3559. 
 
3.2.1.4.  tert-Butoyloxymethyl 2α,3β,23-triacetoxy-urs-12-en-28-oate 159 
To a stirred solution of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156 (0.104 g, 0.16 
mmol) in acetone (10 mL), DBU (110 µL, 0.744 mmol) was added dropwise. After 
stirring for 10 minutes, chloromethyl pivalate (56 µL, 0.41 mmol) was added dropwise 
and the mixture stirred overnight. The ending of the reaction was determined on TLC.  
The solvent was evaporated under reduced pressure and the residue was partitioned 
between EtOAc (40 mL) and water (3 x 25 mL). The organic layer was collected and 
dried over anhydrous Na2SO4. The crude product was purified by column 
chromatography, eluting with hexane / EtOAc (70 : 30 to 80 : 20) to give tert-
butoyloxymethyl 2α,3β,23-triacetoxy-urs-12-en-28-oate  159 as a white solid (52 mg, 
42 %); mp 73-76
 °
C; max/cm
-1
 1741 (C=O), 1735 (C=O); 
1
H NMR (400 MHz, CD3OD) 
δ 5.67 (2H, s), 5.23 (1H, t, J = 3.6 Hz, H-12), 5.13-5.19 (1H, m, H-2), 5.01 (1H, d, J = 
10.4 Hz, H-3), 3.82 (1H, d, J = 11.8 Hz, H-23
a
), 3.61 (1H, d, J = 11.8 Hz, H-23
b
), 2.20 
(1H, d, J = 11.2 Hz, H-18), 2.03 (3H, s, OCOCH3), 1.99 (3H, s, OCOCH3), 1.94 (3H, s, 
OCOCH3), 1.81-2.15 (4H, m), 1.80-1.84 (1H, m), 1.60-1.69 (3H, m), 1.56-1.59 (1H, m), 
1.39-1.54 (4H, m), 1.22-1.39 (6H, m), 1.17 (6H, s), 1.13, 1.12 (2 x 3H, s), 1.01-1.06 
(2H, m), 0.95 (3H, s, H-24), 0.89 (3H, s, H-26), 0.87 (3H, d, J = 6.4 Hz, H-29), 0.80 
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(3H, s, H-27);
 13
C NMR (100 MHz, CD3OD) δ176.9 (C=O, C-28), 175.9 (C=O), 170.9 
(C=O, OCOCH3), 170.8 (C=O, OCOCH3), 170.7 (C=O, OCOCH3), 137.9 (quat, C-13), 
132.1 (quat), 130.9 (CH), 128.4 (CH), 125.3 (=CH, C-12), 79.4 (CH), 74.9 (CH, C-3), 
69.6 (CH, C-2), 67.6 (CH2, C-23), 64.8 (CH2, C-6), 52.6 (CH, C-18), 47.4 (CH, C-9), 
43.4 (quat), 41.8 (quat C-17), 39.5 (quat, C-4), 38.8 (quat, C-14), 38.3 (quat C-8), 37.6 
(quat, C-10), 36.3 (CH2, C-22), 32.2 (CH2 C-7), 30.2 (CH2, C-21), 30.0 (CH2, C-6), 
28.7 (CH2, C-15), 27.5 (CH2, C-16), 25.9 (CH2, C-11), 23.6 (CH3), 22.9 (CH3), 22.6 
(CH3), 22.5 (CH3, C-27), 20.0 (CH3, C-30), 19.3 (CH3, OCOCH3), 19.2 (CH3, 
OCOCH3), 17.5 (CH3, OCOCH3), 16.5 (CH3, C-25), 16.1 (CH3, C-26), 16.0 (CH3, C-
29), 12.8 (CH3, C-24); HRMS (ESI), Found: MNa
+
, 751.4392 Calc. for C42H64O10Na 
MNa
+
, 751.4397. 
 
3.2.1.5.  2α, 3β, 23-O-triacetylmadecassic acid 160 
To a stirred and ice cooled (0
0
C) solution of madecassic acid 41 (0.2 g, 0.4 mmol), 
acetic anhydride (0.2 mL, 1.2 mmol) was added and stirred overnight at room 
temperature, with the progress of the reaction being monitored by  TLC. The solvent 
was evaporated under reduced pressure and the residue was partitioned between EtOAc 
(30 mL) and water (3 x 20 mL). The organic layer was collected and washed with aq. 
1M HCl (20 mL), saturated NaHCO3 solution (20 mL), then brine (20 mL), and dried 
over anhydrous Na2SO4. The crude product (198 mg) was purified by column 
chromatography on silica, eluting with DCM / EtOAc (60 : 40) to give 2α, 3β, 23-O-
triacetylmadecassic acid 160 as white solid (34 mg, 13.5%); mp 148-150
0
C; max/cm
-1
 
3500 (OH), 1739 (C=O), 1724 (C=O), 1718 (C=O); 
1
H NMR (400 MHz, CD3OD) 
δ5.25 (1H, t, J = 4.0 Hz, H-12), 5.19-5.22 (1H, m, H-2), 4.93 (1H, d, J = 10.4 Hz, H-3), 
4.27 (1H, br. s, H-6), 3.88 (1H, d, J = 12 Hz, H-23
a
),  3.73 (1H, d , J = 11.6 Hz, H-23
b
),  
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2.21 (1H, d, J = 11.2 Hz, H-18), 2.13 (2H, s), 1.97-2.07 (3H, m), 2.01, 1.99 (2 x 3H, s, 
OCOCH3), 1.94 (3H, s, OCOCH3), 1.97-2.07 (2H, m), 1.51-1.73 (6H, m), 1.46 (3H, s, 
H-24), 1.36 (2H, s), 1.26 (3H, s, H-26), 1.09 (6H, s), 1.02-1.12 (2H, m), 1.06-1.12 (2H, 
m), 0.95 (3H, s, H-30), 0.88 (3H, d, J = 6.8 Hz, H-29); 
13
C NMR (100 MHz, CD3OD) 
δ180.1 (quat; C=O), 171.1 (C=O, OCOCH3), 170.8 (C=O, OCOCH3), 170.7 (C=O, 
OCOCH3), 137.7 (quat, C-13), 125.2 (CH, C-12), 75.1 (CH, C-3), 69.7 (CH, C-3), 66.5 
(CH, C-6), 64.8 (CH2, C-23), 52.9 (CH, C-18), 47.9 (CH, C-9), 47.7 (CH, C-5), 45.5 
(CH, C-19), 42.3 (CH, C-20), 42.2 (quat, C-17), 39.9 (quat, C-4), 38.9 (quat, C-14), 
38.9 (quat, C-8), 38.6 (quat, C-10), 37.2 (CH2, C-22), 36.7 (CH2, C-7), 30.3 (CH2, C-
21), 28.0 (CH2, C-15), 27.7 (CH2, C-16), 23.9 (CH2, C-11), 22.7 (CH3, C-27), 20.1 
(CH3, C-30), 19.6 (CH3, OCOCH3), 19.3 (CH3, OCOCH3), 19.3 (CH3, OCOCH3), 17.5 
(CH3, C-25), 17.4 (CH3, C-26), 16.2 (CH3, C-29), 14.3 (CH3, C-24); HRMS (ESI) 
Found: MNa
+
, 653.3659 Calc. for C36H54O9 Na MNa
+
, 653.3666.
 
 
 
3.3.  Electrophysiology 
The same materials and methods as described in Chapter 2 were employed in the 
electrophysiology experiments.  
 
3.4.  Results and discussion 
3.4.1.  Semi -synthesis 
Asiatic acid 40 and madecassic acid 41 were isolated from the ethyl acetate extract of C. 
asiatica. 2α,3β,23-triacetoxy-urs-12-en-28-amide 157 was synthesized following the 
method of Zhang et al., 2009 with slight modifications, Scheme 1. 2α,3β,23-triacetoxy-
urs-12-en-28-oic acid 156, 2α,3β,23-trihydroxy-urs-12-en-28-amide 158, and 2α, 3β, 
23-O-triacetylmadecassic acid 160 were also synthesized following the method of 
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Zhang et al., 2009 Scheme 2 [264]. The 2-O, 3-O, 23-O-triacetylasiatic acid prodrug 
159 was synthesized by the modified method of Nudelman et al., 1992 [265], Scheme 2.  
 
Scheme 1. Reagents and conditions; (i)  Ac2O / Pyr (13%). 
 
 
Scheme 2. Reagents and conditions; (i) Ac2O / Pyr (52%), (ii) SOCl2 (iii) 
NH3.H2O, THF (55 %) over 2 steps, (iv) 4M aq. NaOH, MeOH / 
THF  (77%), (v) DBU / chloromethyl pivalate (42%). 
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The replacement of the 3 hydroxyl groups of asiatic acid 40 with 3 acetoxy groups 
results in 3 additional carbonyl peaks in the 
13
C NMR spectrum of the 2α,3β,23-
triacetoxy-urs-12-en-28-oic acid 156, at δ 171.0, 170.8, and 170.7 ppm, and 3 additional 
methyl singlets in 
1
H NMR, at δ 2.04, 1.99, and 1.95 ppm. In the 2α,3β,23-triacetoxy-
urs-12-en-28-amide 157, all three carbonyl peaks in the 
13
C NMR (C=O, 170.9), (C=O, 
170.8), (C=O, 170.7) and signals for 9 protons on 
1H NMR at δ 2.04 (3H, s), 1.99 (3H, 
s), 1.94 (3H, s) were present. The peak for –CONH2 appears at δ 182.0 ppm instead of δ 
180.0 ppm for the –COOH group in 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156. The 
deprotection of the 3 acetoxy groups results in the disappearance of the peaks for the 
carbonyls and methyls in the 
13
C NMR, and the signals for 9 protons in the 
1
H NMR 
spectra.  For 2-O, 3-O, 23-O-triacetylasiatic acid prodrug 159, there were an additional 
2 signals for carbonyl carbons in the 
13
C NMR, at δ 176.9 and 175.9 ppm , and in 1H 
NMR spectrum there was a 9 protons singlet at δ 1.17 ppm for the But group.  
 
For 2α, 3β, 23-O-triacetylmadecassic acid 160, 4 additional carbonyl peaks in the 13C 
NMR, and signals for an additional 12 protons in the 
1
H NMR spectra were expected. 
There were only 3 additional carbonyl peaks in the 
13
C NMR spectrum, at δ 171.0, 
170.8, 170.7 ppm and in the 
1
H NMR spectrum there were signals for an 9 additional 
protons, at δ2.04, 1.99, and 1.94 ppm. The analysis of the gCOSY, HMQC, and HMBC 
spectra as described in page 72 led to the conclusion that the hydroxyl group at C-6 
position was the one which was not acylated during this process. 
 
3.4.2.  Electrophysiology 
 
The screening results of synthesized compounds are summarised in Table 4. 
2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156 showed remarkable differences in its 
effects on GABAA receptors in comparison to asiatic acid 40. At a concentration of 100 
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µM, it induced a small current (15 ± 2.12 nA) at the α2β2γ2L GABAA receptor, when 
applied alone, and positively modulated the EC10 GABA-induced current by 26 ± 6.14 
%, Figure 44, while on other GABAA receptor subtypes, it did not induce a direct 
current, but there was a slight negative modulation of the GABA-induced current, AII.7.  
 
Table 4: Screening results of synthesized compounds on different GABAA 
receptor subtypes. 
 
Compounds alone and in 
combination with EC10 or EC50 
GABA 
Effect on different GABAA receptor 
subtypes 
α1β2γ2L α2β2γ2L α5β3γ2L 
Asiatic acid 40 (100  µM) No effect No effect No effect 
Asiatic acid 40 (100 µM) + EC10 
GABA 
87.1 ± 2.0% 
inhibition 
58.6 ± 0.25%  
inhibition 
81.3 ± 1.2% 
inhibition 
Madecassic acid 41 (100  µM) No effect No effect No effect 
Madecassic acid 41 (100  µM) + 
EC10 GABA 
No effect 56.2 ± 0.75%   
inhibition 
No effect 
2α,3β,23-triacetoxy-urs-12-en-28-
oic acid 156 (100 µM)  
No effect 15 ± 2.12 nA No effect 
2α,3β,23-triacetoxy-urs-12-en-28-
oic acid 156 (100 µM) + EC10 
GABA 
3.86 ± 0.86% 
inhibition 
26.0 ± 6.1 %  
potentiation 
19.5 ± 0.82% 
inhibition 
2α,3β,23-triacetoxy-urs-12-en-28-
amide 157 (100 µM) 
No effect No effect No effect 
2α,3β,23-triacetoxy-urs-12-en-28-
amide 157 (100 µM) +  EC10 
19.7 ± 0.84% 
inhibition 
12.0 ± 1.4 % 
inhibition 
8.01 ± 1.6% 
inhibition 
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GABA 
2-O, 3-O, 23-O-triacetylasiatic acid 
amide 157 (100 µM) +  EC80 
GABA 
No effect No effect No  effect 
2α,3β,23-trihydroxy-urs-12-en-28-
amide 158 (100 µM)  
No effect No effect No effect 
2α,3β,23-Trihydroxy-urs-12-en-28-
amide 158 (100 µM) +  EC50 
GABA 
75.1 ± 0.56% 
inhibition 
77.3 ± 0.25  % 
inhibition 
53.5 ± 0.65% 
inhibition 
2-O, 3-O, 23-O-triacetylasiatic acid 
prodrug 159 (100 µM) 
No effect No effect No effect 
2-O, 3-O, 23-O-triacetylasiatic acid 
prodrug 159 (100 µM) EC10 GABA 
22.5 ± 2.0% 
inhibition 
7.95 ± 0.52 % 
inhibition 
3.20 ± 0.19% 
inhibition 
2α, 3β, 23-O-triacetylmadecassic 
acid 160 (100 µM) 
No effect No effect No effect 
2α, 3β, 23-O-triacetylmadecassic 
acid 160 (100 µM) +  EC10 GABA 
46.5 ± 1.2 %  
inhibition 
40.3 ± 0.58%  
inhibition 
63.1 ± 1.4%   
inhibition 
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Figure 44: Typical traces for the effect of 2α,3β,23-triacetoxy-urs-12-en-28-
oic acid 156 on the EC10 (10 μM) GABA-induced current on 
α2β2γ2L GABAA receptor.  
 
Unlike 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156, 2α,3β,23-triacetoxy-urs-12-en-
28-amide 157, at a concentration of 100 μM, inhibited the EC10 GABA-induced current 
by 12.0 ± 1.4% and negatively modulated the GABA-induced current on all three 
subtypes of GABAA receptors, with the greatest modulation at α1β2γ2L receptors (19.7 ± 
0.84% inhibition). Upon co-application with a higher concentration of GABA (EC50 and 
EC80), this compound did not show any effect on the GABA-induced current at the 
α1β2γ2L subtype of GABAA receptor, Figure 45.  
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Figure 45: A. Typical traces for the effect of 2α,3β,23-triacetoxy-urs-12-en-
28-amide 157 on the EC10 (3.0 μM) GABA-induced current at the 
α1β2γ2L GABAA receptor. B. Typical traces for the effect of 2α,
3β,23-triacetoxy-urs-12-en-28-amide 157 on the EC80 (100 μM) 
GABA-induced current at α1β2γ2L GABAA receptor. (For the 
other traces for amide 157 see AII.8 and AII.9.) 
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3.4.2.1. 2α,3β,23-trihydroxy-urs-12-en-28-amide 158 
 
2α,3β,23-trihydroxy-urs-12-en-28-amide 158 has same structural features as asiatic acid 
40, except for an amide group instead of the carboxylic acid group at the C-17 position. 
This compound did not induce a direct current, when applied alone, but negatively 
modulated the GABA-induced current at all three subtypes of GABAA receptors at a 
concentration of 100 μM. In the initial screening, 2α,3β,23-trihydroxy-urs-12-en-28-
amide 158 inhibited the EC50 GABA-induced current by 75.1% at α1β2γ2L; by 77.3% at 
α2β2γ2L and by 53.5% at the α5β3γ2L GABAA receptor subtype. The IC50 values for this 
compound were thus calculated from dose-response curves for all three receptor 
subtypes. Moreover, when the modulation of the GABA-induced current by 2α,3β,23-
trihydroxy-urs-12-en-28-amide 158 is compared to that of asiatic acid 40, it is evident 
that the substitution of the –COOH group by  a –CONH2 group results in enhanced 
negative modulation of the α1β2γ2L (IC50, 14 µM) and α2β2γ2L (IC50, 28 µM) subtypes of 
GABAA receptors. The negative modulation of the α5β3γ2L receptor (IC50, 134 µM) was 
lower than that of asiatic acid 40, Figures 46 (A, B), 47 (A, B), and 48 (A, B).  
Table 5:  IC50 comparison of the compounds 
Compounds  IC50 on different GABAA receptor 
subtypes 
α1β2γ2L α2β2γ2L α5β3γ2L 
Asiatic acid 40  37µM 427µM 64 µM 
Madecassic acid 41  No effect 428 µM No effect 
2α,3β,23-trihydroxy-urs-12-en-28-amide 158 14 µM 28 µM 134 µM 
2α, 3β, 23-O-triacetylmadecassic acid 160 828 µM 106 µM 205 µM 
 
Page | 112  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46: A. Dose-response curve for the effect of 2α,3β,23-trihydroxy-urs-
12-en-28-amide 158 on the EC50 (30 μM) GABA-induced current 
at the α5β3γ2L receptor;  B. Typical traces for the negative 
modulation of EC50 (30 μM) GABA- induced current by different 
concentrations of 2α,3β,23-trihydroxy-urs-12-en-28-amide 158 at 
α5β3γ2L receptor.  The data for dose-response curve are the Mean ± 
SEM (n = 3-4 oocytes). 
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Figure 47: A. Dose-response curve for the effect of 2α,3β,23-trihydroxy-urs-
12-en-28-amide 158 on the EC50 (30 μM) GABA-induced current 
at the α1β2γ2L receptor B. Typical traces for the negative 
modulation of the EC50 (30 μM) GABA-induced current by 
different concentration of 2α,3β,23-trihydroxy-urs-12-en-28-
amide 158 at the α1β2γ2L receptor. The data for dose-response 
curve are the Mean ± SEM (n = 3-4 oocytes). 
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Figure 48: A. Dose-response curve for the effect of 2α,3β,23-trihydroxy-urs-
12-en-28-amide 158 on the GABA EC50 (100 μM) induced 
current at the α2β2γ2L receptor; B. Typical traces for the negative 
modulation of the EC50 (100 μM) GABA-induced current by 
different concentration of 2α,3β,23-trihydroxy-urs-12-en-28-
amide 158 on the α2β2γ2L receptor. The data for dose-response 
curve are the Mean ± SEM (n = 3-4 oocytes). 
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3.4.2.2.  2α, 3β, 23-O-Triacetylmadecassic acid 160 
 
The substitution of four hydroxyl groups of madecassic acid by acetoxy groups was 
attempted but only three of the hydroxyl groups were acylated, the exception being the 
hydroxyl group at C-6 position. The resultant novel compound 160 was screened and 
interestingly, it negatively modulated the GABA-induced current on all three GABAA 
receptors. The greatest modulation was found on α2β2γ2L with an IC50 of 106 µM, which 
was followed by α5β3γ2L (IC50, 205 µM), and α1β2γ2L (IC50, 828 µM), Figures 49-51. 
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Figure 49: A. Dose-response curve for effect of 2α, 3β, 23-O-
Triacetylmadecassic acid 160 on the EC50 (30 μM) GABA-
induced current at the α5β3γ2L receptor; B. Typical traces for the 
negative modulation of the EC50 (30 μM) GABA-induced current 
by different concentrations of 2α, 3β, 23-O-triacetylmadecassic 
acid 160 on the α5β3γ2L  receptor. The data for dose-response curve 
are the Mean ± SEM (n = 3-4 oocytes). 
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Figure 50: A. Dose-response curve for the effect of 2α, 3β, 23-O-
triacetylmadecassic acid 160 on the EC50 (30 μM) GABA-
induced current on α1β2γ2L GABAA receptor; B. Typical traces for 
the negative modulation of the EC50 (30 μM) GABA-induced 
current by different concentration of 2α, 3β, 23-O-
triacetylmadecassic acid 160 on α1β2γ2L receptor. The data for 
dose-response curve are the Mean ± SEM (n = 3-4 oocytes). 
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Figure 51: A. Dose-response curve for the effect of 2α, 3β, 23-O-
triacetylmadecassic acid 160 on the EC50 (100 μM) GABA-
induced current on α2β2γ2L GABAA receptor; B. Typical traces for 
the negative modulation of the EC50 (30 μM) GABA-induced 
current by different concentrations of 2α, 3β, 23-O-
triacetylmadecassic acid 160  on α2β2γ2L GABAA receptor. The 
data for dose-response curve are the Mean ± SEM (n = 3-4 
oocytes). 
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The blood brain barrier (BBB) limits the entry of charged or polar drug molecules into 
the brain. One of the strategies which can be used to enhance drug uptake into the brain 
is to make neutral prodrugs which can traverse the BBB and such agents widely used 
for the treatment of neurological diseases [266]. The location of α5-containing GABAA 
receptors, which are responsible for cognition and memory, is mostly restricted to the 
hippocampus of the brain [243] so, for the drug to be effective, it must cross the blood 
brain barrier. Considering these facts, an ester prodrug of acylated asiatic acid 156 was 
synthesized and screened against different subtypes of GABAA receptors. At a 
concentration of 100 μM this compound 159 did not induce any current when applied 
alone. It did, however, negatively modulate the EC10 GABA-induced current (by 22.5 ± 
2.0 nA) at the  α1β2γ2L receptor subtype. At the α2β2γ2L and α5β3γ2L receptor subtypes 
there was a slight negative modulation, by 7.95 ± 0.52 % and 3.20 ± 0.19 %, 
respectively, AII.10. 
 
3.4.3.  Binding interaction of amide 158 
 
Further studies on the binding interaction of the most active compound (2α,3β,23-
trihydroxy-urs-12-en-28-amide 158) revealed that the effects of this compound on 
α1β2γ2L receptors, Figure 52, and α2β2γ2L, Figure 53, are not sensitive to the 
benzodiazepine antagonist flumazenil. At the α5β3γ2L receptor, the effects of this 
deprotected amide are not affected by the inverse agonist L655,708, which is selective 
for this subtype over α1β2γ2L and α2β2γ2L receptors, Figure 54. These results indicate a 
different binding site for this molecule from the high affinity benzodiazepine binding 
site of GABAA receptors. 
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Figure 52: Effect of flumazenil on 2α,3β,23-trihydroxy-urs-12-en-28-amide 
158 induced inhibition of the EC50 GABA-induced current on 
α1β2γ2L receptors. 
 
 
 
 
 
 
 
 
 
 
Figure 53: Effect of flumazenil on 2α,3β,23-trihydroxy-urs-12-en-28-amide 
158 -induced inhibition of the EC50 GABA-induced current on 
α2β2γ2L receptors.  
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Figure 54: Effect of L655, 708 on 2α,3β,23-trihydroxy-urs-12-en-28-amide 
158  induced inhibition of the EC50 GABA-induced current on 
α5β3γ2L receptors.  
 
In previous studies, asiatic acid 40 and its derivatives have been reported to exhibit 
various pharmacological effects, for example the inhibition of rabbit muscle glycogen 
phosphorylase a (GPa), with the derivatives being more active than asiatic acid itself. 
Asiatic acid benzyl ester produced the greatest inhibition, with an IC50 of 3.8 µM, 
whereas asiatic acid 40 had an IC50 of 17 µM. Moreover, compounds with a 2α-OH 
group (asiatic acid 40) were found to be more active inhibitors of GPa than those with a 
2β-OH group [264]. Two different sets of asiatic acid 40 derivatives were prepared and 
tested;  
• those with the C-17 carboxylic acid group esterified by ethyl bromoacetate, and 
the ethyl ester was then converted to various primary and secondary amides, and  
• those in which the 1,3-dihydroxy groups of ring A of asiatic acid 40 were 
modified to generate substituted 1,3-dioxane derivatives. These derivatives have 
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been reported to be effective for the protection of CCl4-induced liver damage in 
rats [267].  
 
Aniline-derived derivatives of asiatic acid 40  have also been reported to be more active 
anti-proliferative agents on MGC-803, NICI-H460, HepG2, Hela, and 7404 cancer cells 
than asiatic acid itself [268]. 
 
Asiatic acid 40  derivatives, particularly three compounds, AS-2 161, AS-2-9-006 162, 
and AS-9-006 163, Figure 55 have been reported to lead to improvements in 
scopolamine-induced memory impairment, the enhancement of cognitive performance 
in the water maze test, and increased choline acetyltransferase activity in the 
neuroblastoma cell line, S-20Y [269]. In the protection of Aβ-induced neurotoxicity, 
asiatic acid 40 was more protective (97%) than its derivatives [117]. To date, however, 
to the best of our knowledge, no investigation involving the study of asiatic and 
madecassic acid 41 derivatives on recombinant GABAA receptors has been reported. In 
particular, there have been no studies on asiatic acid derivatives and their cognition 
enhancing effects in terms of GABAergic system.  
 
 
Figure 55: Structures of AS-2, AS-2-9-006, and AS-9-006  
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In the present study, it has been found that one of the derivatives of asiatic acid (2α,3β,
23-trihydroxy-urs-12-en-28-amide 158) did not induce any current when applied alone. 
However, it negatively modulated the GABA-induced current at all three GABAA 
receptors. The greatest modulation was at α1β2γ2L (IC50, 14 µM), then α2β2γ2L (IC50, 
28µM), and then α5β3γ2L (IC50, 134 µM). It is noticeable that substitution of the C-17 
carboxylic acid group (asiatic acid 40) by –CONH2 (2α,3β,23-Trihydroxy-urs-12-en-28-
amide 158) results in greater negative modulation of the GABA-induced current at the 
α1β2γ2L and α2β2γ2L GABAA receptors, and reduced negative modulation at the α5β3γ2L 
receptor. At the same time, although madecassic acid 41 negatively modulated the 
GABA-induced current only at α2β2γ2L, the derivative of this molecule (acylated 
madecassic acid 160) negatively modulated the GABA-induced current at all three 
GABAA receptors; the greatest modulation was observed at α2β2γ2L (IC50, 106 µM), then 
α5β3γ2L (IC50, 205 µM), and then α1β2γ2L (IC50, 828 µM).  
 
It is thus evident that the three hydroxyls groups of asiatic acid are essential for the 
negative modulation of the GABA induced current. At the same time, substitution of the 
carboxylate group at the C-17 position– by the carboxamide group resulted in enhanced 
modulation of two subtypes. These structure activity relationships are in agreement with 
previous studies, where the triol group of asiatic acid was reported to be essential for 
protection against Aβ-induced neurotoxicity [117]. 
   
3.5.  Conclusion 
Based on the results of the current study, and the involvement of α5-containing GABAA 
receptors in cognition and memory, it can be concluded that the 2α,3β,23-trihydroxy-
urs-12-en-28-amide 158 may be a lead compound for the treatment of cognition and 
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memory. However, as it is evident that the effect of this molecule is not selective for 
α5β3γ2L receptor, molecules which are selective for α5β3γ2L, need to be synthesized. At 
the same time, in addition to be being tested on α5β3γ2L receptor, studies in animal 
models of cognition and memory impairment should be conducted.  It would also be of 
interest to examine the uptake of the pivaloyl ester 159 across the BBB, and whether 
this compound is indeed hydrolyzed to 2α,3β,23-triacetoxy-urs-12-en-28-oic acid by 
esterases. 
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CHAPTER 4 
 
 
Extraction, isolation, and structure elucidation of 
compounds from Passiflora incarnata, and their testing 
on different GABAA receptor subtypes 
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4.  Introduction 
Passiflora incarnata, which belongs to the family Passifloraceae, is used extensively in 
European traditional medicine for the treatment of anxiety, nervousness, constipation, 
dyspepsia, mild infections, and insomnia. Numerous pharmacological studies have 
supported the use of this plant as an anxiolytic [153, 270-273] except the study of Elsas 
et al., 2010 which reported that different extracts of passionflower are not anxiolytic but 
are anxiogenic [154]. 
 
The involvement of the GABAergic system, particularly GABAA receptors, has been 
suggested to be responsible for the anxiolytic effects of passionflower extracts [156, 
274], but, to the best of our knowledge, no investigations on recombinant GABAA 
receptors expressed in Xenopus laevis oocytes using the two electrode voltage clamp 
technique have been reported.  In addition, despite various pharmacological studies on 
the anxiolytic effects of this plant, there is no consensus on the active compounds which 
are responsible for this activity [155]. 
 
The aims of this project are the extraction, isolation, structural elucidation, and 
quantification of compounds from passionflower, and their testing on three different 
GABAA receptor subtypes. 
 
Extraction of the plant was performed using a Soxhlet extractor, while for the isolation, 
chromatographic (thin layer chromatography, flash column chromatography) techniques 
were employed and quantification was performed using HPLC. Structure elucidation 
involved 
1
H NMR, 
13
C NMR, cDEPT, gCOSY, gHMQC, and gHMBC NMR 
spectroscopy, and mass spectrometry. For testing on the receptors, the different 
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subtypes of GABAA receptors were expressed in Xenopus laevis oocytes and the current 
was measured using the two electrode voltage clamp technique. 
 
4. 1.  Materials and Methods for extraction and isolation 
4.1.1.  Materials for extraction and isolation 
Vitexin and isovitexin were isolated but were also purchased, along with orientin, 
isoorientin (homoorientin), kaempferol, chrysin, and apigenin, from Biopurify 
Phytochemicals Ltd, China. Whole Passiflora incarnata plant was obtained from 
Newtons Pharmacy, 119 York Street, Sydney, Australia and fresh whole Passiflora 
incarnata plant was collected from Herbalistics Pty Ltd. Bli Bli, Queensland, Australia.    
Whatman
TM
 extraction thimbles (cellulose, single thickness, 43 mm × 123 mm) were 
obtained from GE Healthcare Life Sciences, UK. Reveleris (Grace Davidson Discovery 
Science) aluminium backed TLC plates.  
 
4.1.2.  Instrumentation 
The same instruments as described in section 2.1.2 were used for the extraction, 
isolation and structural elucidation of compounds from passionflower, in addition to a 
Reveleris
®
 X2 flash chromatography system (Grace Davidson Discovery Science),  
freeze dryer (Christ Alpha 1-4, B. Braun Biotech International), and Shimadzu high 
performance liquid chromatography system equipped with LC-20 AD solvent delivery 
system, an SPD-M20 A diode array detector, an SIL-20AHT autosampler , FRC-10A 
fraction collector, DGU-20A5R degassing unit, and CBM-20A communication bus 
module. 
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4.1.3. Collection and extraction of Passiflora incarnata 
 The identity of the whole Passiflora incarnata plant was confirmed by Dr. George Li, 
Senior Lecturer, Pharmaceutical Chemistry (Herbal Medicines). After grinding into 
coarse powder, 63.577 g of the plant was subjected to extraction, in a Soxhlet extractor, 
with petroleum ether, followed by DCM, then EtOAc, and EtOH (350 mL). After each 
extraction, the solvent was allowed to cool down and evaporated under reduced pressure 
to give the crude extracts; petroleum ether extracts (1.476 g), DCM extracts (0.821 g), 
EtOAc extracts (0.676 g), and EtOH extracts (3.992 g). In addition to the whole plant, 
the passionflower extracts (100 mL), which is sold to patients, was also purchased from 
the same source. After removing some of the solvent under reduced pressure, the rest of 
the sample was freeze dried to give the dried extracts (8.615 g). 
 
For comparative HPLC analysis, passionflowers were collected from two different 
sources (dried whole plant from Newtons Pharmacy and fresh whole plant from 
Herbalistics Pty Ltd, Queensland, Australia). After grinding into coarse powder, 4.0 g of 
each was extracted with EtOH (120 mL) by maceration, which was followed by 
filtration through sinter funnel, and evaporation under reduced pressure to get the crude 
extracts  ( 279 mg, freshly collected and 234 mg, collected from Newtons Pharmacy) 
 
4.1.4.  Isolation and structural elucidation of vitexin 81 and isovitexin 82 
The ethanol extracts (3.85 g) was subjected to flash column chromatography on normal 
phase silica. Firstly, the extracts was adsorbed onto a small amount of silica then loaded 
onto the column, which was eluted with EtOAc/hexane (1:1), followed by DCM/MeOH 
(100:0 to 0:100). Finally, 1% NH3 in MeOH solution was used to ensure all compounds 
had been eluted from the column.  A total of 29 fractions (250 mL of each) were 
collected. All the fractions were analysed by TLC and similar fractions were combined 
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and pooled. After 1 day, two distinct layers were observed in fraction 23, which had one 
major spot, along with three minor spots on TLC. The top layer was collected and 
evaporated under reduced pressure to give isovitexin 82 as an amorphous yellow 
powder, (61 mg); mp 238-241
0
C (lit. mp 244-246
0
C [275]); 
1
H NMR (400 MHz, 
DMSO-d6); δ13.52 (1H, s, 5-OH), 7.89 (2H, d, J = 8.8 Hz, H-2',6'), 6.89 (2H, d, J = 8.8 
Hz, H-3',5'), 6.74 (1H, s, H-3), 6.47 (1H, s, H-8), 4.84 (1H, s, H-1''), 4.55 (1H, d, J = 9.6 
Hz), 4.02 (1H, t, J = 9.2 Hz, C4''-H),  3.05-3.18 (3H, m);
 13
C NMR (100 MHz, DMSO-
d6); δ182.3 (C=O, C-4), 163.9 (quat, C-2), 161.5 (2 × quat, C-5,7), 161.0 (quat, C-4'), 
156.5 (quat, C-8a), 128.9 (2 × CH, C-2',6'), 121.4 (quat, C-1'), 109.3 (quat, C-6), 116.3 
(2 × CH, C-3',5'), 103.75 (quat, C-4a) 103.2 (CH, C-8), 94.0 (=CH, C-3), 82.0 (CH, C-
5''), 79.4 (CH, C-3''), 73.4 (CH, C-1''), 71.0 (CH, C-2''), 70.5 (CH, C-4''), 61.9 (CH2, C-
6''); ESI-MS: m/z (%) 433 (100 %), [M + H]
+
. 
 
The bottom layer was kept for one more day, and, once again, two different layers were 
obtained. The top layer was collected and then evaporated under reduced pressure to 
give vitexin 81 as an amorphous yellow powder (135 mg); mp 259-263
0
C (lit. mp 262-
264
0
C [275]); 
1
H NMR (400 MHz, DMSO-d6); δ13.53 (1H, s, 5-OH), 7.90 (2H, d, J = 
8.8 Hz, H-2',6'), 6.89 (2H, d J = 8.8 Hz, H-3',5'), 6.75 (1H, s, H-3), 6.48 (1H, s, H-6), 
4.82 (1H, s, H-1''), 4.54 (1H, d, J = 9.6 Hz), 4.02 (1H, t, J = 8.8 Hz, H-4''),  3.08-3.18 
(6H, m); 
13
C NMR (100 MHz, DMSO-d6); δ182.3 (C=O, C-4), 163.9 (quat, C-2), 162.6 
(2 x quat, C-5,7),161.6 (quat, C-4'), 156.5 (quat, C-8a), 128.9 (2 × CH, C-2',6'), 121.5 
(quat, C-1'), 116.4 (2 × CH, C-3', 5'), 109.3 (CH, C-6), 103.7 (quat, C-4a), 103.2 (quat, 
C-8), 94.0 (CH, C-3), 82.0 (CH, C-5''), 79.3 (CH, C-3''), 73.4 (CH, C-1''), 71.0 (CH, C-
2''), 63.4 (CH, C-4''), 61.88 (CH2, C-6''); ESI-MS: m/z, 433 (100%), [M + H]
+
. 
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4.1.5.  Isolation and structural elucidation of sucrose 
The ethanol extracts fractions 24-25 (971 mg), which had three common spots, were 
combined and, after evaporation of the solvent under reduced pressure, subjected to 
flash chromatography. A total of 60 fractions (20 mL) were collected and analysed by 
TLC. Fractions 43 -47 (245 mg, three common spots) were combined and the solvent 
was evaporated under reduced pressure.  The residue was subjected to automated flash 
chromatography (Reveleris
®
 X2, Grace, Discovery Sciences), eluting with DCM/MeOH 
(100:0 to 0:100) with a run time of 28 minutes. A total of 56 fractions (20 mL) were 
collected. From fractions 48-49 white crystals were obtained and the structure was 
confirmed as sucrose by single crystal X-ray diffraction. 
 
4.2. HPLC analysis of Passiflora incarnata 
The chemical constituents of passionflower extracts (EtOH and the extracts purchased 
from herbal chemist shop) were analysed by high performance liquid chromatography. 
The column used for analysis was Aquasil, C18 (Thermo Fisher Scientific, dimension 
(mm): 100 × 2.1; particle size: 5 μ). The eluting system was A (50 mM phosphoric acid 
in water) and B was acetonitrile (ACN). Four different gradient systems (AI.4- AI.7) 
were evaluated in order to obtain a suitable gradient that offered the optimum 
separation.  
In each case, the flow rate was 0.8 mL/min but and injection volume was either 10 or 20 
μL. The second gradient system (AI.5) was considered to be suitable as the mobile 
phase for all the analyses. 
 
4.2.1. Quantification of isovitexin 82 in ethanol extracts 
A standard curve for isovitexin was generated from different concentrations of 
isovitexin (0.01, 0.02, 0.04, 0.1 mg/mL) in MeOH. Two different concentrations of the 
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EtOH extracts (0.3 and 0.5 mg/mL) were prepared after dissolving in Milli-Q water,  the 
peak areas for different concentrations of isovitexin were plotted in Microsoft Excel 
2010, and the slope was calculated. The concentration of isovitexin 82 in the EtOH 
extracts was calculated from this standard curve. 
 
4.2.2. Comparative HPLC analysis of two differently sourced Passionflower 
samples 
 
The HPLC analysis of the ethanolic extracts, which were obtained from two different 
passionflower sources, was conducted, as per the methods described in section 4.2.  
Briefly, 5 mg of the extract was dissolved in MeOH, and then analysed by HPLC 
following the method described in section 4.2.   
 
4.3.  Results and discussion 
4.3.1. Isolation and structure elucidation of isovitexin 82, vitexin 81 and 
sucrose 
4.3.1.1. Isovitexin 81 and vitexin 82 
The 
1
H NMR spectrum of the ethanolic extracts showed the greatest number of peaks, 
in comparison to the other extracts, and repeated column chromatography led to the 
isolation of isovitexin 82 and vitexin 81, as yellow amorphous powders, and sucrose 
crystals. 
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The electrospray ionization mass spectrum (ESI-MS) of first top layer of fraction 23 
contained a molecular ion peak at m/z 433 corresponding to [M+H]
 +
 for isovitexin 82 
(C21H20O10). In the 
1
H NMR spectrum, the peak at δ 13.52 ppm corresponds to 5-OH 
group, while the 2 × two proton doublets at δ 7.89 (J = 8.8 Hz) and δ 6.89 (J = 8.8 Hz) 
correspond to H-2', 6' and H-3', 5' respectively. This assignment was further confirmed 
by the 2D NMR (gCOSY) which indicates correlation between these protons. The 
multiplet at δ3.05-3.18 indicates the presence of a glycosyl moiety on the flavonoid. In 
the 
13C NMR spectrum, the peak at δ 182.2 ppm indicates presence of carbonyl carbon 
(C=O, C-4). The C-3',5' and C-2',6') carbons resonate at δ 128.8 and 116.3 ppm, 
respectively. 
 
The electrospray ionization mass spectrum (ESI-MS) of the compound isolated from the 
second top layer of fraction 23 contained a molecular ion peak at m/z 433 corresponding 
to [M+H]
+
 for vitexin 81 (C21H20O10). In the 
1
H NMR spectrum, the peak at δ 13.53 
ppm corresponds to the 5-OH group. The two doublets at δ 7.90 ppm (J = 8.8 Hz) and δ 
6.89 ppm (J = 8.8 Hz) corresponds H-2',6' and H-3',5' respectively. This was further 
confirmed from the 2D NMR (gCOSY) that indicates correlation among these protons. 
The multiples at 3.05-3.18 indicate the presence of a sugar moiety in the flavonoid. In 
13
C NMR (DMSO-d6, 100 MHz), the peak at δ 182.2 ppm indicates presence of 
carbonyl carbon (C=O, C-4). The carbons at (CH, C-3', 5') and (CH, C-2', 6') resonates 
at 128.3 and 116.4 ppm with two intense peaks. 
 
4.3.1.2. Sucrose 
Repeated column chromatography of the ethanolic extracts of passionflower gave white 
crystals; the structure was established as sucrose by single crystal X-ray diffraction, 
Figure 56. 
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Figure 56: Single crystal X-ray diffraction structure of sucrose 
 
4.3.2. HPLC analysis of Passiflora incarnata 
 
Analysis by HPLC revealed that the ethanolic extracts and the extracts purchased from 
the herbal chemist contained isovitexin 82, vitexin 81, orientin 83, and isoorientin 85, 
but did not contain kaempferol 72, chrysin 93, or apigenin 80. In addition to the peaks 
for these standard compounds, both extracts contained additional peaks in their HPLC 
chromatograms. The chromatogram of the ethanol extracts contained peaks with 
retention times of 16.5, 15.1, 13.4, 13.1, and 11.7 min. On the other hand, the HPLC 
chromatogram of the purchased extracts contained peaks with retention times of 16.3, 
14.6, 14.25, 14.0, 12.0, 11.5, 10.5, 7.25, 5.5, 2.1 and 2.0 min., and it is evident that, in 
comparison to the ethanolic extracts, the purchased extracts contain more polar 
compounds, Figure 57-60.  
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Figure 57: HPLC chromatogram of a mixture of the standard compounds 
which have previously been isolated from passionflower. 
 
 
Figure 58: Expansion of the HPLC chromatogram of the ethanolic extracts 
of passionflower. 
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Figure 59:  HPLC chromatogram of the purchased extracts of passionflower. 
 
Figure 60: Expansion of the HPLC chromatogram of the purchased extracts 
of passionflower. 
 
4.3.2.1. Quantification of isovitexin 82 in ethanolic extracts 
Isovitexin 82 was quantified as described in the materials and methods, (Section 4.2.1), 
and from the analysis of the peak areas in the HPLC chromatogram, it was found to be 
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Orientin
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Page | 136  
 
the most abundant flavonoid in both extracts, which is in agreement with the results of a 
previous study, where isovitexin was reported to be the major flavonoid in Passiflora 
incarnata [276] . The calibration curve for standard isovitexin showed good linearity 
over the concentration range (10-100 μg/mL), as demonstrated by the correlation 
coefficient of the regression line (R
2 
= 0.9996). The amount of isovitexin in EtOH 
extracts was determined as 0.2 mg/mL in 0.4 mg/mL of extract. 
 
4.3.2.2.  Comparative HPLC analysis on two differently sourced passion flower 
samples 
The HPLC chromatograms obtained for the EtOH extracts of two different 
passionflowers did not show any significant difference in their chemical profile (AI.11 
and AI.12). 
 
4.4. Electrophysiology 
4.4.1.  Results of screening of different passionflower extracts. 
 
The screening results of crude ethanol and aqueous extracts from passionflower on 
different GABAA receptor subtypes is summarised in Table 6. 
 
Table 6: Effects of crude passionflower extracts on different subtypes of 
GABAA receptors. 
Extracts alone and in 
combination with EC10 
GABA 
Effect on different GABAA receptor subtypes 
α1β2γ2L α2β2γ2L α5β3γ2L 
Ethanol extracts (100 µg/mL) 382  ±  61 nA 464  ±  39 nA 1645  ±  135 nA 
Ethanol extracts (100 µg/mL) 
+ EC10 GABA 
2010 ± 578% 
potentiation 
192 ± 19% 
potentiation 
1135 ± 45% 
potentiation 
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Aqueous extracts (100 
µg/mL) 
No effect No effect 17.0  ±  2.5 nA 
Aqueous extracts (100 
µg/mL) + EC10 GABA 
11.8  ±  3.9% 
inhibition 
19.6 ± 0.99%) 
potentiation 
68.5 ± 2.5% 
potentiation 
 
The crude ethanolic extracts (at a concentration of 100 μg/mL) induced direct currents 
at all three subtypes of GABAA receptor, with the greatest current at α5β3γ2L (1645 ± 135 
nA), followed by α2β2γ2L (464 ± 39 nA), α1β2γ2L (382 ± 61 nA). In addition to the 
induction of a direct current, the crude ethanolic extracts also positively modulated the 
EC10 GABA-induced current on all three subtypes of receptors, with the greatest 
modulation at α1β2γ2L (2010 ± 578%), followed by α5β3γ2L (1135 ± 45%), and   α2β2γ2L 
(192 ± 19%), Figure 61 and 62. 
 
  
 
 
 
 
 
 
 
 
 
Figure 61: Typical traces showing the effect of crude ethanolic 
passionflower extracts on the α5β3γ2L subtype of GABAA receptor. 
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Figure 62: Typical traces showing the effect of crude passionflower 
ethanolic extracts on the α1β2γ2L subtype of GABAA receptor. 
 
On the other hand, the aqueous extracts (at a concentration of 100 µg/mL) did not 
induce any direct current at α1β2γ2L and α2β2γ2L GABAA receptors, but induced a small 
direct current (17.0 nA) at α5β3γ2L receptors, when applied alone. The aqueous extract 
produced small positive modulation of the EC10 GABA-induced current at α5β3γ2L and 
α2β2γ2L, with greatest modulation on α5β3γ2L (68.5 ± 2.5%) receptors. 
 
The involvement of the GABAergic system, particularly affinity for GABAA receptors, 
has been suggested for the different pharmacological effects of passionflower extracts 
(active ingredients of Pascoflair® 425 mg). This extract inhibited the uptake of [
3
H]-
GABA in rat cortical synaptosome without any effect on GABA and GABA 
transaminase activity. It also inhibited the binding of [
3
H]-SR95531 to GABAA 
receptors [156]. 
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Grundmann et al., 2009 confirmed the presence of vitexin 81, isovitexin 82, orientin 83, 
and isoorientin 85, as major components of Pascoflair
® 
by HPLC analysis, and reported 
that, at a dose of 375 mg/kg, this extracts showed anxiolytic activity, which is 
comparable to diazepam. The involvement of GABAA receptors in this activity has also 
been reported as a result of a study, where the effects of passionflower has been 
attenuated by flumazenil, an antagonist of the benzodiazepine biding site of GABAA 
receptors [155].  Passipay, a hydro-alcoholic extracts of passionflower from Darouk 
Pharmaceutical Company (Tehran, Iran) has been reported for its anticonvulsant effect 
in PTZ-induced model in rats. This effect was reversed by the benzodiazepine 
antagonist flumazenil, indicating the involvement of the GABAA receptor.  In another 
study, the same authors suggested that Passipay may be useful for the treatment of 
absence seizures (eplileptic seizures which are characterize by a brief loss and return of 
consciousness) and this effect is mediated through the GABAergic system [150, 277].  
 
To date, however, to the best of our knowledge, no study has been reported which 
examines the effects of passionflower extracts on recombinant GABAA receptors 
expressed in Xenopus laevis oocytes. In the present study, it has been found that ethanol 
(EtOH) extracts of passionflower induced direct currents on all three (α1β2γ2L, α2β2γ2L, 
and α5β3γ2L) GABAA receptor subtypes, and also positively modulated the GABA- 
induced current on all three GABAA receptor subtypes.  
 
The results obtained with the ethanolic extracts thus support the previous reports, which 
reported the involvement of GABAA receptors in the different pharmacological effects 
of passionflower extracts. However, these results are in partial disagreement with those 
of Elsas et al., 2010 who found that the whole passionflower extracts induced a direct 
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GABAA current in rat brain hippocampal slices, but did not modulate the GABA-
induced current [154].  
 
The extract purchased from a herbal chemist did not induce a direct current (when 
applied alone); it negatively modulated (11.8 ± 3. 9%) the GABA-induced current at 
α1β2γ2L (19.6 ± 0.99%), and positively modulated this current at α2β2γ2L and α5β3γ2L (68.5 
± 2. 5%) receptors. Contrasting effects for different passionflower extracts have also 
been reported previously. For example, it has been found that a hydro-alcoholic extract 
(at 400 mg/kg) of passionflower showed anxiolytic effects, whereas an aqueous extract 
(at 400 mg/kg) had a sedating effect [273].  
 
 
4.4.2.  Results of screening of different pure compounds from passionflower. 
 
The results of the screening of the pure compounds from passionflower are summarised 
in Table 7.  
Table 7: Effects of pure compounds of passionflower on different subtypes of 
 GABAA receptors. 
Compounds alone and in 
combination with EC10 and/or  
EC50 GABA 
Effect on different GABAA receptor subtypes 
α1β2γ2L α2β2γ2L α5β3γ2L 
Isovitexin 82 (100  µM) No effect  No effect No effect 
Isovitexin 82 (100 µM) + EC10 
GABA 
23.3 ± 1.6% 
inhibition 
3.01 ± 0.5% 
inhibition 
15.1  ±  2.2 %  
inhibition 
Vitexin 81 (100  µM) No effect  No effect No effect 
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Vitexin 81 (100  µM) + EC10 
GABA 
24.6 ± 3.63% 
inhibition 
6.05 ± 1.5% 
inhibition 
16.2 ± 1.9% 
potentiation 
Isoorientin 85 (100  µM) No effect  No effect No effect 
Isoorientin 85 (100  µM) + EC10 
GABA 
16.2 ± 2.7% 
inhibition 
48.2 ± 0.77% 
inhibition 
13.9 ± 1.7 % 
inhibition 
Isoorientin 85 (100  µM) + EC50 
GABA 
22.3 ± 0.27% 
inhibition 
11.62 ± 0.20%  
inhibition 
No effect 
Orientin  83 (100  µM) No effect  No effect No effect 
Orientin 83 (100  µM) + EC10 
GABA 
14.3 ± 1.1% 
inhibition 
35.8 ± 0.44%  
inhibition 
12.5 ± 0.80% 
inhibition 
Orientin 83 (100  µM) + EC50 
GABA 
16.3 ± 0.68%  
inhibition 
5.51 ± 0.02 % 
inhibition 
No effect 
Apigenin 80 100  µM No effect  No effect No effect 
Apigenin 80 (100  µM) + EC10 
GABA 
9.18 ± 0.72% 
inhibition 
34.8 ± 0.60 % 
inhibition 
7.40 ± 2.6% 
inhibition 
Apigenin 80 (100  µM) + EC50 
GABA 
19.2± 0.72% 
inhibition 
20.0 ± 1.5% 
inhibition 
No effect 
Kampferol 72 (100  µM) No effect  No effect No effect 
Kampferol 72  (100  µM) + EC10 
GABA 
9.01 ± 0.70% 
potentiation 
43.0 ± 1.5% 
inhibition 
35.5 ± 0.51% 
inhibition 
Kampferol 72  (100  µM) + EC50 
GABA 
3.02 ± 0.50% 
potentiation 
33.4 ± 2.1% 
inhibition 
48.3 ± 1.2% 
inhibition 
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All the compounds, at a concentration of 100 µM, did not induce a direct current when 
applied alone, and all negatively modulated the EC10 and/or EC50 GABA-induced 
current, except for a slight positive modulation by Kaempferol 72 at α1β2γ2L receptors. 
At α2β2γ2L receptors, isoorientin 85 and orientin 83 inhibited the EC10 GABA-induced 
current by 48.2 ± 0.77% and 35.8 ± 0.44% respectively. However, at higher GABA 
concentration (EC50, 100 µM), the magnitude of the inhibition was smaller; 11.6 ± 
0.20% by isoorientin 85 and 5.51± 0.02% by orientin 83, Figure 63-64. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63: Typical traces for the effect of isoorientin 85 on α2β2γ2L subtype 
of GABAA  receptor.  
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Figure 64: Typical traces for the effect of isoorientin 85 on α2β2γ2L GABAA 
receptor.  
 
Although some studies have reported the sedative and anxiolytic effects of 
passionflower extracts, there is a controversy surrounding the constituents responsible 
for the observed pharmacological effects [155]. As mentioned earlier, in an in vivo 
study, an extract of passionflower with flavonoids as major compounds (as indicated by 
HPLC) produced anxiolytic effects, which are  believed to be mediated by the 
GABAergic system, particularly GABAA receptors [155]. However, these results are 
not in agreement with those from the investigation of Soulimani et al., 1997 where, the 
mixture of vitexin, isovitexin, orientin, and isoorientin (at a dose of 500 to 18000 
mg/kg, corresponding to dry plant) did not show any anxiolytic effects in the staircase 
test [273].  
 
GABAA receptors can be modulated by different types of ligands, including 
barbiturates, steroids, and benzodiazepines.  Theses ligands interact with different 
allosteric binding sites of GABAA receptors. Based upon their biological  activities, 
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different classes of compounds acting at the benzodiazepine binding site are referred to 
as positive allosteric modulators, antagonists, or negative allosteric modulators [278].  
Benzodiazepines themselves act as a positive allosteric modulators by enhancing the 
channel opening frequency and thus provide anxiolytic, muscle relaxant, anticonvulsive, 
and sedative effects [279]. 
 
To be regarded as an anxiolytic, compounds should thus be agonists or positive 
allosteric modulators of GABAA receptors. In the present study, the effect of 
passionflower flavonoids (vitexin 81, isovitexin 82, orientin 83 and isoorientin 85) was 
investigated on three different recombinant GABAA receptor subtypes. None of the 
flavonoids (at a concentration of 100 µM) induced a direct current when applied alone 
but they negatively modulated the GABA-induced current on all three subtypes of 
GABAA receptors, with the negative modulation ranging from 5 to 35%.  
 
Similar results have been reported for other flavonoids by other research groups.  For 
example, quercetin 73 and apigenin 80 have been investigated for their effect on the 
GABA-mediated ionic current at GABAA receptors. Instead of potentiating the current, 
these flavonoids antagonized α1β2γ2S GABAA receptors expressed in Xenopus laevis 
oocytes [280]. These results are in agreement with the results of the present study, in 
which the flavonoids from passionflower negatively modulated the GABA-induced 
current on all three GABAA receptor subtypes.  The results of the present study are also 
in agreement with the results of Soulimani et al., 1997 and Goutman et al., 2003 [273, 
280],  but are in disagreement with the results of Grundmann et al., 2008 [155].  
 
It has, however, been reported that the flavonoid glycosides are not responsible for their 
biological activity, rather it is their aglycones which are responsible for their effects. 
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The metabolism of flavonoids in human is also not clear but it is assumed that, after 
hydrolytic cleavage of the sugar moiety in the digestive tract, the aglycones are 
absorbed. Flavonoid glycosides are actually readily metabolised by organisms, and the 
activation of GABAA receptors may be due to their metabolites [281], which suggests 
that the CNS depressant effects of glycosyl flavonoids are not directly mediated through 
classical GABAA receptors [281]. 
 
4.4.2.1.  Kaempferol 72 
 
Amongst all the pure compounds, kaempferol 72 exhibited the greatest inhibition of the 
EC50 GABA-induced current at α2β2γ2L and α5β3γ2L GABAA receptors. On α2β2γ2L 
receptors, it inhibited EC50 GABA-induced current by 33.4 ± 2.1% and on α5β3γ2L by 
48.3 ± 1.2%. From dose-response curve the IC50 values were calculated, on α2β2γ2L, it 
inhibited 100 µM (EC50) GABA-induced current with an IC50 of 178μM and on α5β3γ2L, 
it inhibited 30 µM (EC50) GABA-induced current with an IC50 of 1228 μM, Figure 65 
(A-B) and 66 (A-B). 
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A.  
 
 
 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
 
Figure 65: A. Dose-response curve for the negative modulation of EC50 
GABA-induced current by kaempferol 72 on GABAA receptor 
with subunit composition of α2β2γ2L; B. Typical traces for the 
negative modulation of GABA-induced current by various 
concentration of kaempferol on α2β2γ2L receptor.  The data for the 
dose-response curve are the Mean ± SEM (n=3-4 oocytes). 
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A.  
 
 
 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
Figure 66: A. Dose-response curve for the negative modulation of EC50 
GABA-induced current by kaempferol 72 on GABAA receptor 
with subunit composition of α5β3γ2L; B. Typical traces for the 
negative modulation of EC50 GABA-induced current by different 
concentration of kaempferol on α5β3γ2L receptor. The data for 
dose-response curves are the Mean ± SEM (n=3-4 oocytes). 
 
1 10 100 1000
0
50
100
[Kaempferol] (M)
G
A
B
A
 E
C
5
0
 r
es
p
o
n
se
 %
 
2000 nA 
60 s 
14092014_a5b3g2L_DRC_kaempferol
C
h
a
n
n
e
l 
1
 (
n
A
)
-6000
-4000
-2000
0
2000
5:15:00 5:20:00 5:25:00 5:30:00 5:35:00 5:40:00 5:45:00 5:50:00 5:55:00 6:00:00 6:05:00 6:10:00 6:15:00 6:20:00
 5:12:25.000 AM
14092014_a5b3g2L_DRC_kaempferol
C
h
a
n
n
e
l 
1
 (
n
A
)
-6000
-4000
-2000
0
2000
5:15:00 5:20:00 5:25:00 5:30:00 5:35:00 5:40:00 5:45:00 5:50:00 5:55:00 6:00:00 6:05:00 6:10:00 6:15:00 6:20:00
 5:12:25.000 AM
14092014_a5b3g2L_DRC_kaempferol
C
h
a
n
n
e
l 
1
 (
n
A
)
-6000
-4000
-2000
0
2000
5:15:00 5:20:00 5:25:00 5:30:00 5:35:00 5:40:00 5:45:00 5:50:00 5:55:00 6:00:00 6:05:00 6:10:00 6:15:00 6:20:00
 5:12:25.000 AM
14092014_a5b3g2L_DRC_kaempferol
C
h
a
n
n
e
l 
1
 (
n
A
)
-6000
-4000
-2000
0
2000
5:15:00 5:20:00 5:25:00 5:30:00 5:35:00 5:40:00 5:45:00 5:50:00 5:55:00 6: 0:00 6: 5:00 6:10:00 6:15:00 6:20:00
 5:12:25.000 AM
14092014_a5b3g2L_DRC_kaempferol
C
h
a
n
n
e
l 
1
 (
n
A
)
-6000
-4000
-2000
0
2000
5:15:00 5:20:00 5:25:00 5:30:00 5:35:00 5:40:00 5:45:00 5:50:00 5:55:00 6:00:00 6:05:00 6:10:00 6:15:00 6:20:00
 5:12:25.000 AM
14092014_a5b3g2L_DRC_kaempferol
C
h
a
n
n
e
l 
1
 (
n
A
)
-6000
-4000
-2000
0
2000
5:15:00 5:20:00 5:25:00 5:30:00 5:35:00 5:40:00 5:45:00 5:50:00 5:55:00 6:00:00 6:05:00 6:10:00 6:15:00 6:20:00
 5:12:25.000 AM 14092014_a5b3g2L_DRC_kaempferol
C
h
a
n
n
e
l 
1
 (
n
A
)
-6000
-4000
-2000
0
2000
5:15:00 5:20:00 5:25:00 5:30:00 5:35:00 5:40:00 5:45:00 5:50:00 5:55:00 6:00:00 6:05:00 6:10:00 6:15:00 6:20:00
 5:12:25.000 AM
30 μM (EC
50
) 
GABA 
1 μM 10 μM 100 μM   30 μM   
Kaempferol 
3 μM 300 μM   
Page | 148  
 
4.4.2.2.  Binding interaction of kaempferol 72  
 
Further investigation on the binding interaction of kaempferol 72 revealed that the effect 
of this molecule is not sensitive to benzodiazepine antagonist flumazenil on α2β2γ2L 
subtype of GABAA receptor. On α5β3γ2L, the effect of kaempferol is not sensitive to 
selective inverse agonist L655, 708 which indicates that this molecule may not interact 
with the high affinity benzodiazepine binding site of GABAA receptors, Figure 67-68. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 67: Effect of flumazenil on kaempferol 72-induced inhibition of EC50 
GABA-induced current on α2β2γ2L GABAA receptor. 
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Figure 68: Effect of L655, 708 on kaempferol 72-induced inhibition of EC50 
GABA-induced current on α5β3γ2L GABAA receptor.   
Kaempferol 72 is a naturally occurring flavonol type flavonoid reported to be isolated 
from passionflower and also present in other plants including Apocynum venetum [143, 
282]. 
 
 
In the present study, the presence of kaempferol 72 was not detected in EtOH and 
purchased extracts by HPLC analysis, but the isolation of this molecule from 
passionflower has been reported earlier, so, it was purchased for testing on recombinant 
GABAA receptors.  
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In previous pharmacological studies, kaempferol 72 isolated from the anxiolytic 
fractions of Ginkgo biloba extracts reported as a potent inhibitor of MAO-A and MAO-
B, with enhanced inhibition of MAO-A with an IC50 of 7 x 10
-7 
M. However, in ex-vivo 
experiments, this compound had no effect on rat MAO-A, and on the concentration of 
other neurotransmitters, which include dopamine, noradrenaline, 5-hydroxytryptamine 
and 5-hydroxyindoleacetic acid. It also protected NMDA-induced neuronal toxicity in 
rat cortical cultures but was not preventive against DSP-4-induced noradrenergic neuron 
toxicity in in-vivo model [283].  It has also been reported that the fractions, which are 
rich in kaempferol or quercetin from Tilia americana var. Mexicana showed anxiolytic 
effect in elevated plus maze test in mice [284]. Recently, Grundmann et al., 2009 
reported that kaempferol isolated from the aqueous extracts of Apocynum venetum 
exerted anxiolytic effect in elevated plus maze in mice. Moreover, this effect was 
partially antagonised by benzodiazepine antagonist flumazenil indicating the 
GABAergic response of this molecule [282]. To date, however, to the best of our 
knowledge, no investigation of kaempferol 72 has been conducted on recombinant 
GABAA receptors. The present study, thus, investigated the effect of kaempferol on 
three different GABAA receptor subtypes. At a concentration of 100 µM, it did not 
induce direct current, when applied by alone but potentiated 3 µM GABA-induced 
current by 9% on α1β2γ2L receptor, and negatively modulated of EC50 GABA-induced 
current on α2β2γ2L and α5β3γ2L receptors with an IC50 of 178 μM and 1228 μM 
respectively. Moreover, the effect of kaempferol 72 was not sensitive to benzodiazepine 
antagonist flumazenil on α2β2γ2L and L655, 708 on α5β3γ2L GABAA receptor subtype 
suggesting the interaction of kaempferol is not with high affinity benzodiazepine 
binding site of GABAA receptor. 
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The results for kaempferol of the present study are not congruent with the results of the 
studies from Grundmann et al., 2009 and Perez - Ortega et al., 2008 [282, 284]. As 
mentioned earlier, to become an anxiolytic, a compound either needs to be an agonist or 
a positive allosteric modulator of GABAA receptors, particularly on α2β2γ2L GABAA 
receptor.  For example, the anxiolytic and muscle relaxant effects of diazepam are 
mediated through α2βγ2, and α3βγ2 containing receptors [219].  In the present study, 
instead of potentiation, kaempferol negatively modulated GABA induced current on 
α2β2γ2L GABAA receptor subtype. It is to be noted here that the amount of kaempferol 
mentioned in Perez - Ortega et al., 2008 study was much lower than that of quercetin, 
and in previous electrophysiological study, quercetin acted as an antagonist on α1β2γ2S 
GABAA receptor subtype [280] . 
However, based on the results of present study, and the study conducted by Sloely et al., 
2000, it can be assumed that the anxiolytic effect of kaempferol may not be mediated 
through the GABAergic system but instead by the inhibition of monoamine oxidases 
(MAOs).  
 
4.5. Conclusion  
In the present study, the ethanolic extract of passionflower, containing the flavonoids 
vitexin 81, isovitexin 82, orientin 83, and isoorientin 85, led to the opening of the Cl
- 
channel and positive modulation of the GABA-induced current at all three subtypes of 
GABAA receptors. These results contrast with those obtained with the pure components 
from passionflower, where the individual flavonoids had no effect on recombinant 
GABAA receptors when applied alone, and negatively modulated the GABA-induced 
current. The reason for this discrepancy may be due to the fact that the ethanolic 
extracts themselves contain GABA, along with other compounds. Passionflower has 
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been reported to contain the greatest amount of GABA (629 mg/100 g of dried plant) 
among 21 plants which were investigated [285].  In addition, it is believed that after 
systemic administration, the sugar moieties but not aglycones are important for the CNS 
depressant activities [281]. So, in order to have a clearer idea of the mechanism of 
action of passionflower extracts, individual pure compounds (and combinations of pure 
compounds) need to be tested on animal models for their putative anxiolytic and 
sedative effects. 
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CHAPTER 5 
  
Extraction, isolation, and structure elucidation of compounds 
from Vitis vinifera, and their testing on different GABAA 
receptor subtypes 
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5.  Introduction 
Vitis vinifera L. belongs to the family Vitaceae, and is one of the most widely grown 
food crops in the world [286]. Extracts and pure compounds from this plant have been 
found to be effective in the treatment of various neurological disorders, the details of 
which have been covered in Section 1.7.2. In a preclinical study, the oral administration 
of a hydroalcoholic extract of Vitis vinifera to rats (400 mg/kg, for a period of 45 days) 
led to an improvement in aluminium-induced deficiencies in short-term memory, 
cognition, anxiety, locomotion, and muscular activities [287].  
 
trans-ε-Viniferin 111, a naturally occurring phenol isolated from Vitis vinifera, inhibits 
the uptake of [
3
H]-noradrenaline and [
3
H]-5-HT in a dose-dependent manner in rat brain 
(this inhibition is more selective for [
3
H]-noradrenaline than for [
3
H]5-HT). trans-ε-
Viniferin also inhibits both monoamine oxidase A (MAO-A) and monoamine oxidase B 
(MAO-B) activity, with a more selective, dose-dependent, inhibition of MAO-B [288]. 
 
The suppression of β-amyloid (Aβ) fibril formation is an important target for the 
treatment of Alzheimer’s disease (AD), and trans-ε-viniferin glucoside (at 
concentrations of 5 and 10 μM) inhibits fragment Aβ (25-35), as well as  full length 
((Aβ (1-40) and Aβ (1-42)), peptide aggregation [252, 253].  
 
Resveratrol 110, which is the monomer of trans-ε-viniferin, has been shown to improve 
scopolamine-induced memory impairment by interacting with muscarinic cholinergic 
receptors in rats [289]. It has also been found to inhibit the GABA-induced current in 
GABAC  receptors expressed in Xenopus laevis oocytes (IC50, 28.9 ± 2.8 μM) [194]. To 
date, however, no investigations have been reported on the modulatory effects of 
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resveratrol 110, and its dehydrodimer trans-ε-viniferin 111, on different GABAA 
receptor subtypes, expressed in Xenopus laevis oocytes.  
 
The present study thus aimed to extract, isolate, and identify the structure of the natural 
products from the underground trunk of Vitis Vinifera, and to test them on different 
GABAA receptor subtypes expressed in Xenopus laevis oocytes, using the two electrode 
voltage clamp technique. 
 
5. 1. Materials and Methods 
5.1.1.  Materials for the extraction and isolation 
trans-ε-Viniferin was purchased from Cfm Oskar Tropitzsch GmbH, Germany, and 
resveratrol from Sigma-Aldrich, Castle Hill, Australia. Whatman
TM
 extraction thimbles 
(cellulose, single thickness, 43 mm × 123 mm) were obtained from GE Healthcare Life 
Sciences, UK.  The preparative TLC plates were Uniplate 
TM
 (Silica gel GF, preparative 
layer with UV 254, 20 x 20 cm, 500 µ, Analtech, Inc., Newark, USA).  
 
5.1.2.  Instrumentation 
The same instrumentation as described in Section 2.1.2 was used for the extraction, 
isolation, and structural elucidation of compounds from Vitis vinifera.  
 
5.1.3. Collection and extraction of Vitis vinifera underground trunk  
The dried underground trunk of Vitis vinifera was collected from India, and identified 
by Dr George Li, Senior Lecturer, Pharmaceutical Chemistry (Herbal Medicines), 
Faculty of Pharmacy, the University of Sydney, ground into coarse powder (24.565 g), 
and extracted in a Soxhlet extractor under reflux, using solvents (190 mL) of increasing 
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polarity; DCM (bp 41
0
C), followed by EtOAc (bp 77
0
C), and then EtOH (bp 78
0
C). 
After extraction for 8 h, the solvent was allowed to cool, and evaporated under reduced 
pressure to give the crude extracts; DCM extracts (0.134 g), EtOAc extracts (1.007 g), 
and EtOH extracts (0.794 g). 
 
5.1.4.  Isolation and structure elucidation of resveratrol 110 and trans-ε-
viniferin 111 
The ethyl acetate extracts (0.632 g) was adsorbed onto a small amount of silica, and the 
silica was loaded onto the column and subjected to flash column chromatography on 
silica, eluting with hexane / ethyl acetate (100 : 0 to 0 : 100), then EtOAc / methanol 
(100 : 0 to 0 : 100).  A total of 112 fractions (20 mL) were collected and analysed by 
TLC; identical fractions were combined. Fractions 42-46, which had one common spot, 
were combined, and the solvent was evaporated under reduced pressure to give pure 
resveratrol (32 mg). The structure of the resveratrol was determined by comparing its  
1
H and 
13
C NMR spectroscopic data, and mass spectrum with published data [290]. 
 
Resveratrol 110 was obtained as an amorphous yellow powder (32 mg); mp, 258-265
0
C 
(lit mp, 252-255
0
C [291]); 
1
H NMR (400 MHz, DMSO-d6), ppm); δ7.32 (2H, d, J = 8.8 
Hz, H-2',6'),   6.93 (1H, d, J = 16.0 Hz, =CH), (6.77, 1H, d, J = 16.0 Hz, =CH), 6.74 
(2H, d, J = 8.8 Hz, H-3',5'),  6.41  (2H, d, J = 2.4 Hz, H-2,6),  6.13 (1H, t, J = 2.0 Hz, H-
4 );
 13
C NMR (100 MHz, DMSO-d6), ppm); δ158.2 (quat,C-3,5), 156.9 (quat, C-4'), 
139.8 (quat, C-1), 129.0 (2 x CH, C-3',5'), 127.9 (2 x CH, C-2',6'), 127.3 (quat, C-1'), 
125.6 (CH, C-2), 115.0  (=CH, C-8), 104.3 (CH, C-6), 101.2 (=CH, C-7);
 
MS (ESI): 
m/z,
 
227 (M-H)
+
. 
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Fractions 49-50 (27 mg), which had one major common spot along with 2 other spots, 
were combined, evaporated under reduced pressure, and subjected to preparative thin 
layer chromatography on silica, eluting with hexane/ethyl acetate (20:80). After 
separation, the plate was dried in air; the band of interest was removed from the glass 
with a spatula, suspended in MeOH (50 mL) for 30 minutes, filtered through No. 1 
Whatman filter paper, and evaporated under reduced pressure to give pure trans-ε-
viniferin (17 mg). The structure was confirmed as trans-ε-viniferin from an analysis of 
its spectroscopic data (
1
H and  
13
C NMR) and mass spectrum, and comparison with 
published data [292].  
 
trans-ɛ-Viniferin 111 was obtained as an amorphous light brown powder (17 mg); mp, 
187-191
0
C (lit mp, 187-189
0
C [293]); 
1
H NMR (400 MHz, CD3OD); δ7.02 (2H, AA' 
multiplet, H-2',6') 6.63 (2H, BB', multiplet, H-3',5'), 7.13 (2H, AA', multiplet, H-2''',6'''), 
6.75 (2H,  BB', multiplet, H-3''',5'''), 6.80 (1H, d,  J = 16.0 Hz, H-7'), 6.55 (1H, d,  J = 
16.0 Hz, H- 8'), 6.63 (2H, d, J = 2.0 Hz, H-2'',6'' ), 6.56 (1H, br. s, H-4''),  6.23 (2H, d, J 
= 6.8 Hz, 3'',5''), 6.16 (2H, multiplet, H-5,7), 5.34 (1H, d, J = 6.8 Hz, H-2), 4.32 (1H, d, 
J = 6.4 Hz, H-3), ;
 13
C NMR (100 MHz CD3OD, ppm); δ 161.3 (quat, C-7a), 158.6 
(quat, C-3''), 158.3 (quat, C-5''), 157.1 (quat, C-4'), 157.0 (quat, C-1'''), 145.9 (quat, C-
4), 135.5 (quat, C-1'), 132.4 (=CH, C-8'), 128.9 (=CH, C-7'), 128.9 (2 x CH, C- 2''', 6'''), 
127.32 (2 x CH, C-2',6'), 126.8 (quat, C-1''), 122.24 (quat, C-6), 118.6 (quat, C-3a), 
114.9 (2 x CH, C-3''', 5'''), 114.8 (2 x CH, C-3',5'), 109.9 (2 x CH, C-2'', 6''), 106.0 (CH, 
C-4'') 102.9 (quat, C-4'''), 100.8 (CH, C-5), 95.4 (CH, C-7), 93.4 (CH, C-2), 56.8 (CH, 
C-3); ESI-MS: m/z (%) 453.04 (100%) [M-H]
+
. 
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5.1.5. Electrophysiology 
The electrophysiology experiments were conducted as described previously (Section 
2.3). 
 
5.1.6.  Data analysis 
Data analysis was performed as described previously, with slight modifications [294]. 
The analysis was performed using GraphPad Prism version 5. Dose-response curves 
were obtained from the currents recorded for the applied GABA concentrations (EC10 
for potentiation and EC50 for inhibition) in the presence of a range of resveratrol 110 
and trans-ε-viniferin 111 concentrations. The data was expressed as a percentage of the 
averaged maximum current (Imax) and fitted by non-linear regression with the Hill 
equation; 
 
I/Imax = [A]
nH/ (ECnH50+ [A]
nH) 
 
where; [A] is the agonist concentration, nH is the Hill coefficient and EC50 is the 
effective concentration that produced a response of 50% of Imax . 
 
Similarly, inhibition curves were produced from the peak currents recorded from the 
range of trans-ε-viniferin 111 concentrations applied in the presence of a fixed 
concentration (EC50) of GABA. The results are expressed as a percentage of the peak 
current (Imax) obtained from the application of the GABA concentration alone. The 
concentration that inhibited 50% of Imax (IC50) was estimated from fitting the data to the 
Hill equation, in which the concentration of the trans-ε-viniferin 111 was substituted for 
the agonist concentration.  
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5.2. Results 
5.2.1. Isolation and structural elucidation of resveratrol and trans-ε-viniferin 
5.2.1.1. Resveratrol 110 
 
 
The electrospray ionization mass spectrum (ESI-MS) of the compound isolated from the 
ethyl acetate extracts (fractions 42-46) contained a molecular ion peak at m/z (%) 227 
(100) [M-H]
+
, which correlates to the molecular formula of resveratrol 110 (C14H12O3). 
In the 
1
H NMR spectrum there are two doublets, at δ 6.93 and δ 6.77, with a coupling 
constant of 16.0 Hz, for the trans-alkene protons. Another key peak is that for the 
aromatic H-4 position, which is the most shielded (δ 6.13 ppm) and is a triplet, with a 
coupling constant of 2.4 Hz [290]. 
 
5.2.1.2.  trans-ɛ-Viniferin 111 
 
 
The electrospray ionization mass spectrum (ESI-MS) of ethyl acetate extracts (fractions 
49-50) contained a molecular ion peak at m/z 453 corresponding to [M-H]
+
 for trans-ε-
viniferin 111 (C28H22O6). In the 
1H NMR spectrum there are two doublets, at δ6.55 and 
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6.80, with a coupling constant of 16.0 Hz, indicating the presence of two trans-alkene 
protons. There are 2 AA' BB' spin systems in the molecule; the first AA' signal, at δ 
7.02 ppm represents the H-2', 6' protons, while the first BB' signal δ 6.63 ppm 
corresponds to H-3',5'. The second AA' signal represents H-2''',6''' (at δ 7.13 ppm) and 
the corresponding BB' signal at δ 6.75 corresponds to H-3''',5'''. 
 
5.3.  Electrophysiology 
5.3.1.  Screening of Vitis vinifera extracts 
5.3.1.1. Ethyl acetate extracts 
The crude EtOAc extracts (at a concentration of 100 μg/mL), when applied alone, 
induced a direct current at all subtypes of GABAA receptors. The greatest current (56.0 
± 15nA) was at α1β2γ2L, which was followed by α5β3γ2L (46.0 ± 9.9 nA), and then α2β2γ2L 
(15.0 ± 2.8 nA). The crude EtOAc extracts also modulated the GABA-induced current 
at all three subtypes of GABAA receptors, but to different extents. At α1β2γ2L and α2β2γ2L 
receptors, it negatively modulated the EC10 GABA-induced current, by 31.8 ± 0.71% 
and 45.0 ± 4.3%, respectively, but at α5β3γ2L receptors, it positively modulated the 
GABA-induced current by 133 ± 1.4%, Figure 69 (A-C). 
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Figure 69:  Typical traces for the effect of crude EtOAc extracts at A. α1β2γ2L 
B. α2β2γ2L and C. α5β3γ2L subtypes of GABAA receptors.  
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5.3.1.2.  Ethanol extracts 
 At a concentration of 100 μg/mL, the electrophysiology traces for the ethanol extracts 
showed a similar trend in results to those for the crude ethyl acetate extracts, but with 
different magnitudes; the crude EtOH extracts induced a current of 86.0 ± 17 nA on the 
α1β2γ2L, 60.5 ± 13 nA on the α2β2γ2L, and 33.5 ± 2.4 nA on the α2β2γ2L. The crude EtOH 
extracts also modulated the GABA-induced current at all three subtypes of recombinant 
GABAA receptors, negatively modulating all three subtypes; α1β2γ2L (23.0 ± 6.0%), 
α2β2γ2L ( 61.3 ± 14%), and α5β3γ2L  (114 ± 40%), Figure 70 (A-C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page | 163  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 70: Typical traces for the effect of crude EtOH extracts at A. α1β2γ2L; 
B. α2β2γ2L ; and C. α5β3γ2L   subtypes of  GABAA receptors.  
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It is worthy of note that the application of both extracts desensitized receptors to a great 
extent and the receptor function did not normalize even after a 20 minute wash off 
period.  
 
5.3.1.3.  Resveratrol 110 
 
The addition of the maximal GABA concentration (1 mM) induced a large inward 
current (IGABA) at all three receptor subtypes, confirming the expression of the respective 
GABAA receptors by the oocytes. The current was not inhibited by either 10 or 100 μM 
of zinc chloride, indicating the incorporation of a γ2L subunit [236], Figure 71. 
Resveratrol 110, at a concentration of 100 μM induced a small current (22.0 ± 3.5 nA) 
at the α1β2γ2L but not at the α2β2γ2L or α5β3γ2L subtypes of the GABAA receptor. It did 
not modulate the GABA-induced current at α2β2γ2L and α5β3γ2L subtypes of GABAA 
receptors, but potentiated the GABA-induced current at α1β2γ2L (by 126 ± 15%). In a 
dose-response experiment, involving the co-application of a fixed dose of GABA (EC10, 
3.0 μM) with different doses of resveratrol, resveratrol positively modulated the GABA-
induced current in a dose-dependent manner, with an EC50 value of 58μM, Figure 72. In 
addition, the effect of resveratrol was not sensitive to the benzodiazepine antagonist 
flumazenil, Figure 73, indicating that it may not interact with the high affinity 
benzodiazepine binding site, which is sensitive to flumazenil and is located at the 
interface of the α and γ subunits [278, 295]. 
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Figure 71: Typical traces for the effect of 10 μM and 100 μM ZnCl2  on the 
GABA (100 μM) induced current at A. α1β2γ2L;  B. α2β2γ2L; C. 
α5β3γ2L subtypes of GABAA receptors.  
500 nA 
60 s 
01092014_a2b2g2L_DRC MA_a1b2g2L_screening AA, res_ viniferin
Ch
an
ne
l 1
 (n
A)
-1500
-1000
-500
0
500
2:49:00 2:50:00 2:51:00 2:52:00 2:53:00 2:54:00 2:55:00 2:56:00 2:57:00 2:58:00 2:59:00 3:00:00 3:01:00 3:02:00 3:03:00 3:04:00 3:05:00
 2:48:26.000 AM
01092014_a2b2g2L_DRC MA_a1b2g2L_screening AA, res_ viniferin
Ch
an
ne
l 1
 (n
A)
-1500
-1000
-500
0
500
2:49:00 2:50:00 2:51:00 2:52:00 2:53:00 2:54:00 2:55:00 2:56:00 2:57:00 2:58:00 2:59:00 3:00:00 3:01:00 3:02:00 3:03:00 3:04:00 3:05:00
 2:48:26.000 AM
01092014_a2b2g2L_DRC MA_a1b2g2L_screening AA, res_ viniferin
Ch
an
ne
l 1
 (n
A)
-1500
-1000
-500
0
500
2:49:00 2:50:00 2:51:00 2:52:00 2:53:00 2:54:00 2:55:00 2:56:00 2:57:00 2:58:00 2:59:00 3:00:00 3:01:00 3:02:00 3:03:00 3:04:00 3:05:00
 2:48:26.000 AM
100 µM GABA 
10 µM  100 µM 
ZnCl2 
A. 
B. 
1000 nA 
30 s 
18112014_a2b2g2L_viniferin DRC_testing against FZM
Ch
an
ne
l 2
 (n
A)
-3000
-2000
-1000
0
1000
13:00 13:30 14:00 14:30 15:00 15:30 16:00 16:30 17:00 17:30 18:00 18:30 19:00 19:30 20:00 20:30 21:00 21:30 22:00 22:30 23:00 23:30 24:00 24:30 25:00 25:30 26:00
 12:12:58.000 AM
18112014_a2b2g2L_viniferin DRC_testing against FZM
Ch
an
ne
l 2
 (n
A)
-3000
-2000
-1000
0
1000
13:00 13:30 14:00 14:30 15:00 15:30 16:00 16:30 17:00 17:30 18:00 18:30 19:00 19:30 20:00 20:30 21:00 21:30 22:00 22:30 23:00 23:30 24:00 24:30 25:00 25:30 26:00
 12:12:58.000 AM
18112014_a2b2g2L_viniferin DRC_testing against FZM
Ch
an
ne
l 2
 (n
A)
-3000
-2000
-1000
0
1000
13:00 13:30 14:00 14:30 15:00 15:30 16:00 16:30 17:00 17:30 18:00 18:30 19:00 19:30 20:00 20:30 21:00 21:30 22:00 22:30 23:00 23:30 24:00 24:30 25:00 25:30 26:00
 12:12:58.000 AM
100 µM GABA 
10 µM  100 µM 
ZnCl2 
C. 
500 nA 
60 s 
22112014_a5b3g2L_against L655708
Ch
an
ne
l 2
 (n
A)
-1000
-500
0
500
4:24:00 4:24:30 4:25:00 4:25:30 4:26:00 4:26:30 4:27:00 4:27:30 4:28:00 4:28:30 4:29:00 4:29:30 4:30:00 4:30:30 4:31:00 4:31:30 4:32:00 4:32:30 4:33:00
 4:23:50.000 AM
22112014_a5b3g2L_against L655708
Ch
an
ne
l 2
 (n
A)
-1000
-500
0
500
4:24:00 4:24:30 4:25:00 4:25:30 4:26:00 4:26:30 4:27:00 4:27:30 4:28:00 4:28:30 4:29:00 4:29:30 4:30:00 4:30:30 4:31:00 4:31:30 4:32:00 4:32:30 4:33:00
 4:23:50.000 AM
22112014_a5b3g2L_against L655708
Ch
an
ne
l 2
 (n
A)
-1000
-500
0
500
4:24:00 4:24:30 4:25:00 4:25:30 4:26:00 4:26:30 4:27:00 4:27:30 4:28:00 4:28:30 4:29:00 4:29:30 4:30:00 4:30:30 4:31:00 4:31:30 4:32:00 4:32:30 4:33:00
 4:23:50.000 AM
100 µM GABA 
10 µM  100 µM  
ZnCl2 
Page | 166  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 72: A. Dose-response curve for the effect of resveratrol 110 on the 
GABA-induced (EC10, 3.0 µM) current at the α1β2γ2L GABAA 
receptors B. Typical traces for the positive modulation of GABA 
induced current (EC10, 3.0 µM) by different concentrations of 
resveratrol. The data for the dose- response curves are the Mean ± 
SEM (n=3-4 oocytes). 
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Figure 73: Traces showing the positive modulation of the GABA-induced 
current (EC10, 3.0 µM) by resveratrol, which is insensitive to 
benzodiazepine antagonist flumazenil. The data for the dose-
response curve are the Mean ± SEM (n=3-4 oocytes). 
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outward current for trans-ε-viniferin 111 at the α5β3γ2L subtype of GABAA receptor. 
trans-ε-Viniferin negatively modulated the GABA-induced (IGABA) current at all three 
subtypes; inhibiting the EC50 GABA-induced current by 78% at α5β3γ2L, 75% at α1β2γ2L, 
and 54% at the α1β2γ2L subtype. In dose-response experiments, involving the co-
application of the EC50 GABA with various concentration of trans-ε-viniferin, trans-ε-
viniferin inhibited the GABA-induced current in a dose-dependent manner. The greatest 
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inhibition was observed at the α1β2γ2L subtype (IC50, 58μM), followed by α2β2γ2L (IC50, 
19μM), and α5β3γ2L (IC50, 21μM), Figure 74 (A-F). 
 
From binding interaction studies, it has been revealed that the effect of trans-ε-viniferin 
at the α1β1γ2L and α2β2γ2L GABAA subtypes is not affected by the benzodiazepine 
antagonist flumazenil, indicating that it may not interact with the high affinity 
benzodiazepine binding site, which is sensitive to flumazenil. At the same time, the 
effect of trans-ε-viniferin at α5β3γ2L is not sensitive to L-655,708, a preferential inverse 
agonist at the α5β3γ2L GABAA receptor subtype, Figure 75 (A-C) [296]. 
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Figure 74:  Dose-response curve and typical traces for the effect of trans-ε-
viniferin 111 on different subtypes of GABAA receptors A-B: 
α1β2γ2L; C-D: α2β2γ2L;  E-F: α5β3γ2L. The data for the dose response 
curves are the Mean ± SEM (n=3-4 oocytes). 
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Figure 75:  A. Effect of flumazenil on trans-ε-viniferin 111-induced 
inhibition of EC50 GABA-induced current at α1β2γ2L subtype; B. 
Effect of flumazenil on the trans-ε-viniferin induced current at 
α2β2γ2L subtype; C. Effect of L-655,708 on the trans-ε-viniferin-
induced current at α5β3γ2L receptors.  
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In the present study, we report the differential effects of resveratrol 110, and its 
dehydrodimer trans-ε-viniferin 111, at different subtypes of GABAA receptors 
expressed in Xenopus laevis oocytes. The effects of resveratrol on ligand-gated ion 
channels have been investigated by many researchers, and it has been reported that the 
neuro-protection afforded by resveratrol 110 in a cerebral ischemia model is a result of 
its interaction with NMDA receptors [297].  Resveratrol has been found to inhibit the 
acetylcholine-induced current in rat α3β4 nicotinic acetylcholine receptors (IC50, 25 
μM), to inhibit the GABA-induced current in GABAC receptors, and to potentiate the 5-
HT induced current in 5-HT3A receptors [194,298, 299]. We have found that resveratrol, 
from Vitis vinifera, had no effect on the different subtypes of GABAA receptors (except 
α1β2γ2L) when applied alone. It did, however, positively modulate the GABA-induced 
current in the α1β2γ2L subtype (but not the α2β2γ2L and α5β3γ2L subtypes) in a dose-
dependent manner. It thus appears that α1 subunit is essential for the modulatory effect 
of this compound on GABAA receptors. Moreover, the effect of resveratrol is not 
sensitive to benzodiazepine antagonist flumazenil, indicating that its binding site is 
distinct from the high affinity benzodiazepine binding site.  
 
Although resveratrol and trans-ε-viniferin 111 are present in comparable amounts in 
grapes [300], the pharmacological effects of trans-ε-viniferin have not been thoroughly 
investigated [288], despite it having been found to be more active than resveratrol in 
some biological assays. For example, it is more active than resveratrol in inducing the 
relaxation of rat thoracic aorta preparations, has greater in vitro antioxidant activity, is a 
more potent  inhibitor of platelet-derived growth factor-induced cell proliferation, and 
induces nitric oxide generation in vascular smooth muscle cells (VSMCs) [300-302]. A 
number of reports of the modulatory effect of resveratrol on ion channel receptors have 
been published [194, 297, 299] but, to date, no reports on the modulatory effect of 
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trans-ε-viniferin have been published. In the present study, trans-ε-viniferin, the 
dehydrodimer of resveratrol, has been shown to negatively modulate the GABA-
induced current (IGABA) in all three subtypes of GABAA receptor, in a dose-dependent 
manner. The effect of trans-ε-viniferin at the α1β2γ2L and α2β2γ2L is also not sensitive to 
benzodiazepine antagonist flumazenil, while the effect at the α5β3γ2L subtype is not 
sensitive to inverse agonist L-655,708, indicating that this compound does not interact 
with the high affinity benzodiazepine binding site. 
 
5.4. Conclusion 
 
In conclusion, despite the structural similarity between resveratrol 110 and trans-ε-
viniferin 111, these compounds modulate the GABA-induced current in GABAA 
receptors in different ways. The effects of trans-ε-viniferin are more selective towards 
α1β2γ2L compared to α2β2γ2L and α5β3γ2L receptors. Moreover, the effect on α1β2γ2L  is not 
sensitive to the effect of flumazenil, which is an antagonist on GABAA receptors, and is 
clinically used for reducing the sedative effect of midazolam, and as an antidote for 
benzodiazepine overdose [303]. As trans-ε-viniferin act as a negative allosteric 
modulator at all three subtypes of GABAA receptors, in order to increase the selectivity, 
analogues of this compound should be designed and, in addition to being tested on 
GABAA receptors, should be tested in animal models. 
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Appendix I:   HPLC analysis of Passiflora incarnata and Centella asiatica 
 
Table AI.1:  Gradient system for the analysis of EtOH extracts of Centella 
asiatica 
 
A. 10 % ACN with 0.2 % phosphoric acid B. 90% ACN with 0.2 % phosphoric acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AI.2:  HPLC chromatogram of EtOH extracts of freshly collected 
Centella asiatica. 
Time (minutes) % B (Acetonitrile), Day 1 
0 11 % 
18 13 % 
33 20 % 
43 25 % 
50 75 % 
52 82% 
64 95% 
69 11 % 
82 11 % 
82 Stop 
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Figure AI.3:  HPLC chromatogram of EtOH extracts of purchased Centella 
asiatica. 
 
Table AI.4: Gradient system 1 for the analysis of passionflower  
A: Water with 50 mM Phosphoric acid   B: ACN 
 
 
 
 
 
 
 
 
 
 
 
Time (minutes) % B (Acetonitrile) 
0 6 % 
14 30 % 
25 100 % 
31 20 % 
39 6 % 
40 Stopped 
45  
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Table AI.5: Gradient system 2 for the analysis of passionflower  
 
 
 
Table AI.6: Gradient system 3 for the analysis of passionflower  
 
 
 
 
 
 
 
Table AI.7: Gradient system 4 for the analysis of passionflower  
 
 
 
 
 
 
Time (minutes) % B (Acetonitrile) 
0 6 % 
14 20 % 
25 70 % 
31 100 % 
39 6 % 
40 6 % 
45 Stopped 
Time (minutes) % B (Acetonitrile) 
0 6 % 
14 20 % 
25 50 % 
31 100 % 
39 6 % 
40 6 % 
45 Stopped 
Time (minutes) % B (Acetonitrile) 
0 10% 
20 20% 
30 50 % 
35 100% 
39 6 % 
40 Stopped 
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Figure AI.8:   Standard curve for the quantification of isovitexin 82 in EtOH 
extracts of passionflower. 
 
Table AI.9: Calculation of amount of isovitexin 82 from standard curve. 
 
Isovitexin Standard Curve 
Sample 
Concentration 
(mg/ml) Peak Area 
  0 0 
S1 0.01 43.3895 
S2 0.02 79.2909 
S3 0.04 159.0652 
S4 0.1 412.251 
U1 (0.3 mg/ml) 0.0138 56.3967 
U2 (0.5mg/ml) 0.0244 99.8912 
 
y = 4099.8x 
R² = 0.9996 
0
50
100
150
200
250
300
350
400
450
0 0.02 0.04 0.06 0.08 0.1 0.12
Peak Area 
Concentration (mg/ml) 
Isovitexin Standard Curve 
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Figure AI.10:  HPLC chromatogram of EtOH extracts of passionflower. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AI.11: HPLC chromatogram of EtOH extracts of purchased  
 passionflower. 
 
 
 
 
Minutes 
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Figure AI.12: HPLC chromatogram of EtOH extracts of freshly collected 
passionflower. 
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Appendix II: Electrophysiology traces 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AII.1: Typical traces for the effect of different crude extracts of Centella 
asiatica on the EC10 GABA-induced current at α1β2γ2L subtype of 
GABAA receptor. 
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Figure AII.2: Typical traces for the effect of different crude extracts of Centella 
asiatica on the EC10 GABA-induced current at α2β2γ2L subtype of 
GABAA receptor. 
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Figure AII.3: Typical traces for the effect of different crude extracts of Centella 
asiatica on the EC10 GABA-induced current at α5β3γ2L subtype of 
GABAA receptor. 
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Figure AII.4: Typical traces for the effect of asiaticoside 38 A. α5β3γ2L B. 
α2β2γ2L; C. α1β2γ2L  receptors. 
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Figure AII.5: Typical traces for the effect of madecassoside 39 A. α1β2γ2L B. 
α2β2γ2L; C. α5β3γ2L  receptors. 
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Figure AII.6: Typical traces for the effect of by ethyl-α-D fructofuranoside 153 
at A. α1β2γ2L ; B. α5β3γ2L; C. α2β2γ2L  receptors. 
600 nA 
60 s 
07062014_a5b3g2L_Centella_Synthesized compounds
Cha
nne
l 1 (
nA)
-220
-200
-180
-160
-140
-120
49:00 49:20 49:40 50:00 50:20 50:40 51:00 51:20 51:40 52:00 52:20 52:40 53:00 53:20 53:40 54:00 54:20 54:40 55:00
 12:48:42.000 AM
07062014_a5b3g2L_Centella_Synthesized compounds
Cha
nne
l 1 
(nA
)
-1000
-800
-600
-400
-200
0
58:00 59:00 1:00:00 1:01:00 1:02:00 1:03:00 1:04:00 1:05:00 1:06:00 1:07:00 1:08:00 1:09:00 1:10:00 1:11:00 1:12:00 1:13:00 1:14:00 1:15:00 1:16:00 1:17:00 1:18:00 1:19:00 1:20:00 1:21:00 1:22:00 1:23:00
 12:58:00.000 AM
07062014_a5b3g2L_Centella_Synthesized compounds
Cha
nne
l 1 
(nA
)
-1000
-800
-600
-400
-200
0
58:00 59:00 1:00: 0 1:01:00 1: 2: 0 1:03: 0 1:04:00 1:05:00 1:06:00 1: 7:00 1: 8:00 1:09:00 1:10:00 1:11:00 1:12:00 1:13:00 1:14:00 1:15:00 1:16:00 1:17:00 1:18:00 1:19:00 1:20:00 1:21:00 1:22:00 1:23:00
 12:58:00.000 AM 07062014_a5b3g2L_Centella_Synthesized compounds
Ch
an
ne
l 1
 (n
A)
-1000
-800
-600
-400
-200
0
58:00 59:00 1:00:00 1:01:00 1:02:00 1:03:00 1:04:00 1:05:00 1:06:00 1:07:00 1:08:00 1:09:00 1:10:00 1:11:00 1:12:00 1:13:00 1:14:00 1:15:00 1:16:00 1:17:00 1:18:00 1:19:00 1:20:00 1:21:00 1:22:00 1:23:00
 12:58:00.000 AM
100 μM Ethyl α-D 
fructofuranoside 
3 μM (EC10) GABA 
500 nA 
60 s 
020614_a2b2g2L DRC_testing of AS _ Ethyl Fructo
C
h
a
n
n
e
l 
2
 (
n
A
)
-2000
-1500
-1000
-500
0
500
1000
7:24:00 7:25:00 7:26:00 7:27:00 7:28:00 7:29:00 7:30:00 7:31:00 7:32:00 7:33:00 7:34:00 7:35:00 7:36:00 7:37:00 7:38:00 7:39:00 7:40:00 7:41:00 7:42:00 7:43:00 7:44:00 7:45:00 7:46:00 7:47:00 7:48:00 7:49:00 7:50:00 7:51:00 7:52:00 7:53:00 7:54:00
 7:23:58.000 AM
20 14_a2b2g2L DRC_testing of AS _ Ethyl Fructo
C
ha
nn
el
 2
 (
nA
)
-2000
-1500
-1000
-500
0
500
1000
7:24:00 7:25:00 7:26:00 7:27:00 7:28:00 7:29:00 7:30:00 7:31:00 7:32:00 7:33:00 7:34:00 7:35:00 7:36:00 7:37:00 7:38:00 7:39:00 7:40:00 7:41:00 7:42:00 7:43:00 7:44:00 7:45:00 7:46:00 7:47:00 7:48:00 7:49:00 7:50:00 7:51:00 7:52:00 7:53:00 7:54:00
 7:23:58.000 AM
020614_a2b2g2L DRC_testing of AS _ Ethyl Fructo
C
ha
nn
el
 2
 (
nA
)
-2000
-1500
-1000
-500
0
500
1000
7:24:00 7:25:00 7:26:00 7:27:00 7:28:00 7:29:00 7:30:00 7:31:00 7:32 00 7:33:00 7:34:00 5:00 7:36:00 7:37:00 7:38:00 7:39:00 7:40:00 7:41 00 7:42:00 7:4 :00 4:00 7:45:00 7:46:00 7:47:00 7:48:00 7:49:00 7:50:00 7:51:00 7:52:00 3:00 7:54:00
 7:23:58.000 AM
020614_a2b2g2L DRC_testing of AS _ Ethyl Fructo
C
ha
nn
el
 2
 (
nA
)
-2000
-1500
-1000
-500
0
500
1000
7:24:00 7:25:00 7:26:00 7:2 00 7:28 00 7:29 00 7:30 00 7:31 00 7:32 00 7:33 0 7:34 00 7:35 00 7:36 00 7:3 00 7:38:00 7:39 0 7:40 7:41 0 7:42 00 7 43 0 7:44 00 7:45 00 7:46 00 7:4 00 7:48 0 7:49 7:50 0 7:51 00 7 52 00 7:53 0 7:54 00
 7:23:58.000 AM
100 μM Ethyl α-D 
fructofuranoside 
10 μM (EC10) GABA 
260514_Fructo furanoside_AS_MS_AMA_on a1b2g2L
Ch
an
ne
l 2
 (n
A)
-1500
-1000
-500
0
23700 23760 23820 23880 23940 24000 24060 24120 24180 24240 24300 24360 24420 24480 24540 24600 24660 24720 24780 24840 24900 24960 25020 25080 25140
 6:34:52.250 AM
260514_Fructo furanoside_AS_MS_AMA_on a1b2g2L
Ch
an
ne
l 2
 (n
A)
-1500
-1000
-500
0
23700 23760 23820 23880 23940 24000 24060 24120 24180 24240 24300 24360 24420 24480 24540 24600 24660 24720 24780 24840 24900 24960 25020 25080 25140
 6:34:52.250 AM
260514_Fructo furanoside_AS_MS_AMA_on a1b2g2L
Ch
an
ne
l 2
 (n
A)
-1500
-1000
-500
0
23700 23760 23820 23880 23940 24000 24060 24120 418 424 430 436 442 48 54 60 66 72 78 84 90 96 502 508 514
 6:34:52.250 AM
500 nA 
120 s 
100 μM Ethyl α-D 
fructofuranoside 
30 μM (EC50) 
GABA 
B. 
260514_Fructo furanoside_AS_MS_AMA_on a1b2g2L
Ch
an
ne
l 2
 (n
A)
-1500
-1000
-500
0
500
1000
20760 20880 21000 21120 21240 21360 21480 21600 21720 21840 21960 22080 22200 22320 22440 22560 22680 22800 22920 23040
 5:44:58.250 AM
260514_Fructo furanoside_AS_MS_AMA_on a1b2g2L
Ch
an
ne
l 2
 (n
A)
-1500
-1000
-500
0
500
1000
20760 20880 1000 21120 21240 21360 21480 21600 1720 21840 21960 22 80 2 200 22320 22440 22560 2680 2 800 22920 23 40
 5:44:58.250 AM
260514_Fructo furanoside_AS_MS_AMA_on a1b2g2L
Ch
an
ne
l 2
 (n
A)
-1500
-1000
-500
0
500
1000
20760 20880 21000 21120 21240 21360 2 480 216 0 21720 21 40 21960 22080 222 0 22320 2440 2 560 2680 28 0 2920 3040
 5:44:58.250 AM
260514_Fructo furanoside_AS_MS_AMA_on a1b2g2L
Ch
an
ne
l 2
 (n
A)
-1500
-1000
-500
0
500
1000
20760 20880 21000 112 124 36 48 60 72 184 96 208 220 232 44 56 68 2 80 292 2304
 5:44:58.250 AM
100 μM Ethyl α-D 
fructofuranoside 
3 μM (EC10) 
GABA 
A. 
C. 
Page | 208  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure AII.7: Typical traces for the effect of 2α,3β,23-triacetoxy-urs-12-en-28-
oic acid 156 at A. α1β2γ2L ; B. α5β3γ2L receptors. 
 
 
 
 
 
 
 
 
Figure AII.8: Typical traces for the effect of 2α,3β,23-triacetoxy-urs-12-en-28-
amide 157 on α2β2γ2L subtype of GABAA receptors.  
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Figure AII.9: Typical traces for the effect of 2α,3β,23-triacetoxy-urs-12-en-28-
amide 157 on α5β3γ2L GABAA receptor.  
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Figure AII.10:  Typical traces for the effect of 2α,3β,23-triacetoxy-urs-12-en-28-
oic acid prodrug 160 on the EC50 and EC10 GABA-induced 
current on A. α5β3γ2L; B. α1β2γ2L and C. α2β2γ2L GABAA receptors.  
 
 
 
 
 
 
 
 
 
 
Figure AII.11: Typical traces showing the effect of crude ethanolic 
passionflower extracts on the α2β2γ2L subtype of GABAA receptor. 
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Figure AII.12: Typical traces showing the effect of aqueous passionflower 
extracts on A. α1β2γ2L; B. α2β2γ2L and C. α5β3γ2L GABAA 
receptors.  
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Figure AII.13: Typical traces for the effect of isovitexin 82 on A. α1β2γ2L; B. 
α5β3γ2L and C. α2β2γ2L GABAA receptors. 
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Figure AII.14: Typical traces for the effect of vitexin 81 on A. α1β2γ2L; B. α5β3γ2L 
 receptors. 
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Figure AII.15: Typical traces for the effect of vitexin 81 on α2β2γ2L subtype of 
GABAA receptor 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure AII.16: Typical traces for the effect of isoorientin 85 on α1β2γ2L subtype 
of GABAA receptor.  
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Figure AII.17: Typical traces for the effect of isoorientin 85 on α2β2γ2L subtype 
of GABAA  receptor.  
 
 
 
 
 
 
 
 
Figure AII.18: Typical traces for the effect of isoorientin 85 on α2β2γ2L   GABAA 
receptor.  
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Figure AII.19: Typical traces for the effect of orientin 83 on A. α1β2γ2L; B. 
α2β2γ2L and C. α5β3γ2L GABAA receptors. 
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Figure AII.20: Typical traces for the effect of apigenin 80 on A. α2β2γ2L B. 
α2β2γ2L; C. α5β3γ2L  GABAA receptors. 
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Appendix III:  Spectroscopic data (NMR, Mass and  IR Spectra) 
 
 
Figure AIII.1: 
1
H NMR spectrum of madecassic acid 41 in DMSO-d6.  
 
Figure AIII.2: 
1
H NMR spectrum of madecassic acid 41 after D2O shake in 
DMSO-d6.  
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Figure AIII.3: 
13
C NMR spectrum of madecassic acid 41 DMSO-d6.  
 
 
Page | 220  
 
 
Figure AIII.4: Mass spectrum of madecassic acid 41.  
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Figure AIII.5: 
1
H NMR spectrum of ethyl α-D-fructofuranoside 153 in CD3OD.  
 
 
Figure AIII.6: 
13
C NMR spectrum of ethyl α-D-fructofuranoside 153 in CD3OD.  
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Figure AIII.7: Mass spectrum of ethyl α-D-fructofuranoside 153.  
 
 
 
Figure AIII.8: 
1
H NMR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 
156 in CD3OD.  
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Figure AIII.9: 
13
C NMR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 
156 in CD3OD. 
 
Figure AIII.10: Mass spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156. 
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Figure AIII.11:   IR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 156. 
 
 
Figure AIII.12: 
1
H NMR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-amide 
157 in CD3OD. 
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Figure AIII.13: 
13
C NMR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-amide 
157 in CD3OD. 
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Figure AIII.14: Mass spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-amide 157. 
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Figure AIII.15:  IR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-amide 157. 
 
 
 
Figure AIII.16: 
1
H NMR spectrum of 2α,3β,23-trihydroxy-urs-12-en-28-amide 
158 in CD3OD. 
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Figure AIII.17: 
13
C NMR spectrum of 2α,3β,23-trihydroxy-urs-12-en-28-amide 
158 in CD3OD. 
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Figure AIII.18:  HR-mass spectrum of 2α,3β,23-trihydroxy-urs-12-en-28-amide 
158. 
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Figure AIII.19:  IR spectrum of 2α,3β,23-trihydroxy-urs-12-en-28-amide 158. 
 
 
Figure AIII.20: 
1
H NMR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 
prodrug 159 in CD3OD. 
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Figure AIII.21: 
13
C NMR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 
prodrug 159 in CD3OD. 
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Figure AIII.22:  HR-mass spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid 
prodrug 159. 
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Figure AIII.23:  IR spectrum of 2α,3β,23-triacetoxy-urs-12-en-28-oic acid prodrug 
159. 
 
 
Figure AIII.24: 
1
H NMR spectrum of 2α, 3β, 23-O-triacetylmadecassic acid 160 
in CD3OD. 
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Figure AIII.25: 
13
C NMR spectrum of 2α, 3β, 23-O-triacetylmadecassic acid 160 
in CD3OD. 
 
Figure AIII.26:  gCOSY spectrum of 2α, 3β, 23-O-triacetylmadecassic acid 160 
in CD3OD. 
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Figure AIII.27:  gHMQC spectrum of 2α, 3β, 23-O-triacetylmadecassic acid 160 
in CD3OD. 
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Figure AIII.28:  HR-mass spectrum of 2α, 3β, 23-O-triacetylmadecassic acid 160. 
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Figure AIII.29:  IR spectrum of 2α, 3β, 23-O-Triacetylmadecassic acid 160. 
 
 
Figure AIII.30: 
1
H NMR spectrum of isovitexin 82 in DMSO-d6. 
 
Page | 238  
 
 
 
Figure AIII.31: 
13
C NMR spectrum of isovitexin 82 in DMSO-d6.  
 
 
Figure AIII.32:  Mass spectrum of isovitexin 82.  
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Figure AIII.33: 
1
H NMR spectrum of vitexin 81 in DMSO-d6.  
 
 
Figure AIII.34: 
13
C NMR spectrum of vitexin 81 in DMSO-d6. 
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Figure AIII.35: Mass spectrum of vitexin 81.  
 
  
Figure AIII.36: 
1
H NMR spectrum of resveratrol 110 in DMSO-d6. 
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Figure AIII.37: 
13
C NMR spectrum of resveratrol 110 in DMSO-d6. 
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Figure AIII.38: Mass spectrum of resveratrol 110. 
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Figure AIII.39: 
1
H NMR spectrum of trans-ɛ-viniferin 111 in CD3OD.  
 
 
Figure AIII.40: 
13
C NMR spectrum of trans-ɛ-viniferin 111 in CD3OD.  
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Figure AIII.41: Mass spectrum of trans-ɛ-viniferin 111.  
 
 
 
 
 
 
 
 
 
